PAGE 1 Losing a Million Minds: Confronting the Tragedy of Alzheimer's Disease and Other Dementias April 1987 NTIS order #PB87-183752 PAGE 2 Library of Congress Catalog Card Number 87-619805 For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, DC 20402-9325 (order form on p. 539) PAGE 3 Foreword Congressional concern about the plight of those suffering from Alzheimers disease and other dementias has steadily mounted for the past five years. This report grew out of a previous OTA report on Technology and Aging in America; it was requested by the following seven committees: l U.S. Senate: Committee on Finance, --Committee on Labor and Human Resources, Committee on Veterans Affairs, and Special Committee on Aging. l U.S. House of Representatives: -Committee on Energy and Commerce, Committee on Science and Technology, and Select Committee on Aging. In addition to the requesting committees, the House and Senate subcommittees that appropriate funds to the Department of Health and Human Services have frequently expressed interest, as have the Senate Committee on the Budget and the House Committee on Ways and Means. Members and staff of the requesting committees, other committees, and personal staff have been directly involved in identifying subjects that are covered in this report. The unusual length of this report is testimony to the diversity of issues associated with dementia that fall within the jurisdiction of various committees. Writing this report involved collection of more than 10)000 pages of existing documents and preparation of more than 40 papers by outside experts under contract to OTA. Many of the OTA contract reports have been released to the National Technical Information Service or published elsewhere (see appendix C). OTA staff also gathered information through discussions with more than 130 congressional staff and hundreds of othersincluding government employees at the State and Federal levels and representatives of more than 100 nongovernment organizations in the United States and other countries. The resulting document has been reviewed by the projects advisory panel and more than 50 other experts in various relevant fields. More than one hundred other individuals have reviewed specific chapters or early drafts. On behalf of OTA, I wish to express my thanks to the myriad of individuals who contributed either directly or indirectly to this study. It distills a mass of information into a form that I hope will be useful to policy makers. As with all OTA reports, however, the content is the sole responsibility of OTA and does not necessarily constitute consensus of or endorsement by the advisory panel or the congressional Technology Assessment Board. ,.. Ill PAGE 4 . Advisory Panel for OTA Assessment of Disorders Causing Dementia Daniel Wikler, Chairman Program in Medical Ethics, University of Wisconsin Medical School Departments of Philosophy and History of Medicine John Blass Cornell University Medical College, and Director, Dementia Research Service Burke Rehabilitation Center Stanley Brody University of Pennsylvania Medical School Department of Physical Medicine and Rehabilitation, and Wharton School of Finance Donna Campbell Veterans Administration Geriatric Research and Education and Care Center Bedford, MA Gill Deford National Senior Citizens Law Center Los Angeles, CA Karl Girshman Hebrew Home of Greater Washington Lisa Gwyther Duke University Medical Center Center for the Study of Aging and Human Development Family Support Program Thomas Jazwiecki Office of Reimbursement and Financing American Health Care Association Purlaine Lieberman Equitable Life Assurance Society of the United States William Markesbery Professor of Pathology and Neurology University of Kentucky College of Medicine Paul Nathanson University of New Mexico Institute of Public Law Nancy Orr Hillhaven Corporation Special Care Units Diana Petty Family Survival Project San Francisco, CA Dominick Purpura Albert Einstein College of Medicine Betty Ransom National Institute on Adult Daycare, and National Center on Rural Aging National Council on the Aging Donald Schneider Management Health Systems Rensselaer Polytechnic Institute School of Management Jerome Stone President, Alzheimers Disease and Related Disorders Association Sallie Tisdale Writer and Long-Term Care Nurse Portland, OR Ramon Vane College of Human Services San Diego State University Philip Weiler Department of Community Health, and Director, Center for Aging and Health, University of California, Davis, School of Medicine Peter Whitehouse Alzheimers Neuroscience Center and Department of Neurology, Case Western Reserve School of Medicine; Division of Behavioral Neurology, University Hospitals of Cleveland NOTE: OTA appreciates and is grateful for the valuable assistance and thoughtful critiques provided by the advisory panel members. The panel does not, however, necessarily approve, disapprove, or endorse this report. OTA assumes full responsibility for the report and the accuracy of its contents. iv PAGE 5 OTA Dementia Project Staff Roger Herdman, Assistant Director, OTA Health and Life Sciences Division Gretchen S. Kolsrud, Biological Applications Program Manager Robert M. Cook-Deegan, Project Director Dana A. Gelb, Research Analyst L. Val Giddings, Analyst Katie Maslow, Analyst Teresa S. Myers, Research Analyst Authors Under Contract Nancy Mace, Consultant in Gerontology, Towson, MD Mary Ann Baily, George Washington University David Chavkin, Maryland Disability Law Center Catherine Hawes, Research Triangle Institute, North Carolina Support Staff Sharon Kay Oatman, Administrative Assistant Linda Rayford, Secretary Barbara Ketchum, Secretary Bryan Harrison, Office Automation Systems Analyst PAGE 6 CONTENTS Chapter Page l. Dementia: Prospects and Policies . . . . . . . . . . 3 2. Characteristics of Persons With Dementia . . . . . . . . 59 3.The Diseases: Diagnosis, Treatment, and Scientific Background. . . . 87 4.The Family.. . . . . . . . . . . .................135 5. Making Decisions for Those With Dementia . . . . . ., .........169 6.Long-Term Care Services and Settings: An Introduction. . . . . . .201 7. Programs and Services That Specialize in the Care of Persons With Dementia ...241 8. Patient Assessment and Eligibility for Services . . . ................273 9. Personnel and Training . . . . . . . . . . ........329 10. Quality Assurance in Long-Term Care: Special Issues for Those With Dementia. ,369 11. Medicaid and Medicare as Sources of Funding for Long-Term Care of Patients With Dementia . . . . . . . . . . ........415 12. Financing Long-Term Care for Persons With Dementia . . . . . ..447 13. Basic Biomedical Research Policy . . . . . . . . . . .479 Appendixes Page A. The Characteristics of Nursing Home Residents With Dementia ...............499 B. Contractors and Workshop Participants . . . . . ...............506 C. Major Contracts Written for OTA and Where They Can Be Obtained ..........511 D.Glossary of Acronyms and Terms . . . . . . . . . . .514 Index . . . . . . . . . . . . . . . ......527 PAGE 7 Chapter 1 Dementia: Prospects and Policies "It may be two or three decades before a favorable treatment is available. If this is so, developing increasingly efficient health care delivery grows in importance on a more immediate time scale. David Drachman chairman of the Scientific Advisory Board, Alzheimers Disease and Related Disorders Association, July 28, 1986. Old family values do not need restoration simply because they have not diminished. The fact is that government and agency services supplement but do not supplant family services. The evidence points unmistakably to the need for family-focused services to alleviate the burden of parent care, These are basic to all other efforts and can only be made available by social policy. Alzheimers patients are not eligible for skilled care [as defined by Medicare and Medicaid], though they need the most skilled care of all. Elaine Brody before the Subcommittee on Health and Long-Term Care, Select Committee on Aging, and Subcommittee on Health and the Environment, Committee on Energy and Commerce, U.S. House of Representatives, Aug. 3, 1983. Most families are heroically fighting a devastating illness. Supporting them can be rewarding to professionals and, we believe, a legitimate goal for the Congress. We must be realistic and not oversell our abilities to dramatically cut costs or resolve problems, but cannot turn our backs on the families of 2 or 3 million people. Families can do so much for themselves; however, five things need the leadership of Congress: 1. ongoing support for research, 2. support for training of professionals, 3. provision of a variety of alternative respite services, 4. equitable funding for quality long-term care when it is necessary, and S equitable disability policies. Nancy Mace before the Subcommittee on Health and Long-Term Care, Select Committee on Aging, and Subcommittee on Health and the Environment, Committee on Energy and Commerce, U.S. House of Representatives, Aug. 3, 1983. PAGE 8 CONTENTS Page Goals of public Policy Related to Dementia 4 Federal Policy Priorities . . . 5 Organization of the Report . . . 6 Reasons for Increased Interest in Dementia . . . . . . 6 Policy Interest in Dementia . . . 8 What Is Dementia? . . . . . 8 Symptoms of Dementia . . . 8 Disorders Causing Dementia . . 9 Course of the Illnesses . . . . 13 Magnitude of the Problem . . . 15 Prevalence of Dementia . . . 15 Costs of Dementia . . . . 16 Coordinating Services for Those With Dementia . . . . . . 22 The Care System . . . . . 22 Inventory of Services . . . . 23 Senior Services . . . . . 25 Acute Care Services . . . . 26 Long-Term Care Services . . . 26 Social Services . . . . . 28 Mental Health Services . . . 29 Groups of Special Concern . . . 30 Those Without Families . . . 31 Minority Groups . . . . . 31 Individuals Experiencing Onset of Dementia in Middle Age. . . 32 Rural Residents. . . . . . 33 Veterans . . . 0 . . . 33 Those With Low Incomes . . . 34 Caregivers . . . . . . 34 Policy Issues.. . . . . . . 36 Should There Be Special Programs for Dementia? . . . . . . 36 Diagnosis and Treatment. . . . 38 Legal and Ethical Concerns . . . 39 Education and Training . . . 40 Delivery of Long-Term Care . . 42 Page Biomedical Research . . . . 47 Health Services Research. ..,... . 48 Chapter 1 References . . . . 51 Tables Table No. Page l-1. Disorders Causing or Simulating Dementia . . . . . . 10 l-2. ICD-9 Codes for Disorders Causing Dementia . . . . . . 12 l-3. California State Listing of Acquired Cognitive Impairments . . . 13 l-4. Current and Projected Cases of Severe Dementia in the United States, 1980-2040 . . . . . . 16 l-5. Care Services for Individuals With Dementia . . . . . . 25 l-6. Care Settings for Individuals With Dementia . . . . . . 25 l-7. Federal Roles in Dementia Issues . 37 l-8. Federal Funding for Research on Dementia, 1976-87 . . . . 47 Figures Figure No. Page l-1. Current and Projected Cases of Severe Dementia in the United States, 1980-2040 . . . . . 3 1-2. Contribution of Elderly Age Groups to Projected Increase in Cases of Severe Dementia . . . . . . 17 l-3, 1986 Estimated Costs of Nursing Home Care . . . . . . . 18 l-4. Personal Payments for Health Care and Health Insurance. . . . 19 l-5. Out-of-Pocket Expenditures by Type of Service and Care, Estimated for 1986 . . . . . . . 28 l-6. Number of Veterans Age 65 and Over . . . . . . 33 l-7. Prevalence and Annual New Cases of Dementia, U.S. Veterans, 1980-2000. 34 PAGE 9 Chapter 1 Dementia: Prospects and Policies Disorders causing dementiathe loss of mental functions in an alert and awake individual will constitute a large and growing public health problem until well into the next century. Today, an estimated 1.5 million Americans suffer from severe dementia-that is, they are so incapacitated that others must care for them continually. An additional 1 million to 5 million have mild or moderate dementia (27). Ten times as many people are affected now as were at the turn of the century (79). The number of people with severe dementia is expected to increase 60 percent by the year 2000. Unless cures or means of prevention are found for the common causes of dementia, 7.4 million Americans will be affected by the year 2040-five times as many as today (see figure 1-1). The middle line on figure 1-1 assumes no change over time in the probability of developing severe dementia at a given age, and it does not hinge on new births but rather projects cases of dementia based on those already born. Further increases in life expectancy would increase the number of cases expected, and finding means to prevent dementing disorders would lower it. The public has only recently become aware of the problems posed by dementing illnesses. Dementia and Alzheimers disease (AD) have become household words only in the last few years. Efforts of national organizations, such as the Alzheimers Disease and Related Disorders Association (ADRDA), have emphasized the plight of families and publicized the problems faced by nationally famous individuals who have developed dementia (e.g., Rita Hayworth). The most prevalent disorder causing dementia, Alzheimers disease, has risen from relative obscurity to the cover of Newsweek magazine, the pages of Life, and prime-time television ((Do You Remember Love? a made-for-television movie aired by CBS in May 1985), One book on caring for patients with dementia, The 36-Hour Day (74), has sold over 500,000 copies, and several other books for the general public have found sizable audiences (2 1 ) 48,84). Figure 1-1 .Current and Projected Cases of Severe Dementia in the United States, 1980.2040 *r I 1 I I 1 1 1980 J 2000 2020 2040 Year SOURCE: P.S. Cross and G.J. Gurland, The Epidemiology of Dementing Disorders, contract report prepared for the Office of Technology Assessment, 1966. Interest among health and social service professionals has risen in parallel with public awareness. Medical attention to Alzheimers disease began to increase in the 1970s, catalyzed in 1976 by an editorial in a medical journal calling attention to the high prevalence and perniciousness of the disease (61) and by activities supported by various Federal research institutes (the National Institute on Aging, the National Institute on Neurological and Communicative Disorders and Stroke, and the National Institute of Mental Health). Dozens of professional books, special is3 PAGE 10 4 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias sues of professional journals, and symposia proceedings on problems related to dementia have appeared since then. Two new journalsthe American Journal of Alzheimers Care, for caregivers, and Alzheimers Disease and Associated Disorders: An International Journal, for scientists and clinical investigators-deal specifically with this topic. Professional recognition of the problems posed by dementia is also reflected in (and partly caused by) increased funding for biomedical research and training. Federally funded research on dementing conditions has increased from $3.9 million in 1976 to an estimated $67 million in 1987. Federal funding has been supplemented by support from nongovernment organizations and foundations such as ADRDA, the American Federation for Aging Research, and the John Douglas French Foundation on Alzheimers Disease. Most recently, policy makers have become concerned with problems related to dementia because of the substantial costs of dealing with the diseases, and the relatively poor financial coverage of long-term care services needed by individuals with dementia and their families (14). GOALS OF PUBLIC POLICY RELATED TO DEMENTIA Consensus on the goals of public policy related to dementia is necessary as a background for policy change. Policy goals presuppose a set of accepted premises. One such premise is that individuals with dementia should be accorded the same respect for their person that they could have expected if they had not lost mental abilities. This does not imply, however, that the same decisions will always be reacheddecisions to forgo lifesustaining treatment, for example, may be more acceptable in the presence of irreversible dementia than without it. Another common assumption is that the family has the best interests of a dependent person with dementia in mind, and the best available information about what the patient would have wished. This is not always the case, but it is a starting point for many medical, financial, and legal decisions, and puts the burden of proof on those who believe that the assumption is unwarranted in a particular case. A final assumption is that the government has some role in protecting the rights and health of an individual with dementia, although the proper degree of government involvement in financing, coordinating, and directly providing services is subject to debate. The degree to which funds should be transferred from one generation to another is an underlying unresolved issue in many public policies. Transfers within families are generally left to the individuals involved, but many government programs either directly transfer funds from one group to another (e.g., Social Security and Medicare for older Americans, and education and recreation subsidies for the young) or attempt to enforce familial responsibilities in public programs (e.g,, requiring spouses to pay expenses incurred under Medicaid). The care of dependent adults has been a traditional concern, but the aging of the population has brought out the uncertainties and lack of consensus much more forcefully in recent decades, and public policies reflect these tensions. Overall policy goals can be roughly categorized into two groups: those intended to diminish the magnitude of the problem for future generations, and those directed at ameliorating problems already facing patients with dementia and those who care for them, which are relevant now and in the next few years. The long-term goals include searching for ways to eliminate the diseases causing dementia, or at least to diminish their severity and consequences. The ultimate solution for the problem of dementia would be a technical fix-a fully effective way to prevent all dementing diseases, or a drug or surgical procedure to reverse their symptoms. There is no assurance that such a solution is possible at all, and it is certainly not likely in the next several years. That does not detract from the long-term practical benefits of supporting research, but it does suggest that it would be unwise to rely exclusively on the hope of a cure for all the diseases. A balanced pol- PAGE 11 Ch. lDementia: Prospects and Policies 5 icy will ensure support for research combined with efforts to address existing problemsto deal with those who now have dementia or will develop it before there are technical means to prevent or eradicate it. Near-term goals include training caregivers (family, volunteer, and professional), improving care practices in acute and long-term care, and devising means to pay for the catastrophic expenses brought on by dementing illness. Some policies can influence both immediate and long-term goals. Research on clinical care and service delivery, for example, can both improve current practice and assist future generations. Education raises general awareness and also improves the prospects for finding an ultimate solution. Several general short-term goals are repeatedly stressed in the literature dealing with the care of persons with dementia, although they are rarely stated explicitly. Some of these objectives are: l to preserve maximum independence of the affected individual; l to provide a continuum of carea full range of services available at different stages of illness and adaptable to changes in the individuals family, finances, and needs; l to efficiently coordinate the provision of care to maximize the match between available services and the needs and preferences of the individual and the family; l to preserve the dignity of the affected individual; l to reduce the severity of symptoms; l to treat medical problems that may worsen dementia or cause pain and suffering; l to cultivate preserved abilities and reduce the adverse effects of lost abilities; l to foster the integrity of the family and minimize family stress; and l to distribute the catastrophic costs of caring for those with dementia across the population without encouraging overuse of publicly financed services. Attaining these goals may not be possible in many cases, and consensus on how best to achieve them has proved elusive. The role of government in assuring quality and paying for long-term care, for example, is the subject of extensive debate, and current policies reflect this lack of consensus, FEDERAL POLICY PRIORITIES The Federal Government can influence the problems posed by disorders causing dementia in hundreds of ways, many of which are described in this report. Federal policy options range from direct intervention to indirect encouragement of others to act. The Federal Government can catalyze actions by State or local governments, citizens groups, or private organizations (e.g., by disseminating information about dementia, services, or methods of caring for patients). In other areas, the Federal Government has a more direct or exclusive role (e.g., support for biomedical research). The ways in which the issues arising from dementing illness are addressed will be subject to political and technical debate, but the objectives of public policy are likely to revolve around these priorities: l support for biomedical research, support for health services research, l education, l financing long-term care, l patient assessment and coordination of services, l increasing the range of services available, and l assuring quality care. Several of the priority areas overlap, and policies that affect one will necessarily have an impact on the others. Programs to educate consumers would, for example, depend on biomedical and health services for reliable information. Educated consumers would, in turn, be in a better position to assure quality care, obtain financing through existing mechanisms, plan their own finances prudently, and become knowledgeable about available services. Policies affecting financing would influence all other aspects of care because payment methods often determine the range of services made available; many observers believe, therefore, that policy change should focus first on financing. Yet no service system can work without all the pieces in place, including available PAGE 12 6 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias trained personnel and mechanisms for coordinatapproach, with greatest efforts centering on those ing services and assessing needs (whether formally areas for which the Federal Government is most or informally). responsible, is most likely to lead to improved care. Policy changes on one front will thus need to be assessed for their overall impact. A balanced ORGANIZATION The issues relating to these policy priorities are covered briefly in this chapter. Other chapters cover issues in greater detail, and contain more specific policy options, with discussions about the advantages and disadvantages of the options. Chapters 2 and 3 provide the technical background for the rest of the assessment: chapter 2 describes the symptoms and special problems related to dementing illnesses, while chapter 3 describes the diagnostic process and treatment methods for the various disorders, and briefly reviews what is known about the most prevalent disorders. Chapter 4 describes how families and other informal caregivers provide care for individuals with dementia. Chapter 5 highlights some of the difficult issues that arise when people develop dementia and can no longer make legal, financial, or medical decisions for themselves. Difficulties in making decisions about medical care are covered in much greater depth in a series of papers commissioned by OTA and reviewed at an OTA workshop. (Those papers-covering philosophical, legal, ethical, and practical aspects of making medical decisions will be published as a supplement to the Milbank Quarterly in 1987.) Chapter 6 begins the section on long-term care. It describes the general system of long-term carewhere it is provided and what it entails and leads into chapters 7 through 12, which deal with more specific aspects of long-term care, Chapter 7 reviews the emerging movement in nursing OF THE REPORT homes, day care centers, and home care services to design programs specifically for those with dementia. Chapter 8 reviews how diagnosis of dementia itself is insufficient to predict care needs, and emphasizes the difficulties in doing so. Chapter 9 covers professional staffing and training. It includes a brief discussion of physician qualifications. It emphasizes long-term care, and especially the training of nurses and nurses aides. Chapter 10 addresses the difficult issue of how to assure quality in the care provided in nursing homes and other long-term care settings. Two chapters deal with how long-term care is structured and financed for those with dementia in the United States. Chapter 11 describes how the Medicare and Medicaid programs are organized, highlighting aspects that are particularly relevant for those with dementia. Chapter 12 builds on that description and discusses the merits of various methods of paying for long-term care. It contains options for changing the financing system, including charity, various private methods, incentives for private savings, private and public insurance, tax incentives, modifications of existing public health programs, and major reform of public financing. The final chapter discusses Federal policies on biomedical research. Several other documents, based in part on activities connected with this OTA study, will be published elsewhere. These documents are listed in an appendix to this report. REASONS FOR INCREASED The new awareness of dementia can be traced to several sources, including the aging of the population, changing medical practices, and the activities of lay organizations. INTEREST IN DEMENTIA Life expectancy at birth has risen from 47.3 years in 1900 to 74.5 years in 1982 (105). More than four of every five Americans born this year can expect to reach age 65, compared with two PAGE 13 C/7. 7Dementia: Prospects and Po/icies l 7 of every five in 1900. The oldest groups are expanding most rapidly. The prevalence of severe dementia rises from approximately 1 percent (ages 65 to 74), to 7 percent (ages 75 to 84), to 25 percent (over age 85) (27). The aging of the population, particularly the rising numbers of those over 85, thus results in many more cases of dementia. Longevity among those over age 65 has also increased dramatically in the last decade (105), adding further to the number of people at risk of developing dementia. These population trends partly explain the greater public awareness of dementia. As physicians and other health professionals see more elderly patients, medical problems associated with aging receive more attention. The creation of the National Institute on Aging in 1974 (Public Law 96-296) resulted in part from greater awareness about aging. But diagnostic classifications have also changed radically. For example, the standard classification system used now for dementiathe Diagnostic and Statistical Manual of the American Psychiatric Association, 3rd edition (DSM-III)-was published in 1980. Diagnostic labeling has changed as well. In the past, neurologists and psychiatrists commonly labeled dementia beginning before age 65 as presenile dementia or Alzheimers disease. Those whose symptoms appeared after age 65 were said to have senile dementia. This distinction has largely been eliminated, with both groups of patients categorized as having Alzheimers disease or dementia of the Alzheimer type. New terminology and shifting theories of causation have unified a large number of disorders under the term dementia. Until recently, many physicians believed that dementia was usually caused by atherosclerosis (a common disease of the blood vessels, often called hardening of the arteries). Many patients were said to have cerebral arteriosclerosis (a particular form of atherosclerosis) based on insufficient evidence. (This is still a common diagnosis in many nursing homes, reflecting outmoded diagnostic practices among referring physicians.) Work done in the United States and Europe from the late 1950s to the present, however, has found that the most common type of dementia is Alzheimers disease (66 percent according to aggregate data from several studies) (64). Several forms of dementia are due to vascular disease, and as a group they constitute the second most common cause of dementia. Vascular diseases causing dementia also have been differentiated and more specifically classified. Many public organizations have formed around issues related to dementing conditions. ADRDA, for example, was created in June 1979 by several family support groups that had sprung up independently throughout the country. It has since become the largest national organization focused on dementia and the needs of caregivers. ADRDA has also played an important role in attracting media attention to the problems faced by families. There are many other national foundationsthe John Douglas French Foundation and national organizations concerned with Huntingtons disease, Parkinsons disease, multiple sclerosis, head injury, stroke, and other brain impairments that cause dementia. Some organizations deal with specific diseases while others, such as the Family Survival Project in California (83), focus on issues common to brain impairment in adults caused by a multitude of diseases. Such nongovernment organizations have helped raise public awareness of the severe problems posed by dementia. Policymakers have also become more interested in dementia, because their constituents express concern and because many problems stemming from dementia affect and are affected by government activities. Finally, the economic costs of dementing illness have caused concern to those who must pay for the care of a loved one and to government administrators and legislators concerned about spending, particularly for long-term care. Individuals with dementia constitute perhaps the largest definable population group of those who require long-term care for extended periods, and payments for long-term care under the Medicaid program account for up to 10 percent of some State budgets (14). PAGE 14 8 Losing a Million Minds: Confronting the Tragedy of A/zheimers Disease and Other Dementias POLICY INTEREST IN DEMENTIA Growing congressional interest in Alzheimers disease is reflected in the number of bills that specifically mention the conditionthree bills (having to do with designation of National Alzheimers Week) in the 97th Congress (1981 to 1982), and 26 in the 98th Congress (1983 to 1984). Several called attention to the problem by designating November as Alzheimers Disease Month, while others dealt with health care and biomedical research. During the 98th Congress, five Alzheimers disease research centers were established by the National Institutes on Aging. In the 99th Congress (1985 to 1986),38 bills were introduced. The major health care issues for patients with dementia have been more directly addressed than in previous Congresses. Another five research centers have been created, a prototype Alzheimers disease registry will soon be started, and several demonstration projects to deliver respite care will be funded. Federal executive agencies have also shown increased awareness of the problems caused by dementia. Most health and social service programs relating to this issue are administered by the U.S. Department of Health and Human Services (DHHS). In 1981, Margaret Heckler created a Task Force on Alzheimers Disease as her first act upon confirmation as Secretary of DHHS. The Task Force issued a report in 1984 (110), and continues to function under the current Secretary, Otis Bowen. In one article, then-Secretary Heckler noted: WHAT IS Dementia is a complex of symptoms that can be caused by many different underlying diseases. The process of classifying dementia requires that symptoms be identified and carefully assessed before the underlying disease or condition causing the dementia is diagnosed. Symptoms of Dementia Although loss of recent memory is its hallmark, the term dementia implies global impairment of mental functions. The symptoms can include loss of language functions, inability to think abstractly, The cost of AD is very high. Many Alzheimers patients are maintained in family homes. The total cost for nursing homes alone is estimated at over $13 billion per year; by 1990 that figure could exceed $41 billion. But the financial cost is in many ways secondary to the real toll that Alzheimers exacts. This disease robs society of the contribution of productive individuals with a wealth of accumulated wisdom and life experience. It also pulls into its eddy friends and family members who give up their own pursuits to look after their afflicted loved ones (46). The Veterans Administration (VA), military health services, and Indian Health Service are also concerned with dementia, because these agencies deliver health and social services to eligible populations, either directly or under contract to other providers. State governments have shown interest in the problems of dementia as well. At least 21 States have major legislative initiatives, including over 80 bills on Alzheimers disease (at least 20 of which became State laws in 1985 and 1986) (3,36,55). Several others have made administrative changes in the absence of new legislation. Some States (e.g., California, Maryland, Kansas, Texas, Minnesota, Rhode Island, and Illinois) have developed carefully planned and widely publicized approaches to problems of dementia. DEMENTIA? inability to care for oneself, personality change, emotional instability, and loss of a sense of time or place. Dementia is different from mental retardation because it indicates a loss of previous abilities. (Those with mental retardation have below average mental ability rather than a loss of previous capabilities; they can also develop dementia if their abilities decline further.) Dementia differs from delirium because delirium is associated with diminished attention or temporary confusion. Delirium implies a tran PAGE 15 Ch. lDementia: Prospects and Policies 9 Photo credit: Office of Technology Assessment S (upper left) goes to the Family Respite Center in northern Virginia for day care (lower left). He is a graphic artist who now has Alzheimers disease. When asked to draw the hand pictured at bottom right, he draws the picture seen in the upper right. Ss drawing is smaller than the model and shows distortion of spacial relationships, incorrect counting of fingers, and misplacement of fingernails. Such errors are typical of those due to damage to the brain caused by Alzheimers disease. sient loss of mental abilities, as during intoxication or following acute head injury. It is not always easy to distinguish dementia from retardation or delirium, particularly among the very old or those about whom there is little available medical information. But differences are usually clear, and diagnostic classification relies on maintaining the distinctions, Disorders Causing Dementia More than 70 conditions can cause dementia (63). Identifying the symptoms leads to a search for the causethe process of diagnosis. The disorders covered in this report (see table 1-1) can be classified into several groups. Degenerative disorders are diseases whose progression cannot be arrested. The ultimate cause of most such diseases is not known, and these disorders cause progressive deterioration of mental and neurological functions, often over years. Alzheimers disease is by far the most prevalent degenerative dementia, found in 66 percent of all cases (64). The remaining disorders in table 1-1 are listed by cause. A few of them can be reversed following treatment, but truly reversible dementia occurs in only 2 to 3 percent of cases (64,80). In most cases, dementia is stable or progressive (although the severity PAGE 16 10 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Table 1-1 .Disorders Causing or Simulating Dementia Dlsorders causing dementia: Degenerative diseases: Alzheimers disease Picks disease Huntingtons disease Progressive supranuclear palsy Parkinsons disease (not all cases) Cerebella degenerations Amyotrophic lateral sclerosis (ALS) (not all cases) Parkinson-ALS-dementia complex of Guam and other island areas Rare genetic and metabolic diseases (HallervordenSpatz, Kufs, Wilsons, late-onset metachromatic Ieukodystrophy, adrenoleukodystrophy) Vascular dementia: Multi-infarct dementia Cortical micro-infarcts Lacunar dementia (larger infarcts) Binswanger disease Cerebral embolic disease (fat, air, thrombus fragments) Anoxic dementia: Cardiac arrest Cardiac failure (severe) Carbon monoxide Traumatic dementia: Dementia pugilistic (boxers dementia) Head injuries (open or closed) Infectious dementia: Acquired immune deficiency syndrome (AIDS) AIDS dementia Opportunistic infections Creutzfeldt-Jakob disease (subacute spongiforn encephalopathy) Progressive multifocal Ieukoencephalopathy Post-encephalitic dementia Behcets syndrome Herpes encephalitis Fungal meningitis or encephalitis Bacterial meningitis or encephalitis Parasitic encephalitis Brain abscess Neurosyphilis (general paresis) Normal pressure hydrocephalus (communicating hydrocephalus of adults) Space-occupying lesions: Chronic or acute subdural hematoma Primary brain tumor Metastatic tumors (carcinoma, leukemia, Iymphoma, sarcoma) Mu/tip/e scierosis (some cases) Auto-immune disorders: Disseminated lupus erythematosis Vasculitis Toxic dementia: Alcoholic dementia Metallic dementia (e.g., lead, mercury, arsenic, manganese) Organic poisons (e.g., solvents, some insecticides) Other disorders: Epilepsy (some cases) Post-traumatic stress disorder (concentration camp syndromesome cases) Whipple disease (some cases) Heat stroke Disorders that can simulate dementia: Psychiatric disorders: Depression Anxiety Psychosis Sensory deprivation Drugs: Sedatives Hypnotics Anti-anxiety agents Anti-depressants Anti-arrhythmias Anti -hypertensives Anti-convulsants Anti-psychotics Digitalis and derivatives Drugs with anti-cholinergic side effects Others (mechanism unknown) Nutritional disorders: Pellagra (B-6 deficiency) Thiamine deficiency (Wernicke-Korsakoff syndrome) Cobalamin deficiency (B-12) or pernicious anemia Folate deficiency Marchiafava-Bignami disease Metabolic disorders (usually cause delirium, but can be difficult to differentiate from dementia): Hyperand hypo-thyroidism (thyroid hormones) Hypercalcemia (calcium) Hyperand hypo-natremia (sodium) Hypoglycemia (glucose) Hyperlipidemia (lipids) Hypercapnia (carbon dioxide) Kidney failure Liver failure Cushing syndrome Addisons disease Hypopituitarism Remote effect of carcinoma SOURCE: Adapted from R. Katzman, B. Leaker, and N. Bernstein, Accuracy of Diagnosis and Consequences of Misdiagnosis of Disorders Causing Dementia, contract report prepared for the Office of Technology Assessment, US: congress, 19SS. can often be reduced by treating other medical Alzheimers disease is marked by distinctive problems that exacerbate the symptoms), Alchanges and loss of nerve cells that can be dethough the diseases causing dementia are gener tected microscopically in brain tissue. The term ally not reversible, they are treatable. Treatment may actually refer to a group of diseases with pos for most cases centers on minimizing the effects sibly different causes and perhaps distinguished of the illness rather than attempting to return to by their symptoms, rate of progression, innormal mental function. heritance patterns, and age at onset. These are PAGE 17 Ch. lDementia: Prospects and Policies l 1 1 grouped under one term because scientific understanding has not progressed sufficiently to distinguish them. Dementia caused by disease of the blood vessels (vascular dementia) accounts for the second largest number of cases in most studies, although the interpretation of such studies is being reevaluated to ascertain the degree to which vascular disease itself can cause dementia. It is clear, however, that vascular disease may worsen the symptoms of dementia. Some cases of dementia can be prevented: Toxic dementias and those caused by infections are clear examples. Once the brain is structurally damaged, however, dementia from these causes is usually permanent. Disorders that can simulate dementia, in contrast, include conditions for which treatment may eliminate dementia. Treatment of these can be instituted in order to restore mental function. Dementia will not invariably disappear with treatment, but it is more likely to do so than for diseases in the other categories. The difference between these diseases and the first category of disorders is the rapidity of improvement and the higher likelihood of complete recovery of mental functions. There is substantial overlap in the categories. Many older people suffering from depression, for example, show signs of dementia. Some reports have found that as many as 31 percent of those thought to have dementia have depression instead (94). Yet the rate of misdiagnosis is not as high today, because physicians have become more sophisticated in separating the various types of dementia and differentiating this condition from other mental symptom complexes. Those thought to be misclassified as depressed have been studied years later and found to be at much higher risk of eventually developing obvious dementia suggesting they had an underlying dementia at the time of misclassification (64). One author notes the continuum from normal mental function to severe dementia including intermediate points such as forgetfulness, at risk of dementia ) and various severities of clinical dementia (62). The overlap between disorders that cause dementia and those that simulate it cannot always be clearly defined with current medical knowledge, and it is sometimes difficult to pinpoint where individuals are on the continuum of mental capacity. Scientific discoveries might shift any one of the degenerative disorders into another category if a cause were found or a treatment discovered that could halt the loss of brain cells. The categories suggested in table 1-1 are intended to clarify and highlight conceptual distinctions rather than to imply that diseases fall neatly into separate categories. The distinctions among disease categories are nonetheless important for several reasons. Those with Alzheimers disease (with or without other conditions) constitute a large portion of patients with dementia. At present there is no cure, and treatment focuses on changing the environment and adapting caregiver behavior to meet the needs of patients, rather than on curing the dementia through medication or surgery. Making the specific diagnosis of Alzheimers disease precludes certain types of therapy, and also highlights the need to begin training caregivers about what to expect and how to deal with the expected worsening dementia. Diagnosis is therefore important in informing families about what to expect, but it is not sufficient to determine care needs without also assessing family support, severity of the disease, and the individual patients symptoms. Decisions about medical care, social services, and family expectations all hinge on accurate diagnosis. The diagnosis of dementing illnesses will be the topic of a consensus development conference at the National Institutes of Health July 6-8, 1987. Public policy priorities differ for those whose dementia can be eliminated. The paramount need of such patients is for accurate diagnosis and appropriate treatment, both of which are aspects of acute medical or mental health care. Public policies to identify these patients can reduce the number misdiagnosed with irreversible dementia and wrongly channeled into long-term care (64). The number of individuals with dementia whose symptoms can be treated and eliminated is estimated at 2 (80) to 3 percent (64), and the costs of unnecessarily providing long-term care for them are likely to offset the costs of diagnosis for all cases of dementia (64). Policy issues related to disorders causing progressive dementia, on the other hand, center on appropriate long-term care for those PAGE 18 . 12 Losing a Million Minds: confronting the Tragedy of Alzheimers Disease and Other Dementias Table 1-2.ICO.9 Codes for Disorders Causing Dementia 094 094.1 290.0 290.1 290.2 290,3 290.4 291 291.1 291.2 294 294.0 294.1 294.8 294.9 310 310.1 310.9 331 331.0 331.1 331.2 331.3 331.5 331.6 331.7 331.8 331.9 333 333.4 437 437.0 437.1 437.2 797 Neurosyphilis General paresis Sanile and presenile organic psychotic conditions Senile dementia, simple type Presenile dementia Senile dementia, depressed or paranoid type Senile dementia with acute confusional state Arteriosclerotic dementia Alcoholic psychoses Korsakovs psychosis, alcoholic Other alcoholic dementia Other organic psychotic conditions (chronic) Korsakovs psychosis, nonalcoholic Dementia in conditions classified elsewhere Other chronic organic psychotic conditions Unspecified chronic organic psychotic conditions Specific nonpsychotic mental disorders following organic brain damage Nonpsychotic cognitive or personality change following organic brain damage Unspecified nonpsychotic mental disorders following organic brain damage Other cerebral degenerations Alzheimers disease Picks disease Senile degeneration of the brain Communicating hydrocephalus Creutzfeldt-Jakob disease Progressive multifocal Ieukoencephalopathy Cerebral degeneration in other disease elsewhere classified Other cerebral degeneration Unspecified cerebral degeneration Other extrapyramidal disease and abnormal movement disorders Huntingtons chorea Other and iii-defined cerebrovascular disease Cerebral atherosclerosis Other generalized ischemic cerebrovascular disease Hypertensive encephalopathy Senility without mention of psychosis Any patients have dementia, but category also includes some without demerit/a: 279 Disorders involving the immune mechanism 279.19 Acquired immune deficiency syndrome (AIDS dementia) 290 290.8 290.9 323 323.0 323.1 323.2 323.3 323.4 323.5 323.6 323.7 323.8 323.9 332 333 333.0 438 Senile and presenile organic psychotic conditions Other senile/presenile organic psychotic conditions Unspecified senile/presenile organic psychotic conditions Encephalitis, myelitis and encephalomyelitis Kuru Subacute sclerosing panencephalitis Poliomyelitis Arthropod-borne viral encephalitis Other encephalitis due to infection Encephalitis following immunization procedures Postinfectious encephalitis Toxic encephalitis Other Unspecified cause Parkinsons disease Other extrapyramidal disease and abnormal movement disorders Other degenerative disease of the basal ganglia Late affects of cerebrovascular disease already affected, and on research to identify new treatments or means of prevention. A different way to classify disorders causing dementia is found in the International Classification of Diseases (see table 1-2) (56). That system, called ICD-9, is used to code diagnoses in most hospitals and clinics, and is the starting point for diagnosisrelated group reimbursement under Medicare. The classification is well adapted for many specific disorders. No specific code exists for several disorders, however, and a large number of diagnostic categories that include many persons with dementia (e.g., someone with Parkinsons disease) do not separate individuals with dementia from those without it. Many diseases listed in table 1-1 do not have ICD-9 codes, and individuals with them would be classified in nonspecific categories. These shortcomings limit the usefulness of ICD-9 in refining epidemiologic studies because it is impossible to specify only those persons who have dementia. The State of California recently reviewed the various systems of nomenclature for dementing disorders (70). The analysts suggested grouping disorders under a new broad category acquired cognitive impairment) according to the subcategories noted in table 1-3. The confusion over terminology may be reduced if revisions of the two most widely used diagnostic classifications are made compatible. Revision of the ICD-9, to be called ICD-10, is scheduled for 1989. DSM-III is a set of guidelines for making diagnosis of mental disorders (7). It is the most widely used classification for the symptoms of dementia, and its criteria have been used in most recent studies. The revision of DSM-III will be called DSM-IV and will likely be made available after release of ICD-10. The two classifications are promised to be more compatible than DSM-III and ICD-9 (70). SOURCE: Irrtematlonal Claaaiflcation of Dkeaaes. 9th Revision Conference. 1975 (Geneva: World Health Organization), vol. 1, 1917-&d vol. 2, 1978: rn&ified by Cod/rrg C/in/es for /CD-9 CM, American Hospital Association, various Issues. PAGE 19 Ch. lDementia: Prospects and Policies 13 Table 1.3.California State Listing of Acquired Cognitive Impairments Primary (cortical) degenerative dementiasDSM-III: Alzheimers disease Picks disease Degenerative dernentias with involvement of motor systems. Amyotrophic lateral sclerosis Cerebella degenerations Guam-Parkinson-dementia complex Huntingtons disease Parkinsons disease Progressive supranuclear palsy Other rare disorders: including Hallervorden-Spatz disease, Kufs disease, Wilsons disease, metachromatic leukodystrophy, adrenoleukodystrophy Vascular: Binswanger disease Cerebrovascular accident: including hemorrhage, stroke, aneurysms (recent and past) Cortical microinfarcts Lacunar infarctions Multi-infarct dementia Postanoxia or postischemiadue to: Carbon monoxide Cardiac arrest Strangulation, asphyxiation, or suffocation Traumatic: Intracranial injury without skull fracture: open and closed Intracranial injury with skull fracture: open and closed Fat embolism Post-traumatic brain syndrome: non psychotic psychotic Auto-immune: Disseminated lupus Multiple sclerosis Primary CNS vasculitis Central nervous system infections: AIDS (primary or opportunistic infections) Behcet syndrome Creutzfeldt-Jakob disease Encephalitis, herpes simplex Fungal, parasitic, and chronic bacterial meningitis, abscesses, and granuloma Neurosyphilis Postencephalitic dementia Progressive multifocal Ieukoencephalopathy Hydrocephalus, adult onset (normal pressure) Space-occupying lesions: Hematomas: including subdural, epidural, and intracerebral Metastatic carcinoma, Iymphoma, leukemia Primary brain tumors Toxic dementias: Alcoholic dementia Drugs: including neuroleptics, diazepam-related hypnotics, anticonvulsants, beta blockers, digitalis Korsakoffs syndrome Metallic poisons: including lead, mercury, arsenic, manganese Organic poisons: including solvents, organophosphates Psychiatric illness presenting as dementia: Chronic schizophrenia Conversion disorder Depression Ganzers syndrome Paranoia Nutritional disorders: Marchiafava-Bignami disease Pellagra Thiamine deficiency (Wernicke-Korsakoff syndrome) Vitamin B-12 or folate deficiency Metabolic disorders: Addison disease Cushing syndrome Hepatic failure Hypercalcemia Hypercapnia Hyperlipidemia Hypoglycemia Hypeand hyper-thyroidism Hypopituitarism Hypeand hyper-natremia Remote effects of carcinoma Uremia Sensory deprivation (agnosia) Other disorders Concentration camp syndrome Epilepsy Heat stroke Whipple disease SOURCE D.A. Lindeman, N.G. Bliwise, G. Berkowitz, et al., Development of a Uniform Comprehensive Nomenclature and Data Collection Protocol for Brain Disorders, Institute for Health and Aging, University of California, San Francisco, June 1986. COURSE OF THE ILLNESSES The course of a dementing illness varies from at work (rather than by a physician). Although one person to another as well as among the differsome disorders appear suddenly, mostincluding ent disorders. A few generalizations can be made, Alzheimers diseaseare insidious. People lose however, about progressive dementing illnesses. some mental ability, usually memory, or begin to Onset is usually noticed by the person with the show poor judgment or incompetence at work. disorder, family members, friends, or colleagues They often succeed in hiding their symptoms for PAGE 20 14 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias months or even years (if symptoms are mild), but the disability eventually becomes serious enough to merit medical investigation. A physician is typically consulted by the individual or family, initiating the diagnostic process. If the indvidual is seen early by a physician knowledgeable about dementia, the first visit will result in the scheduling of appropriate tests or referral to another specialist (usually a neurologist or psychiatrist) who will direct and monitor the use of diagnostic tests. An estimated 80 percent accuracy in diagnosis can be obtained through medical history and physical examination, while 90 percent accuracy can be achieved when these are supplemented by a battery of psychological and laboratory tests and by radiological examinations (63). Once diagnosis is completed, treatment can be started for some dementing conditions (and any other medical conditions detected during diagnostic evaluation). Medications may assist in managing some symptoms (93), the progression of which can be slowed or arrested in a few cases. The focus of most medical management, however, is family education training caregivers to adapt to the patient, simplifying the individuals living space, and referring relatives to family support services (121,122). Current medical management of dementia is based largely on anecdotal reports and clinical impressions rather than on solid data, since there have been relatively few clinical investigations (122). Drug treatment to improve intellectual function and memory has been a topic of intense investigation, but results have not yet shown clinically significant improvement. Drug management of behavioral disorders can benefit patients and ease the burden for caregivers, but it must be carefully planned and monitored (93,122). Diagnosis and treatment can continue for several years. Repeated visits for evaluation may be necessary to establish a final diagnosisparticu larly for cases of early dementia, unusual progression, or atypical symptoms. Treatment, including medication, may be changed from time to time in response to changing needs or adverse drug effects. An individual with dementia also often requires intermittent medical care for other illnesses. Because dementia is most prevalent among the very old, and because the very old are at risk of multiple medical disabilities, it is common for those with dementia to require attention for diseases of the heart, lungs, kidneys, or other organs. Their mental incapacity also places them at increased risk of falls, mistakes in medication, and household accidents. Individuals with dementia frequently need dental care. Those with dentures often lose them or break them; those with other dental problems may not become aware of them until they have become serious or caused undue pain. Most dementing conditions last years, often decades. One recent study found the average duration of illness, from first onset of symptoms to death, was 8.1 years for Alzheimers disease and 6.7 years for multi-infarct dementia (9). The time from diagnosis to death averaged 3.4 years for Alzheimers disease and 2.6 years for multi-infarct dementia, suggesting that patients typically show symptoms for over 4 years before a diagnosis is made. Recent improvements in professional education and increased public awareness may eventually shorten this period. The duration of a dementing illness is unpredictable, howeverAlzheimers disease can last up to 25 years. Patients with dementia generally die of some other illness (17)18)) and dementia is associated with increased overall mortality (64). Alzheimers disease is often cited as the fourth leading cause of death in the United States (although not reflected on death certificates or in official statistics). Such statements assume that each year the number of new cases roughly equals the number of deaths of those with Alzheimers disease (see discussion in ref. 79), and that shortened life expectancy is related to the presence of Alzheimers diseaseboth untested assumptions. Mortality caused by dementing conditions is, in any case, not the only consideration; of equal or greater concern are deterioration of valued human mental capacities, loss of autonomy, and catastrophic expenses caused by the ensuing need for longterm care. Long-term care refers to medical, mental health, and personal services rendered to those with diminished capacity for self-care due to illness. Brain damage caused by a disease process results PAGE 21 Ch. 1Dementia: Prospects and Policies l 15 in loss of mental functions and dependency on others. Long-term care is often needed from the beginning of the disease, and can precede diagnosis. Individuals needs differ markedly. Some remain at home throughout the illness, while others benefit from day care or nursing home placement soon after symptoms are noted. Recent research has shown that the use of formal services is, in fact, more strongly correlated with characteristics affecting the person most responsible for taking care of someone with dementia than with severity of symptoms or other characteristics of the ill individual (23). Yet there would be no dependency on a caregiver if not for the illness. Since all individuals with dementia eventually become dependent (if their disease runs full course), they all require long-term care. Individuals typically need long-term care from onset to death, although the degree to which formal services are used varies. Most families keep someone with dementia at home for as long as possible, often despite extreme cost, health risk, and stress to themselves (12,20,23,37,124). Two general hypotheses about long-term care for persons with dementia are important to public policy, but their validity has not been confirmed. One posits that care needs intensify as the disease worsens until the afflicted person dies. The other suggests that most of the caregiving burden is due to changes in behavior and personality. As the dementia worsens, behavioral problems diminish as the individual becomes weaker, less mobile, and eventually mute. If the second hypothesis were correct, the need for care would be greatest at midcourse of the illness, and services to support families through the worst periods might forestall institutional placement. The complex interactions between the affected persons symptoms and stresses affecting the caregiver and family are equally important in predicting a need for formal long-term care services, but the crucial factors are only now being studied. The concept of a smooth progression of illness and dependency caused by it is illusory, with large variations in types of symptoms, rapidity and severity of progression of disease, and strength and resilience of informal supports. Those with dementia generally die after years of being dependent on others for their care. The cause of death is usually a disease of a different organ systempneumonia, heart disease, or kidney failure, for example. These individuals are logical candidates for hospice care in their last months, with an emphasis on allaying pain and suffering rather than prolonging life. Autopsy following death is often the only means of confirming what disease the person had, but the rate of autopsy in the United States has fallen dramatically, and an accurate diagnosis may never be ascertained. Failure to confirm a diagnosis at autopsy can interfere with accurate genetic counseling and analysis of the efficacy of medical care. MAGNITUDE OF THE PROBLEM The problems posed by disorders causing dementia will increase as the population ages and more people either develop a dementing disorder themselves or must care for a relative or friend. The magnitude of the problem can be gauged by projecting the number of people likely to be affected (the prevalence of dementia), estimating the costs of caring for those who now have dementia, and assessing some of the indirect burdens. Prevalence of Dementia Dementia can be divided into several categories by severity and type. Studies over the past several decades have varied widely in reported prevalence rates. These variations can be attributed to the different age groups studied, the inclusion or exclusion of people in long-term care facilities, degree of severity involved, methods of assessing mental function, or other sample characteristics. Most studies conducted since 1980 have followed DSM-III criteria (7), dramatically reducing the degree of variation from study to study (64). Recent studies show a relatively narrow range of prevalence of severe dementia, from 5 to 7 percent of those over 65, with a median of 6.5 percent (27). Although the criteria for severe dementia vary from study to study, the degree of PAGE 22 16 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias variation for this category is much less than if mild and moderate cases are also included. The extreme variation of results on mild and moderate cases makes projections of future prevalence impossible. Further, those with mild and moderate dementia in community studies are those about whom there is the greatest possibility of diagnostic error. For these reasons, projections of cases have been done only for severe dementia (see table 1-4). The total number of all cases can be estimated from these studies by assuming that for each case of severe dementia, probably at least one person and possibly up to three people have milder dementia and will eventually develop severe dementia if they live long enough. Prevalence is most often reported as a percentage of people age 65 or older affected at a particular time. Average prevalence figures mask significant differences among different age groups. As noted earlier, the prevalence of severe dementia among those 65 to 74 is roughly 1 percent, compared with 25 percent for those over 84 (27). Some authors have used the terms epidemic and rising pandemic to describe the projected increase in prevalence of dementia. Use of such terms is subject to misinterpretation, however, because of their associations with uncontrolled infection. Although the number of people with dementia will rise substantially over the next several decades, it will not do so explosively. (One demenTable 1-4.Current and Projected Cases of Severe Dementia in the United States, 1980-2040 (thousand cases) Age group 1980 2000 2020 2040 Under 65 . . . . . 78 88 150 150 65-74 . . . . . . 160 180 300 290 75-84 . . . . . . 550 860 1,000 1,700 Over 85 ...., . . . . 570 1,300 1,800 5,200 Total cases. ................1,400 2,400 3,300 7,30 0 ~heaa projections are based on prevalence of severe dementia of 1 percent ages 65 to 74, 7 percent 75 to 84, and 25 percent 85 and over (Cross and Gurland, 1966). Cases under 85 have been estimated as follows: the 75,000 current cases (Mortimer and Hutton, 1985) under age 80 correspond to 48 percent of cases in the next oldest cohort (ages 65 to 74) (Cross and Gurland, 19S6). Projections of future cases under 65 have been conservatively calculated as 50 percent of cases in the 65 to 74 cohort, for simplicity and to account partially for those aged 61 to 84. Another method wouid be to use the estimated 13.5 per 100,000 prevalence estimate among those 30 to 59 (Kokman, 1984, as cited in Mortimer and Hutton, 1975), but this is more complicated end more subject to error due to the shifting age structure within this very large age group. The table yieids estimates of cases under age 65 at the conservative end of the range reported (5 to 10 percent of all casesCross and Gurland, 1988). SOURCES: P.S. Cross and B.J. Gurland, The Epidemiology of Dementing Disorders, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1988. tia, associated with acquired immune deficiency syndrome, is epidemic, but uncertainties about its prevalence, reversibility, and mortality preclude accurate projections.) Vascular dementia may drop in prevalence, paralleling the decline of stroke and hypertension. The prevalence of Alzheimers disease, because it accounts for the largest number of cases, will largely determine the overall prevalence of dementia. Alzheimers disease is expected to rise slowly in prevalence, in tandem with aging of the population. Studies show general agreement on the overall prevalence of severe dementia among the population 65 or older, but substantial uncertainty exists about mild and moderate dementia, the oldest age group, ethnic and racial subgroups, nursing home populations, and subtypes of dementia. Some data, for example, suggest that the risk of developing dementia after age 84 begins to decline (79); other data do not support that hypothesis (97), That could be due to real decline, inadequate reporting (since dementia is expected in the very old and therefore not recorded), or insufficient sampling of the very old cohort. Many of these groups about which there is little information are among those expanding most rapidly (see figure 1-2). Policy planning will thus require rigorous investigation of prevalence rates among the very old, minority groups, and nursing home residents, Costs of Dementia Although the exact costs of dementing illness to the Nation cannot be calculated, all agree that they are already high and bound to rise at least in proportion to the expected increase in prevalence. The many studies of costs noted in this section do not provide estimates that are sufficiently accurate and reliable to permit refined policy planning, but they are a starting point for analysis of spending for different services. Policies that affect the largest spending categories (informal care and long-term care) are those accorded high priority by caregivers as well as those concerned about government spending. Overall Costs Two studies have attempted to estimate the overall costs to the Nation of caring for those with PAGE 23 Ch. lDementia: Prospects and Policies l 1 7 Figure 1-2.Contribution of Elderly Age Groups to Projected Increase in Cases of Severe Dementia 4 r I 65-74 1. I J 1980 2000 2020 2040 Year SOURCE: P S Cross and G.J Gurland, The Epidemiology of Demential Disorders, contract report prepared for the Office of Technology Assessment, 1986 dementia. The National Institute on Aging (NIA) sponsored a study that estimated total costs of just over $38 billion in 1983 (51). That study attempted to estimate only those costs exclusively due to dementia, but the projections (particularly those for the largest cost components) were contingent on small pilot studies. A review of these cost estimates, prepared for the State of California, concluded that costs of dementia were large but could not be precisely defined (75). A Battelle Memorial Institute study commissioned by OTA estimated $24 billion to $48 billion total costs (projected to 1985) (10). That study, too, tried to estimate only the costs specifically due to dementia, but it used different projection methods for estimating community and nursing home costs for long-term care. The estimates from these studies are similar in range, but they can be misinterpreted, Both the NIA and Battelle studies estimate costs of diagnosis, treatment, nursing home care, informal care, lost wages, and other indirect costs. Each component is large but cannot rigorously be projected, due to the paucity of relevant information, not study design. In addition to studies of overall costs, some researchers have estimated costs related to dementia stemming from diagnosis, medical treatment, nursing home care, and informal long-term care; these are discussed below. Costs of Diagnosis The costs of diagnosis can be estimated by assuming that 200,000 new cases of severe dementia will occur each year, and that at least as many mild and moderate cases will come to the attention of physicians for diagnostic evaluation. The estimated incidence of 200,000 is calculated by assuming 1.5 million affected people (27) and 7.5 year average duration, based on the average from one recent survey (9). That estimate is conservative, because it is based on figures at the low end of prevalence estimates, assumes only one diagnostic evaluation per case, and neglects those persons who are evaluated for dementia but are not found to have a dementing illness. The cost of diagnosis per case depends on the number of times a patient must be seen (the patient may need periodic reevaluation if dementia is mild or presents atypically), local medical costs, and whether the diagnostic testing is done on an outpatient or inpatient basis (i.e., during repeated clinic visits or in the hospital). outpatient diagnosis entails an estimated $1,000 to $2,000 for physician charges, laboratory tests, neuropsycholog ical testing, brain imaging studies, and ancillary services (64). Costs for the laboratory tests alone can range from about $154 to about $1,110 per patient (65). Those figures suggest that it costs at least $4 OO million to $800 million each year nationwide to diagnose disorders causing dementia. The Medicare programs costs for inpatient diagnosis differ according to geographic location, type of hospital, and discharge diagnosis. A hospital discharging a patient with the diagnosis of Alzheimers disease would be reimbursed from $6,8oo to $7,200 in most areas (87). If all cases were diagnosed following a single hospitalization, the national cost of diagnosis would be approximately $2.8 billion. Although no data show whether inpatient or outpatient diagnosis is more common, a survey of caregivers commissioned by OTA for this assessment did find that 30 percent of patients had never been hospitalized (123). Diagnosis in a hospital could have been done on a maximum PAGE 24 18 Losing a Mi//ion Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias of 70 percent, although the number is likely much lower because most hospitalizations would be for purposes other than initial diagnosis of dementia. Hospital admission for diagnosis is not the norm in most centers; physicians who see many patients with dementia report that inpatient diagnosis is performed only for a small minority of patients. In fact, diagnosis as the sole reason for hospital admission would likely be disallowed for reimbursement under Medicare except in rural areas or special circumstances. Diagnosis is thus largely done on an outpatient basis, with attendant costs in the outpatient range rather than the much higher estimate for inpatient diagnosis. Given all the uncertainties, a firm figure for cost of diagnosis cannot be stated. A reasonable estimate for the national cost of diagnosis would be $500 million to $1 billion each yearhigh, but relatively small compared with long-term care costs. The diagnostic process is more likely to be covered by Medicare and private health insurance than long-term care is, and therefore requires smaller out-of-pocket payment by patients. Costs of Drugs and Medical Services After Diagnosis Once a diagnosis is made, medical management of patients with dementia requires continued visits to physicians, drug treatment of behavioral symptoms and ancillary medical problems, mental health services, and intermittent hospital care for concurrent illnesses. One study estimated these medical costs due to dementia at just over $10 billion in 1983 (51). Another study did not specify costs in dollars, but found that those with dementia were more likely to die during a hospital admission, had longer lengths of hospital stay, and were more likely to be discharged to a nursing home or require home assistance. The study also reported that: ,. Cognitive impairment at the time of admission may be regarded as a marker for sicker, less stable, more clinically complex patients. Such patients can be expected to fare worse than their mentally intact counterparts and to require more intense social service support if they survive to discharge (31). Costs of Nursing Home Care In 1984, total national expenditures for nursing home care reached $32 billion; for 1986, the estimate is $38.9 billion (8). The 1986 estimate includes $19.5 billion from individuals (50 percent), $500 million from insurance (1.3 percent), $10.4 billion in Federal funds (27 percent), $8.2 billion in State and local payments (21 percent), and $3 OO million (0.8 percent) from other sources (8) (see figure 1-3). Medicaid was the single largest payer for nursing homes (29). In 1980, Medicaid accounted for more than three-quarters of the total spent on long-term care under the six largest Federal programs (the other five are Medicare, Older Americans Act programs, State supplements to income, Title XX funds, and VA programs) (22). Nursing home care is a small part of Medicare, and the services covered are restricted to short stays after hospitalization. Nursing home payments under Medicare were only $600 million of $64.6 billion total Medicare outlays in 1984 (8), and accounted for 1.9 percent of the total spent nationwide on nursing home care. Nursing home payments surged from 1.7 percent of all health care expenditures in 1950 to 5.8 percent in 1965, and then to an estimated 9.7 percent in 1986 (8). Health care costs are significant, Figure l-3. 1986 Estimated Costs of Nursing Home Care (biiiions of doilars) Insurance 0.5 (1.30/o) Other 0.3 (0.8/0) Total = $38.9 billion SOURCES: R.H. Arnett j D.R. McKusick, S.T. Sonnefeld, et al., Projections of Health Care Spending to 1990, Hea/fh Care FInanclng Review 7:1-36, spring 1988. PAGE 25 Ch. lDementia: Prospects and Policies 19 Figure l.4. Personal Payments for Health Care and Health Insurance 45 40 35 30 25 20 15 10 5 0 41.7 15.7 65-69 70-74 75-84 85+ Age SOURCE: ICF, Inc., The Role of Medicare in Financing the Health Care of Older Americans, submitted to American Association of Retired Persons, July 1985, table 21, adapted by the Office of Technology Assessment. especially for older Americans (see figure 1-4). Among those over 64, fully 9.9 percent of their expenditures go for health care (compared with 2.6 percent for those under 25, and 5.4 percent for those 55 to 64) (11). The difference is even more dramatic within the older age group, One study estimated out-of-pocket expenditures for health care and health insurance at 6.5 percent of income for those 65 to 69, compared with 15.7 percent for those 75 to 84, and 41.7 percent for those over 85 (54, table 21). The proportion of these expenditures directly caused by dementing illness is not known. The National Nursing Home Survey of 1977 found that 57 percent of nursing home residents had (chronic brain syndrome or senility (112, table 8) as noted by nursing home staff. Most people in these categories likely had what would now be called dementia, although some older adults with mental retardation might also have been misclassified as chronic brain syndrome. A recent sample of people admitted to nursing homes in Texas showed that 40 to 60 percent had diagnoses indicating dementia (103). A sample of 3,427 residents of 52 New York State nursing homes found 41 percent had diagnoses indicating dementia or extensively overlapping with it (32). Both samples used the admitting diagnosis (the accuracy of which depends on the quality of prior medical evaluation and varies widely from site to site) and are likely low for two reasons. First, dementia is commonly missed, especially in the very old, because it is expected, even by many physicians. Second, physicians wishing to facilitate nursing home placement are often willing to list other diagnoses rather than dementia because nursing homes may be less willing to admit dementia patients (58). Researchers at Johns Hopkins Medical School recently undertook the most reliable study to date, but it is small and preliminary. A research team performed thorough diagnostic investigations of 50 residents of a proprietary nursing home in Baltimore. The study found 39 (78 percent) had a dementing condition (an additional 7 residents had other mental diagnoses) (95). More studies of nursing home populations that include rigorous diagnosis could shed light on these disturbingly high figures, Several studies of dementing illness assume that costs can be calculated by taking the proportion of nursing home residents with dementia and multiplying by the overall costs of long-term care. That assumes that all long-term care for individuals with dementia is caused by their dementia, an assumption that creates many potential inconsistencies. One problem is best explained by analyzing an even larger disabled populationthose with arthritis. Symptomatic arthritis is roughly three times more prevalent than severe dementia in the population over 64. Its prevalence in nursing homes approximates that of dementia (112). Cost estimates that assumed arthritis caused nursing home placement would thus yield figures as high as those for dementia. Yet each disorder cannot account for half of all costs. Similar analyses could be done for residents with partial deafness, visual impairment, or incontinence, each highly prevalent in nursing home populations. The difficulty PAGE 26 20 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias in determining why an individual needs personal or nursing services limits the interpretation of simple cost projections. Although it is more plausible that dementia directly causes institutional placement more than arthritis does, no study has confirmed this. The rigorous costs studies that can be performed (as in the case of incontinence, for example) (82) presume carefully constructed models of care that do not exist for individuals with dementia. As a result, the fraction of nursing home costs due to dementia have not been estimated reliably. Yet cost projections for such care are important in considering policy changes that would promote delivery of services to persons with dementia, Information about costs and use rates for services would thus be quite useful for determining longterm care policy. One study attempted to estimate the costs of nursing home care due directly to dementia, and estimated that 3 percent of all elderly people in nursing homes were admitted because of such conditions, with subsequent costs of $1 billion [in 1983 dollars) (104). That figure is almost certainly a significant underestimate because of the strong incentives for underdiagnosis of dementia in nursing homes. That study also reported 36 percent higher labor costs for residents with dementia, in contrast to a 6 percent figure found in New York State (32). Which is the correct figure for the costs of caring for those with dementia is purely speculative; each may be accurate for its own sample. The New York figure, for example, included a large number of nursing home residents who did not have significant functional impairments, and who may have required less care. Given uncertainties in the accuracy of diagnosis, type of service provided, and sensitivity to uncontrolled economic factors, using current estimates to predict costs of public policies should be done only with great caution. Costs of Informal Long-Term Care Most studies report that the majority of longterm care is delivered outside nursing homesin board and care homes, adult day care centers, and patients homes. Costs are extremely difficult to estimate, and most overall projections necessarily underestimate this component. One recent study based on a national sample of long-term care recipients estimated that 1.2 million Americans were receiving informal care (100). That figure compares to the estimated 1.4 million people in nursing homes (26)54). Some authors have estimated that 70 to 90 percent of long-term care is informal care, but it is unclear whether these estimates refer to numbers of persons, proportion of services, or some other measurable factor. If it is true that only 1.2 million Americans now receive informal care, then the magnitude of the problem may be less than previously statedand the cost implications proportionately less worrisome to Federal, State, and local governments. Costs of informal care include the wages and salaries forgone by family members caring for patients, the lost productivity that results when experienced workers leave the work force to care for relatives, and the stresses borne by patients and their families (37,125; see also chs. 2 and 4). The stress induced by loss of mental functions and personality change is enormous for individuals with dementia and for their families, and can lead to illness among caregivers. Such stress can be exacerbated by difficulties in finding and coordinating services to relieve the caregiving burden. The bulk of informal care is delivered first by spouses, then by children (especially daughters) (38,1OO). The burden falls disproportionately on women, The very late onset of most dementing illnesses often means that a woman in her fifties or even late sixties may be the primary caregiver (14). The efforts of spouses and children are not generally captured by economic surveysthe costs of caring are hidden because no one pays for them directly. A few indirect indicators of cost have been identified. Of those responding to the national survey conducted for OTA-which, because the sample was drawn from the national mailing list of ADRDA, likely represents more well-to-do families than average percent reported they had cut back sharply in spending in order to care for their affected relative, 10 percent reported some impact, 22 percent noted little or no impact, and 48 percent had not used their own funds at all (123). (These figures add up to over 100 per- PAGE 27 Ch. IDementia: Prospects and Policies l 2 1 cent because of multiple answers from some respondents.) A survey of women in Philadelphia found that 28 percent of those taking care of dependent mothers had quit their jobs to give care at home, and a similar proportion were considering it or had reduced their hours of work (12). A study of a national sample of long-term care recipients found 9 percent of caregivers had quit their jobs (100). Researchers studying the social breakdown syndrome (a combined index of functional limitations and difficult behavior) concluded that most of the functional limitation and troublesome behavior occurring in the community is unrelated to the presence of a mental disorder in the elderly person. Nonetheless, persons with dementing disorders contribute to the community burden of disability disproportionately (88). These studies are further indications of the cost of informal longterm care for patients with dementia. Finally, two recent studies have been combined to estimate the community costs of caring for those with dementia. A small pilot study of 19 community-dwelling older Americans estimated average costs at $11,700 (in 1983 dollars) to take care of someone with dementia at home, based on what the care would have cost if families hired outside caregivers at prevailing wage rates. This study yielded national estimates of $26.7 billion for such care (50,51). Costs to Government Costs borne by government are of special interest to policy makers. The amount is not known and has not been specifically analyzed in any major national survey. Several factors suggest the services needed by individuals with dementia may be more costly than for other long-term care populations. The duration of nursing home stay for those with chronic brain syndrome and senility in the 1977 National Nursing Home Survey was 5 percent longer than average (111, combining tables H and 8). That figure significantly understates the likely length of nursing home stay for residents who enter because of dementia, for it is averaged over a diverse group of residents who stay for shorter periods. Those with chronic brain syndrome who are still in a nursing home at 90 days are expected to remain approximately 3 years (1,104 days), much longer than for any other diagnostic group. The average expected stay at time of admission is 97 percent greater (72). (These data are not specific to dementia patients, however, because while those in the category of chronic brain syndrome are largely residents with dementia, other groupsincluding a fraction of adults with mental retardation-are also included.) Residents staying longer in a nursing home are more likely to spend down to Medicaid eligibility as they run out of financial resources by paying for care, although that has not been confirmed specifically for those with dementia. The RUG-II long-term care demonstration project in New York State found that patients with diagnoses indicating dementia had levels of disability 6 percent higher than average (32). That higher level of disability would lead to a higher level of careand thus costin turn causing increased State and Federal payments to nursing homes for such residents under the RUG-II payment system (98). Indirect analysis thus suggests that length of stay and level of disability are both higher for residents with diagnoses indicating dementia, and that individuals with dementia are more likely to be publicly subsidized by the Medicaid program and their care is more expensive than average nursing home residents. A range of long-term care costs can be estimated. The maximum possible cost would assume nursing home care for all with severe dementia, with estimates in the range of $33 billion (1.5 million residents times $22,000 per year average cost of nursing homes). The $22,000 is calculated by dividing total estimated costs for nursing homes in 1986 ($32.8 billion) (54) by the estimated number of nursing home residents (1.493 million) (106). That calculation accords well with one estimate based on a direct survey of 25 nursing home residents with dementia, which found costs of $22,500 per resident per year (in 1983 dollars) (49). If the Federal Government paid 30 percent of this, then its costs would be roughly $10 billion. The $10 billion figure has a misleading ceiling, however. A more realistic figure for government costs is based on the assumption that half of current nursing home residents have dementia and PAGE 28 22 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias that Medicare nursing home payments are not for dementia. That hypothesis yields an estimate of $4.4 billion for the Federal Government and $4.1 billion for the States in 1986. That estimate implies that the Federal and State Governments are each bearing roughly 10 to 15 percent of the overall costs of long-term care for those with dementia, with the remainder coming from individuals. (Some individual payments, however, also come indirectly from government through social security, VA pensions, and Supplemental Security Income, which provide over 45 percent of income for those over 65.) These estimates are necessarily quite imprecise, and more refined service planning will require much better information and analysis. The amount of long-term care covered by government programs depends on several factors: degree of subsidy of services, access to services, eligibility criteria for programs, range of services provided, and method of payment. Expanding eligibility, access, range of services, or degree of subsidy would increase government costs, while narrower eligibility or restricted access to facilities would either reduce overall costs or shift expenses to individuals and families. COORDINATING SERVICES FOR THOSE WITH DEMENTIA Although several chronic disorders of old age increasingly confront the American health care system and cause people to need long-term care, several features of dementia make it especially difficult to coordinate services for anyone with this condition. Medical, mental health, and social services are frequently adapted only poorly to the needs and abilities of those with dementia. Services are typically intended for targeted populations, and those with dementia can fall through the cracks. Families are often referred from agency to agency, each of which may exclude individuals with dementia from their services for differentand legitimatereasons (83). That need not be the case. In some regions, referral networks and family support groups have been established to deal with this problem (30, 35,83). Services adapted to patients with dementia are increasingly common, but still serve only a small fraction of the total population. For now, many individuals are left in an administrative limbo between services intended for aged, mentally ill, and acutely ill Americans (13). Some States, local governments, or organizations have developed innovative and effective methods for delivering and coordinating care. The ADRDA chapters in Portland, OR and Atlanta, GA, for example, have developed in-home respite programs (30,35). The Family Survival Project and On-Lok have both coordinated and managed financing of a wide range of services in the San Francisco Bay area (73,83). These programs demonstrate that services for patients with dementia can be provided and financed successfully. Several States have commissioned studies, developed plans, or established special programs that cover individuals with dementia. Georgia, Illinois, Kansas, Maryland, Massachusetts, Rhode Island, and Texas have issued major reports (2,19,38,41, 42,61,92,101). Minnesota has produced a comprehensive plan to serve those with brain impairments (77). California has passed several bills to fund pilot projects and is preparing a Task Force report (90). These States have taken the lead in studying the needs and planning services for those with dementia. The Care System The system for taking care of individuals with dementia includes a wide range of services provided in many settings. The informal care system consists of family, friends, and communities. The formal system consists of government agencies and nongovernmental organizations whose primary purpose is to provide services. Most of the needs of those with dementia are met by the informal care network. Formal service providers are usually used when the informal care system breaks down (e.g., a caregiver moves, gets sick, or dies) or when informal supports are not available (e.g., those without families and living alone), PAGE 29 Ch. lDementia: Prospects and Policies 23 Surveying the history of formal services, two researchers observed that: public policy, in the last 50 years, has responded to the demographic imperatives of an aging society unevenly. In the two areas of income maintenance and medical services there has been substantial, and for the most part effective, response. But public policy has faltered in the area of health/ social services (14). People 65 or older have become much more economically independent, largely as a result of greater general affluence and Federal income support programsprimarily Social Security, government pension plans, and Supplemental Security Income (14,40). Medicare, the main Federal health program for those over 64 or with a disability, has broadened access to acute medical and shortterm transitional care. Medicaid, the health program jointly funded by States and the Federal Government, has increased access to acute medical care for the indigent and become a major funding source for long-term care of the elderly. Longterm care for those who are not indigent and social services in general have not been as heavily subsidized by the Federal Government. The protracted course of most dementing illnesses often leads to years during which an affected individual needs constant supervision. Most of the caregivers activity is directed not at relieving medical problems, but rather at preventing the patient from inflicting harm and at enhancing the quality of the individuals life by taking advantage of preserved mental and physical functions. Those with dementia, for example, often can sing after they lose the ability to speak in long sentences, and they typically retain emotional responsiveness long after their intellectual functions are severely impaired. Long-term supervisory care of the sort needed for someone with dementia is a service not generally covered by government-supported programs (except for the indigent). In addition, government programs usually focus on the person needing care; yet the person and caregiver function as a unit in most cases of dementia. Hiring a trained supervisor occasionally to watch and take care of someone with dementia gives caregivers respitetime needed to perform routine errands, socialize, or reinstate a sense of their own lives. Such services are not widely available, and formal programs generally do not cover them. The system of care for those with dementia has several components. Patients must be medically evaluated, their medical illnesses treated, the severity of their illness assessed, their care needs identified, various services coordinated, and use of services financed. Each of these functions must be performed for each person. The ideal situation is a continuum of care in which the individuals informal supports and formal resources are assessed, and services identified and provided according to varying needs at different times. The system rarely functions smoothly, however, and the long-term care part of the system is particularly noted for its gaps in services and the paucity of financing alternatives. Inventory of Services In the survey undertaken for OTA, those caring for individuals with dementia were asked about their assessment of the importance of various services (regardless of current cost and availability constraints) (see ch. 4). The following 10 services were listed as most important, starting with those most often rated essential or most important: 1. a paid companion who can come to the home a few hours each week to give caregivers a rest; 2. assistance in ]ocating people or organizations that provide patient care; 3. assistance in applying for government programs, such as Medicaid, disability insurance, 4. 5. 6. 7. 8. and income support programs; a paid companion who can come to the home for overnight care so caregivers can go away for one or more days; home care to provide personal care for the individual with dementia, such as bathing, dressing, or feeding in the home; support groups composed of others who are caring for individuals with dementia; special nursing home care programs only for individuals with dementia; short-term respite care in nursing homes or PAGE 30 24 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias 9. 10. hospitals to take care of individuals with dementia while the caregiver is away; adult day care providing supervision and activities away from the home; and visting nurse services for care at home (123). In-home care, information about availability of services and government programs, and various forms of respite care were all highly ranked in the survey. These services do not exactly match those now available. Many of the services could be provided in a variety of settings, or by more than one type of professional. Services are generally provided by agencies that focus on particular target groups in the population. The Federal Government funds services through several programs, including: l l l l l l Medicare, providing acute medical services for those at least 65, disabled, or suffering from end-stage renal disease; Medicaid, a joint State and Federal program to provide acute and long-term care for those with low income; Social Services Block Grants, under title XX of the Social Security Actthe services are not specified by the Federal Government, and States may provide foster care, adult day care, home care, homemaker services, meal preparation and delivery, transportation, or other services; Supplemental Security Income, a Federal program that makes monthly payments to the aged, disabled, and blind with incomes and assets below a Federal standardindividual States may supplement the Federal benefit to cover specific groups, such as those in board and care facilities, and can also cover services such as home care and homemaker services; Services for the Aged, under title III of the Older Americans Actthe range of services and eligibility are determined by States and Area Agencies on Aging (which are affiliated with the Administration on Aging); services may include adult day care, home care, homemaker services, transportation, telephone reassurance, senior center activities, and others; Mental Health Services, under Mental Health Block Grants to the Statesthe services include family counseling, drug use counseling, and support groups, and may include diagnosis and treatment in some areas; and l Income Programs, under Social Security and government pensions programsSocial Security accounts for 37.6 percent and government pensions for 8.5 percent of the income to couples over 64; for individuals, the figures are 44.5 percent from Social Security and 7.8 percent from government pensions (40). Government programs thus can overlap extensively in providing services for persons with dementia, can leave gaps in available services, and can vary in coverage from region to region and from one person to another. In addition to variable coverage, there is also variability of how services are organized. Services are usually organized according to the agency providing them. One study observed: Health services for the aged are multiple, parallel, overlapping, and noncontinuous and at the very least confusing to the elderly consumer. Rarely do they meet the collective criteria of availability, accessibility, affordability, or offer continuity of care in a holistically organized system. Planning for health services for the aged is similarly confused. Parallel systems of service have their own planning mechanisms. As a result, the various planning efforts overlap, contradict, and are unrelated one to the other. Virtually all the services are funded by differing public money streams and have varied administrative arrangements, widely ranging eligibility requirements, and different benefits for the same or similar services (15). Government and nongovernment programs are similar in grouping services into acute medical services, long-term care services, mental health services, senior services, and social services. The specific services included under these groupings often cover similar services and leave gaps among others. Personal care service may be included as a social benefit, a long-term care benefit, or in some cases a medical benefit. In most areas, however, it would not be available under any agency programs. Some of the services are noted in table 1-5. The settings in which the services are provided can be either residential (where the client lives) or nonresidential (a place the client goes to obtain services ). The settings most often used are PAGE 31 Ch. lDementia: Prospects and Policies l 2 5 Table 1-5.Care Services for Individuals With Dementia Adult day care Patient assessment Case management Personal care Chore services Personal emergency Congregate meals response systems Dental services Physical therapy Home delivered meals Physician services Home health aide services Protective services Homemaker services Recreational services Hospice services Respite care Information and referral to Skilled nursing services Speech therapy Legal services Supervisio n Mental health services Telephone reassurance Occupational therapy Transportatio n Paid companion/sitte r SOURCE: Office of Technology Assessment, 1986, listed and briefly defined in table 1-6. Chapter 6 contains a more detailed discussion of the settings, and the way that services and settings are provided and allocated. Senior Services Although dementing conditions are increasingly prevalent with age, only a minority of those in any age group ever develops dementia. Services for older Americans are usually targeted at the needs of the greatest number, and include senior centers, transportation, counseling, and homemaker chores. These are important services, but many programs exclude mentally impaired individuals, and many services useful to most older Americans are not helpful to those with dementia. Departments of aging and Federal agencies have increasingly focused on frail elderly individuals in recent years, but this grouping includes a heterogeneous population with a large variety of medical conditions. Dementing conditions are among the most prevalent and severe age-associated diseases. But recognition of this fact is relatively recent, and services have not fully adapted to the needs of those with dementia. Under the Administration on Aging, several Area Agencies on Aging and LongTerm Care Gerontology Centers have established programs on Alzheimers disease (108,110), but these serve only a small fraction of those with deTable 1-6.Care Settings for Individuals With Dementia Residential settings: In-home services may include home health care, personal care, chore services, and homemaker services to the clients house, apartment, or other residence. Some in-home health services are provided by home health care agencies, most of which are certified by Medicare and must meet Federal standards for staffing and range of services Other services are provided by community agencies funded by Federal, State, and local governments or nongovernmental organizations, Such agencies are generally not licensed or regulated. Nursing homes are health care facilities that provide 24-hour care, nursing, and personal services in an institutional setting. Most are certified to provide care under Medicare and Medicaid to eligible residents, and are regulated by States, subject to Federal and State standards. Board and care facilities are nonmedical residential care facilities that provide room and board and variable degrees of protective supervision and personal care, These range in size from foster care units with a few residents to large domiciliary facilities that house several hundred people. Many board and care facilities are licensed by State governments, but regulations are generally limited to physical structure and fire safety rather than patient care. State mental hospitals are generally large State-funded institutions that provide acute and long-term psychiatric care primarily for mentally ill people, but also for some patients with dementiaespecially those with behavioral symptoms that are difficult to manage. Hospitals are facilities for medical care of those temporarily residing in them. The primary services available are diagnosis and treatment, but hospitals also often serve as foci for rehabilitation, case management, counseling, family support. They may also be affiliated with nursing homes, day care centers, home health agencies, or other settings and services. Hospices are facilities for the care of terminally ill people. The emphasis in hospices is on alleviating symptoms and providing personal support, rather than cure and rehabilitation, Hospice services can be delivered in other settings, if the intent is to diminish suffering rather than prolong life. Nonresidential settings: Adult day care centers are day treatment facilities, some of which provide intensive medical, physical, or occupational therapy. Others provide primarily social activities and personal services for several hours during the day. Adult day care centers are licensed by some States, and must meet fire and safety codes of local jurisdictions, but are not subject to Federal regulation unless they provide services reimbursed by Medicare or Medicaid. Community mental health centers are psychiatric and psychological treatment facilities that provide a variety of mental health services for people with acute and chronic mental illnesses. Most services are provided on an outpatient basis. Most centers were originally developed in accordance with Federal regulations tied to Federal funding but are now regulated by States and funded by them, supplemented by Federal funding through Mental Health Block Grants, outpatient facilities and clinics are medical settings for diagnosis and treatment of diseases, They may also become involved in delivering other services such as case management and counseling, Senior centers are facilities intended for use by older Americans, They are often funded by a combination of private charity and local, State, and Federal Government contributions, Day care, recreational activities, family support, case management, and mental health services are available at some but not all senior centers. SOURCE Off Ice of Technology Assessment, 1986 PAGE 32 26 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias mentia. In most areas, services for the elderly population do not include those specifically intended for individuals with dementia, and are poorly adapted to their needs (59). Although many commentators question whether services should be made available to those with dementia that are not available to similarly disabled groups (108), the degree of mismatch between services and the needs of persons with dementia could clearly be reduced without creating special eligibility groups. Acute Care Services Acute medical care for dementia includes identifying symptoms, diagnosing their cause, and treating illnesses discovered in the diagnostic process. Diagnosis and medical treatment for dementia are generally covered by insurance and government programs to the same extent as other medical conditions. Patients are not excluded from eligibility for acute medical care because of the nature of their symptoms. One inequity, a limitation of outpatient psychiatric care, has been addressed in recommendations of the DHHS Task Force on Alzheimers Disease (110), but that represents a relatively small component of the acute care needs of those with dementia. Methods of prevention also need attention in the acute care system. While there is no known way to avoid the most common dementiaAlzheimers disease-diet, personal habits, and medical care can prevent many of the other disorders (e.g., diet can influence the risk of vascular disease and thus vascular dementia, and cessation of smoking can reduce the likelihood of lung cancer with spread to the brain-one of the most common types of brain tumors in those over 64). Even if the disorders causing dementia cannot be prevented, however, excess disability related to them can be reducedpreventing unnecessary suffering and costs of medical attentionavoiding infections (through vaccination and prompt treatment), careful use of medications (to avoid side effects), and altering personal habits (e.g., stop smoking to enhance lung function and reduce fire hazard, or reduce drinking that intensifies disorientation). Diagnosis and treatment presuppose trained doctors, nurses, and other health professionals. Alzheimers disease and dementia were once the province of specialists such as neurologists and psychiatrists, but the aging of the population and increased awareness of dementia are making these conditions also a problem for family practitioners, internists, and other primary care physicians. In addition, there is a movement in medicine to provide specialized training for those dealing with the medical problems of older people, That type of practice, called geriatrics, is not now a medical specialty, but existing medical boards are offering special recognition of geriatric training (see ch. 9). Medical aspects of dementia are important in such training because dementia is primarily, although not exclusively, a geriatric problem. The main issues in acute medical care are: 1) accurate diagnosis; 2) adequate treatment of general medical problems and controllable symptoms; and 3) training physicians, nurses, nurses aides, and other caregivers. The main mechanisms for improving care are to educate health professionals and to ensure that full diagnostic evaluation and treatments are fairly reimbursed. Long-Term Care Services Although no single definition of long-term care has been accepted, it is generally agreed that its goal is to maintain or improve an individuals ability to function as independently as possible, and that services will be needed over a prolonged period, even if only needed intermittently. Medical care is an essential component, but a variety of other services are also important (60), Longterm care in public policy contexts sometimes means primarily nursing home care, although recent definitions are careful not to so restrict themselves. The White House Conference on Aging, for example, noted: Long-term care represents a range of services that address the health, social, and personal care needs of individuals who, for one reason or another, have never developed or have lost the ability for self-care. Services may be continuous or intermittent, but it is generally presumed that they will be delivered in the long-term) that is, indefinitely, to individuals who have demonstrated need usually measured by some index of functional incapacity (113). PAGE 33 Ch. lDementia: Prospects and Policies l 2 7 In terms of spending, however, Federal longterm care policy is mainly concerned with nursing home care. Even within the nursing home population, there is an important division of types and duration of long-term care. Nursing home care covered by Medicare, for example, is intended for those who primarily need medical treatments and intensive nursing care, called skilled care (e.g., changing of catheters, postsurgical care, and physical therapy) for short periods (generally less than 2 months). Medicaid coverage includes skilled care and also less specifically medical components, called intermediate care, but the emphasis remains on medical, as opposed to supervisory, care. Medical care in nursing homes tends to be needed most by those who are there for fewer than 90 days. Those residing in nursing homes for longer periods differ from others in type of disease (72) and in the services needed (14,52). One study found that those with severe dementia admitted to a VA hospital were much more likely than other patients to come from a nursing home and to still reside in a nursing home one year later (96). Another study found that impairments that include dementia have the longest expected duration of residency in nursing homes among groups studied (72). Some have called attention to the two different populations in nursing homes, calling them short-term long-term care versus long-term long-term care (16), or skilled versus chronic care (52). Individuals with dementia are likely to be in the long-stay group, needing supervisory and personal care more than medical attention. One analysis estimates that those with dementia constitute 60 to 70 percent of the long-stay group (14), making dementia one of the major determinants of those staying longer than 90 days in nursing homes. The distinction between shortand long-stay patients is particularly relevant in considering the potentially catastrophic costs of nursing home care. Catastrophic costs would accrue primarily to the longstay residents of nursing homes. Five percent of Americans 65 and over are in nursing homes at any one time, but only 3.5 percent are long-stay patients (16). That implies the risk of incurring catastrophic long-term care costs is restricted to a smaller fraction of the population than is often cited, and makes risk-sharing through insurance more practical. Nursing home care is by far the largest cost component of long-term care. Costs vary from region to region, ranging from just over $750 per month to over $3,000, A recent study estimates that out-of-pocket costs for hospital care will account for $3.3 billion of the $63 billion total (5.2 percent) spent on inpatient services, and $600 million of the $5.8 billion (10,3 percent) on outpatient services in 1986 (see figure 1-5), That estimate contrasts with $16 billion in out-of-pocket payments of the estimated $32.8 billion (49 percent) spent on nursing home care (54). (The projection of 1986 costs differs from the $38.9 billion used by the Health Care Financing Administration cited earlier (8)as it is based on a different economic model.) Direct comparisons between hospitals and nursing homes are somewhat misleading, however. Nursing home and hospital costs include several components such as room and board, laundry, meal preparation, and cleaning. Residents of nursing homes and hospitals would pay for such (basic living costs even if they were healthy and not in either facility. Other services are needed because of disability, such as nursing care and access to diagnostic treatment facilities, and these costs can be attributed to illness. Yet nursing home and hospital charges do not separate basic from medical service components. Comparisons of nursing home and hospital costs should compare the costs due to illness, not overall costs. The proportion of basic living costs is higher for nursing homes than hospitals, accounting for some of the discrepancy in what is covered by insurance and health care programs. It is unlikely, however, that basic living costs account for all or even most of the differential coverage. There is even evidence to suggest that hospitals are more expensive than nursing homes in delivering the same services (102), and costs in hospitals would more likely be covered by insurance or government health programs. The availability of nursing home beds varies dramatically. In Wisconsin there is a surfeit of beds, particularly in the summer. In other States, health These figures are taken from fiscal year 1982 costs for intwmediate care facility reimbursement in Kansas undm Medicaid ($25.1 1 per day) as the minimum, and for a proprietarjr nonprofit facility in Newr }ork (o\rer $100 per day) as the maximum. he Kansas figure is taken from Health Care Financing Administration data organized b} the American Health Care Asso(.iiition (57). 63-218 0 87 2 QL : 3 PAGE 34 28 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Figure l-5.Out-of-Pocket Expenditures by Type of Service and Care, Estimated for 1986 By type of service 70 60 50 40 30 20 10 o Inpatient Total Out-of-pocket Outpatient Type of service By type of care 10 t I Nursing home Nursing home services SOURCE: ICF, Inc., The Role of Medicare in Financing the Health Care of Older Americans. submitted to American Association of Retired Persons, July 19S5, table 21, adapted by the Office of Technology Assessment. systems agencies or other health planning boards have deliberately restricted the number of nursing home beds available in order to reduce costs under Medicaid. They have done so by using a process called certificate-of-need legislation, requiring a facility to receive State approval before adding beds. The constraint in number of beds has increased pressures for new beds by creating an unmet demand in many States. The dearth of insurance and Medicare coverage of long-term care (particularly for stays of more than 90 days) is not widely recognized by most older Americans. A survey of elderly people performed by Gallup for the American Association of Retired Persons showed that 79 percent believed that Medicare would pay for all or part of their nursing home care (6). Another survey found that only 25 to 47 percent of those asked knew that Medicare does not cover a 6-month nursing home stay (76). Yet Medicare covers less than 2 percent of expenditures for nursing homes, and private insurance pays for less than 1 percent (54). Medicaid is a program intended only for the indigent, and eligibility is contingent on nearly complete depletion of financial resources. Two recent surveys of older people in Massachusetts showed the high risk of families spending down to become financially eligible for Medicaid coverage soon after admission to a nursing home. Among those 75 and over, from 57 to 72 percent would become Medicaid-eligible by the end of one year in a nursing home; the figures for those over 65 were 57 to 83 percent (depending on marital status) (104). Figures for other areas will differ significantly because Medicaid varies in coverage and eligibility from State to State (see ch. 11) (19,67). Social Services Social services include housekeeping, transportation, and assistance in daily living (e.g., dressing, eating, shopping, meal preparation). Social services emphasize providing clients with what they need but cannot do for themselves, regardless of why they cannot do them. These services can be provided at the clients home or in community facilities, and not only at specialized medical or mental health centers. Many services, such PAGE 35 Ch. lDementia: Prospects and Policies l 2 9 as assistance with dressing or meal preparation, are needed by most individuals with dementia. The home services needed by individuals with dementia are a particularly troublesome public policy issue. Medicare home health benefits are intended for use by those who would otherwise be accepting medical care in a hospital or nursing home. Although meal preparation, supervision, and personal care are the services most frequently needed by individuals with dementia at home, they are not covered by Medicare (or by Medicaid in most areas). Some social service agencies include those with dementia among their eligible population groups. The need for those delivering services to be trained to deal with the behavioral problems and mental confusion associated with dementia, however, may prevent some agencies from including persons with dementia in their client groups. In some regions, social services are coordinated with long-term care, health care, mental health care, or senior services (e.g., providing transportation to day care centers or delivering meals on wheels). In most areas, however, social services are only poorly coordinated with other services (19,58). Yet these services are among the ones most desired by caregivers and are significantly less expensive than home health care. Medical and other health and social service administrators are reluctant to increase the range and availability of home services in some areas, however, because of anticipated escalating costs. They fear that such services would be abused by a variety of people who are not ill or needy. The potential for abuse would be reduced if recipients of the service were required to have an assessment of needs (based on diagnosis, functional disability, or some combination of factors), but it is not clear that there is a practical assessment method available that is cheap, accurate, reliable, and auditable. Inexpensive home care for persons with dementia has been successful in some areas, often sponsored or coordinated by local ADRDA chapters or Area Agencies on Aging (30,35,89). A pilot project to train volunteer caregivers about dementia so they can provide social services in the home is beginning under the Senior Companion Program of ACTION. Such programs rely on funding through charity, volunteers, and nongovernment organizations, and the clients family is usually the source of payment. That is an economic way to control use. Another method is to set an upper limit on subsidized benefits by limiting the total days or budget, or through a voucher system (83). Mental Health Services Until the 1960s, institutional care for individuals with dementia was largely provided in State mental hospitals. Public policies to reduce the population in such facilities decreased the number of persons with dementia in mental institutions, and the availability of joint Federal and State coverage of nursing home care accelerated this trend (58,64). One careful investigation suggests that older persons who once would have been sent to mental hospitals are now referred to nursing homes (47 of 50 residents in one nursing home 94 percenthad a mental disorder) (95). The displacement has not been due to transferring residents directly from mental hospitals to nursing homes, however. (In the study just cited, only 1 resident out of 50 had been so transferred.) The data are most simply explained by older persons with behavioral and cognitive symptoms being preferentially admitted to nursing homes instead of mental institutions in recent years. The behavioral aspects of dementia are among the most difficult symptoms to manage, and facilities using a mental health model (focusing on adapting to the individuals behavior) rather than a medical one (focusing on correcting a disability) appear in preliminary studies to benefit people more (25). A pattern of care is emerging that emphasizes careful medical evaluation and drug management, combined with a mental health model of care in nursing homes and day care centers that coordinate their services with available social and aging services. Persons with dementia become dependent because of their inability to understand the intricacies of daily life. Although symptoms are caused by physical brain damage, dependency is induced by loss of mental function, rather than physical disability. That contrasts with arthritis or hip fractures, for example, where immobility is directly caused by joint and bone problems, and the dis- PAGE 36 30 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias ability is easier to observe and measure. There is less opportunity for confusing physical disabilities than mental ones, and concern for overutili zation of health care services overall has engendered a conservative approach that puts the burden of proof on individuals with mental symptoms to show the legitimacy of their needs. The behavioral symptoms of dementia often relegate individuals to categories for which coverage by health programs is ambiguous. They may be eligible for medical care, mental health services, both, or neither. In times of budget restraint, programs typically cut back on services not central to their mandate. Dementia is at the margin of both medical care and mental health services. Patients may be seen by a family physician, an internist, a neurologist, or a psychiatrist, and each specialty has its own orientation for diagnosis and treatment. Agencies delivering mental health services may exclude someone with dementia because their resources only cover drug rehabilitation, for example, or rape counseling, and yet health care programs typically focus on acute rather than long-term care. Those with dementia may thus be left with access to no services except family care at home or nursing home placement. The Federal Government supports mental health research at the National Institute of Mental Health (NIMH) and pays for some mental health services through payments to States. Federal and State Governments jointly fund Community Mental Health Centers (CMHCs) throughout the Nation, but these must deliver a full range of services to all population groups. A recent survey found that at most 20 percent of CMHCs had programs for persons with dementia and their families; these programs were five times as common in CMHCs specialized in mental health for older individuals, and they were heavily used where available (68,69). NIMH has established three Clinical Research Centers on Psychopathology of the Elderly, two of which focus on Alzheimers disease (108). These are important centers for investigating individual needs, treatment methods, and family support mechanisms. They also train many clinicians who can then care for patients in their practice. Yet because of the extent of the problem, the NIMH national centers and those CMHCs covering dementia miss large sections of the population. Findings from these centers must be applied nationwide before most Americans can benefit from them. Mental health services for caregivers are also important. That applies to family caregivers as well as professionals and aides working in home care services, day care centers, and nursing homes. Services for caregivers include support groups, counseling, and treatment of stress-induced disorders. Much of the support for families has been provided by volunteer groups such as ADRDA and dozens of smaller local organizations at little cost to taxpayers. Such support cannot cover the full range of needs, however, and large geographic areas are still not served by such groups. Expanding the range of services and geographic coverage are both high priorities for ADRDA in its current organizational plan (4). Services for caregivers in long-term care facilities are not as well organized, and that issue deserves increased attention from home care, day care, board and care, and nursing home providers. GROUPS OF SPECIAL CONCERN Several groups are of special concern in policy l low-income groups, and discussions of care and services for persons with l caregivers. dementia: Each group has special needs and problems not l l l l l those without families, shared by everyone with dementia that influence minority and ethnic groups, how providers must adapt services. The first four individuals experiencing disease onset in midgroups are at special risk of reduced access to servdle age, ices. They represent especially vulnerable popu individuals residing in rural areas, lations, and those most likely to benefit from public veterans, services. The different risk factors can reinforce PAGE 37 Ch. IDementia: Prospects and Policies l 3 1 one another to identify those in particular jeopardy. A black woman with dementia living in a rural area on low income without a family, for example, would be unlikely to be receiving services but might especially need them. Those without Families Much public interest has centered on problems faced by the families of those with dementia. Yet while many policies designed to improve the situation of someone with dementia rely on relatives or friends who can make decisions about care, finances, or the persons rights, many individuals with dementia do not have families or friends available. A 1975 General Accounting Office study of those age 65 or older in Cleveland, found 13 percent did not have a primary source of help in the event of disability (107). A recent national sample of long-term care recipients found that 10.7 percent lived alone (100). The number without family may be higher for those with dementia because so many are quite old, and likely to be widowed. Extreme old age also increases the chance that someones children are disabled or deceased. People who are not married are more likely than married individuals to reside for long periods in nursing homes (72). They are less likely to have access to alternative services such as day care because of difficulty finding the service and arranging for transportation. Informal care directly provided by families and coordination of care often managed by family members are likewise unavailable. Patients without families are thus disproportionately dependent on formal long-term care services such as nursing home care and case management by public agencies. Special methods of identifying and assisting patients without families are available only in a few areas, however, and there is little information about them. Identifying those without families who may need services is especially difficult, but can be done by alerting police, ministers, grocers, and others in the community to look for older people who may be ill and to refer them to a lead agency. One program that does this is the gatekeeper program in Spokane, WA, which links a Community Mental Health Center, an Area Agency on Aging, and 13 other agencies together in a disseminated referral network with a single central process for screening candidates and determining eligibility for services (67,89). Minority Groups Minority groups have lower average incomes and use fewer public services than comparable groups in the general population. They frequently have different social support systems, religious affiliations, and cultural norms. Disparate minority groups cannot be analyzed as a homogeneous whole. Few studies have been done of older Americans in minority groups in general, and almost no information exists on dementia in particular (73). Although the prevalence of dementia appears similar across national boundaries and races, a few variations have been reported. The high rate of hypertension among blacks and Native Americans may make them more likely to develop vascular dementia (33,1 18). The ratio of vascular dementia to Alzheimers disease also appears higher in Japan, and surveys of Chinese and Taiwanese populations report dramatically reduced prevalence of dementia (although such differences may be due to reporting rather than true prevalence) (78). International studies of prevalence rates in different races can give clues about the expected prevalence among those minority groups in the United States, but rates in native countries can be affected by economic and cultural factors. Life expectancy among most minority groups is rising with more older individuals at risk of developing dementia. Minority groups also tend to be undercounted in the census, so projections of dementia among them would understate the true prevalence in the population. Each of these factors suggests that more minority elderly Americans will develop dementia, and that a higher proportion of persons with dementia will come from minority groups (73,1 18). Direct assessment of the prevalence and cause of dementia among minority groups in the United States is therefore important. Disability among members of minority groups is higher (88), but statistics show lower use of many public services (73). That pattern might be PAGE 38 32 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias altered, however, by programs designed for specific minority populations. The Keiko nursing homes in Los Angeles focus on the needs of Americans of Japanese descent, while the successful OnLok program in San Francisco serves a population that is 70 percent of Chinese descent (73). Social, medical, and long-term care services are usually structured for the majority population and frequently are only poorly adapted to the cultural norms of minority groups. Most minority groups, particularly those with sufficient concentrations of people in an area, have informal networks of family, religious, community, and service supports. These supports generally are also linked at the local level with service providers, but Federal and State Government policies frequently fail to permit local agencies sufficient latitude to take advantage of minority group social supports (118). Service systems for minority groups work best when they take advantage of existing supports within the community. Black Americans tend to rely on churches for social and emotional support; Hispanics often have a network of consejeras (informal counselors) or servidores (people who informally take on the role of providing information and support); the Chinese have Yau Sum (person of good heart ); American Japanese may have Shinsetsu sua hito (kind person) networks; and Native Americans have tribal councils and designated spiritual leaders (73,118). The capacity of such informal supports, as in the majority culture, can be exceeded, Individuals with dementia typically go beyond the ability of the informal system to adapt at some point in the illness, but that point can be delayed by programs that foster informal networks, or that at least do not interfere with them (118). Although family support groups have grown rapidly throughout the United States, the early growth has been concentrated in the majority Caucasian population. In the survey conducted for OTA, drawn from the ADRDA national mailing list, 94.8 percent of respondents were white, 1.6 percent black, and 0.7 percent other (2.9 percent did not respond to this question) (123). That compares with 88.5 percent white, 8.8 percent black, and 2.7 percent other minority in the U.S. census of those aged 55 to 64 (73). Family support groups can, however, be successful among minority groups, as demonstrated by an Hispanic support group started in the Tampa area (47). Outreach to minority groups is high on the agenda of many of the support group organizations, including ADRDA. Individuals Experiencing Onset of Dementia in Middle Age The majority of dementing illnesses do not begin until after age 65. An estimated 5 to 10 percent of persons with dementia, however, develop the disease in middle age (27). The exact proportion of cases that begin before age 65 is uncertain, but an estimated 75,000 Americans under 65 have severe dementia (79). The problems caused by onset in middle age add to those associated with later onset. Individuals who are working almost invariably lose their jobs and are usually unable to find other employment. They and their families not only suffer loss of income, but also incur substantial medical expenses for diagnosis and treatment, often complicated by loss of health insurance caused by unemployment (although this effect should be mitigated by recent changes in Federal law that require extension of health insurance for most categories of employees). In addition, those in middle age are more likely to have young children with financial and emotional needs, who are less likely to understand declining mental function and personality change. Finally, many families discover that finances have been mismanaged for months or years before diagnosis. In many cases, the persons failed to maintain health, automobile, and life insurance payments, left important bills unpaid, or spent family funds frivolously. These problems can be compounded by the difficulty in dealing with public programs. A person under 65 may encounter difficulty establishing eligibility for Social Security Disability Insurance (SSDI) (19). The survey done for OTA of those caring for someone with dementia found that 11 percent had applied for SSDI and 35 percent had been denied benefits (123). That finding is particularly important for those under age 65 because denial PAGE 39 Ch. lDementia: Prospects and Policies l 3 3 of disability benefits also generally precludes Medicare eligibility (19). Those declared ineligible for SSDI are also barred from Medicare coverage; those found eligible for SSDI must wait a minimum of 29 months until they are covered by Medicare (see ch. 11). The House and Senate Appropriations Committees requested that the Social Security Administration address disability policies regarding dementia, in consultation with the National Institutes of Health (conference report on Public Law 99-500). The number of those developing dementia before age 65 could dramatically increase as a consequence of acquired immune deficiency syndrome (AIDS). The majority of those who develop AIDS also develop dementia due to brain infection by the virus that causes the disease (85). They thus become dependent on others for medical and daily care. Nine thousand cases of AIDS were reported in the United States in 1985, and 46,000 to 90,000 are expected in 1991; 20 to 30 percent of the estimated 1 to 1.5 million Americans infected by the AIDS virus as of June 1986 are projected to develop AIDS by 1991 (24). If 70 percent of those with AIDS develop dementia, then the proportion of those with dementia under 65 would almost double. There are several uncertainties in that estimate. The mortality of AIDS is quite high and so the duration of illness would be short. The proportion of those with virus infection who develop dementia but not AIDS is unknown, and the duration might be longer for such individuals. The AIDS pandemic is thus likely to dramatically increase care needs for those under age 65 with dementia, but the amount and duration of needed care are highly uncertainboth overall and for each patient. Rural Residents Rural residents have access to fewer specialized services, and hence a restricted range of long-term care options. Rural areas may be served by a single general physician unfamiliar with dementia, have only one local hospital, and only one nursing home. Few have adult day care or in-home services, and participation in family support groups, the few places they exist, may require substantial travel time, Reduced access to services may be exacerbated if there are no family members in the area to help care for the individual with dementia, or if there are no neighbors nearby to provide intermittent help. Veterans The Veterans Administration is concerned about the rising prevalence of dementia among those eligible for its services (28, 116, 117). The rise in prevalence among veterans will peak 10 to 20 years before it does in the general population because of the special demographics of those who served during World War H, the Korean war, and in Vietnam (see figure 1-6). The care received by veterans depends on why and when their illnesses began. The first priority for VA services goes to those whose disability or illness is service-connected. Dementia is only rarely service-connected (e.g., because of severe head trauma). Other services are provided on a space-available basis. Some VA facilities have developed special programs for those with dementia, but VA hospitals do not guarantee access to long-term care or to specialized services for those with dementia (see figure 1-7). Most VA facilities cover care for diagnosis and treatment of intercurrent illnesses. Veterans Administration hospitals and nursing homes treated over 20,000 veterans with a diagnosis of dementia in fiscal year 1983. Special care units for individuals with dementia have been developed at 12 VA medical centers. Yet the survey of caregivers done for OTA Figure 1.6.Number of Veterans Age 65 and Over SOURCE: Veterans Administration, International Working Group, The Veterans Administration and Demenfla, Recommendations for Patient Care, Research $ and Training, October 1985. PAGE 40 34 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Figure l-7. Prevalence and Annual New Cases of Dementia, U.S. Veterans, 1980=2000 400 I 1 I 150 J 0 i i 1 1 J 1990 2000 Year SOURCE Veterans Administration, International Working Group, The Veterans Administration arrd Dementia, Recornrnerrdatiorrs for Patient Care, Research, and Training $ October 1985, found that 45 percent of those who had applied for extended care were refused VA services, most often because the disability was not service-connected (123). For several reasons, the VA system is under increasing political pressure to provide care to those with dementia and other chronic illnesses. First, the number of veterans reaching advanced age is expanding rapidly (see figure 1-6). In 1980, only 3 million veterans were 65 and older, but this will increase to 9 million by the year 2000 (representing 63 percent of all men 65 and older) (115), Second, veterans and their families often expect the VA to cover all care. Explanations that particular illnesses or disabilities will not be covered often are not understood or are rejected, particularly if families know that the type of care they seek is available at VA facilities in other geographical areas. Those With Low Incomes Americans with low incomes are particularly dependent on government programs. Lack of income restricts them to those services that are free through charity, subsidized, or inherently inexpensive. A substantial proportion of their low income is directly provided by the Federal Government. Among those 65 and over with less than $10)000 income, for example, social security provides on average 82.2 percent of income, compared with 17.8 percent for those with incomes over $30)100 (40), In addition, the Medicaid program to cover medical services is intended primarily for this group, yet both the lack of awareness and the complexity of the program hinder full use of the benefits. Ironically, those with higher incomes may benefit more from Medicaid, particularly the long-term care component, because they have easier access to the information needed to obtain eligibility and can afford to enter a nursing home as private pay clients, who later find they have spent down to Medicaid eligibility. People with lower incomes cannot pay initially, and nursing homes that have a choice prefer to admit private pay residents because Medicaid reimbursement rates are low. Caregivers Middle-aged caregivers are at high risk of becoming secondary victims of dementia. Volunteer groups and government services could productively target this group. The majority of those caring for dependent parents are middle-aged women (12,1OO), a fact that appears to be true not only for dependent older people in general, but also for those with dementia (37). These women may also be responsible for the care of children or adolescents, or may just be starting careers after their children have left home (12). Yet family support groups are the only services available to them in many areas. A recent study of a national sample of long-term care recipients found that roughly three-fourths of caregivers lived with the dependent older person 7 days a week, and only 9.7 percent purchased formal services (100). Of those caring for dependent older people, 44 percent had done so for more than 1 year but less than 4 years, and over 20 percent had been caregivers for 5 years or more. Caregivers who are themselves old face different stresses from those in middle age. Older caregivers are more likely to have an illness that in- PAGE 41 Ch. 1Dementia: Prospects and Policies 35 creases the stress and health risk of caregiving. just the ill person. Decisions about an individuals The finances of a person with dementia and the legal status (and control of family finances) likecaregiver are closely commingled when the carewise affect the person with dementia and the giver is a spouse, so the costs of care can have spouse alike. a catastrophic impact on two or more people, not PAGE 42 36 l Losing a Million Minds: Confronting the Tragedy of A/zheimers Disease and Other Dementias POLICY The problems faced by persons with dementia and their families impinge on public policy in many ways, There is no cure, no means of prevention, and no fully effective treatment for most demen tias. The government strategies for addressing this public health problem are: 1) to support research in hopes of discovering a cure or means of prevention, and 2) to deliver or facilitate delivery of services for those who develop dementia. The roles played by the Federal Government that are relevant to the problems of dementia include: l l l l l l l supporting research, including basic science, clinical research, and the study of health care delivery; directly providing health care to special populations; paying for care through Medicaid, Medicare, Mental Health Block Grants, and tax subsidies; training and educating health professionals and caregivers; assuring the quality of acute and long-term care; planning health and social services; and disseminating information on care, research, and services. Table 1-7 contains a brief list of some of the most important Federal programs that deliver or fund care for persons with dementia. Should There Be Special Programs for Dementia? Any discussion of the governments role in this field must consider whether there should be special programs for individuals with dementia. Furthermore, judgments about the fairness and effectiveness of different policies require a clear distinction between special services, entitlements, and research. Specialized Services Specialized services for those with dementia include support groups, day care centers, nursing home units, and in-home respite care programs designed specifically to aid those with mental impairment. Such specialized emphasis helps in the training of caregivers and focuses attention on ISSUES the special problems of delivering services to those with dementia. The existence of specialized services for one group of diseases need not discourage developing specialized services for others. Patients with cancer, for example, do not receive the same treatment as those with heart disease, and yet may be covered under the same medical program (e.g., Medicare). There is no consensus that persons with dementia should receive specialized services. Yet special care units at nursing homes, special day care centers, special board and care facilities, and even special hospitals for patients with Alzheimers disease are proliferating. The rationales for such units are the opportunity to improve the care of persons with dementia by having better trained staff and adaptive environments, reduced interference with residents without dementing disorders, and the need for activities that specifically take account of diminished intellectual and communicative skills. Many worry, however, that such facilities will become the repository for neglected individuals. At present, no separate guidelines are available for special care units and programs, and philosophies and methods for administering them differ markedly. The ferment of activity in special care is generally improving care for those with dementia, however, and is generating innovative care techniques. Special Entitlements Special entitlements for individuals with dementia would make eligibility for services contingent on a particular diagnosis or type of disability. A special Medicare or Medicaid entitlement for dementia could be created, analogous to the special Medicare eligibility reserved for those with endstage renal disease (although a special dementia entitlement would be primarily for long-term personal, rather than medical, care). Those favoring special entitlements contend that the problems of patients with dementia are so severe and different from those with other disorders that they deserve special eligibility. Others contend that those with dementia are merely one group among many vying for services in a fragmented health care market. They point to other groups with similar prob- PAGE 43 Ch. lDementia: Prospects and Policies l 3 7 Table 1.7.Federal Roles in Dementia Issues Function Primary agency or method Agency delivering service Research: Biomedical research Public Health Service Veterans Administration (VA) Department of Education Research on health services National Center for Health Services Research and Health Care Technology Direct health care: Payment for care: Medicare (acute care) Medicaid (with States) Mental Health Block Grants (with States) Tax policies Contract care Training and education: Quality assurance: Acute care Nursing home care Mental health advocacy block grants to States Adult protective services planning: Assessment (NCHSR/HCTA) NIMH NIH Health Resources and Services Administration (HRSA) VA Health Care Financing Administration (HCFA) Administration on Aging (AOA) National Center for Health Statistics (NCHS) Bureau of the Census Department of Defense VA Indian Health Service HCFA HCFA Department of Treasury DHHS AOA HRSA Veterans Administration Public Health Service HCFA (Medicare) Student Loan Programs HCFA HCFA and States (Medicaid) Office of Assistant Secretary for Planning and Evaluation Off Ice of Assistant Secretary for Health (Alzhelmers Disease Task Force) Public Health Service HCFA (Medicare and Medicaid services) AOA VA (veterans) Department of Defense (military personnel) Indian Health Service (native Americans) National Institutes of Health (NIH) National Institute on Aging (NIA) National Institute of Neurological and Communicate Disorders and Stroke (NINCDS) Other NIH institutes National Institute of Mental Health (NIMH) (Alcohol, Drug Abuse, and Mental Health Administration) the majority of research under the Public Health Service is conducted at universities or medical centers VA investigators; geriatric research, education, and clinical care centers National Institute on Disability & Rehabilitation Research Long-term care gerontology centers Military hospitals and clinics VA hospitals and facilities, contractors Indian Health Service facilities Hospitals, clinics, institutions, other providers Providers through State administrate offices Community Mental Health Centers Internal Revenue Service Indian Health Service VA Long-term care gerontology centers Bureau of Health Professions Geriatric Research, Education, and Clinical Care Centers; Fellowships; Nurse Training, Interdisciplinary Teams NIH Fellowships and Centers; NIMH Fellowships and Centers Teaching hospitals Professional review organizations State certification and inspection offices AOA. others HRSA NIMH Area agencies on aging lnformation dissemination: Public Health Service NIH NIMH Office of Assistant Secretary for Health (Task Force on Alzheimers Disease) AOA Area agencies on aging HCFA (Medicare and Medicaid eliqibility and coverage) SOURCE Off Ice of Technology Assessment, 1986 PAGE 44 38 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias lems in obtaining needed services, particularly long-term care. Other groups also have limited access to long-term care (e.g., adults with mental retardation or adults with spinal injury) and difficulty finding adequate mental health or social services (e.g., schizophrenics or the homeless). Still others may need health services from public programs with limited budgets (e.g., maternal and child health for the indigent under Medicaid). Some of the consequences of developing special entitlements for dementia can be predicted. A special long-term care program for those with Alzheimers disease would face several problems. If based on diagnosis, it would be unduly restrictive (eliminating services for those with multiinfarct or other dementias) or it would be vulnerable to inappropriate utilization because of vague definitions of the conditions covered. Making services contingent on diagnosis or a restricted list of conditions would put severe strain on the accuracy of diagnosis. While special diagnostic centers report 90 percent diagnostic accuracy (64), that proportion would likely drop if there were incentives favoring one diagnosis over another. Physicians wishing to aid their patients would likely list the diagnosis of Alzheimers disease in preference to other dementing conditions if there were any room for doubt, thereby increasing the number of persons reported to have Alzheimers disease even if the true prevalence did not change. If services were triggered by severity of disability, then a method to screen out those with lesser disability would have to be in place, That would likely entail mandatory assessment for eligibility, and would necessitate a measure of mental disability that is quick, accurate, reliable, and auditable. A special entitlement for dementia, or specifically for Alzheimers disease, also raises a question of fairness. An adult with spina bifida, Huntingtons disease, or multiple sclerosis needs many of the same services as an individual with dementia. A special entitlement restricted to persons with Alzheimers disease would likely promote conflict among interest groups for different diseases. A broader definition encompassing related disorders will be vague and difficult to implement. The prudent course appears to involve providing the services most needed but not restricting their use to only those with dementia. Specialized Research Although no consensus exists about the risks and benefits of special care or special entitlements, it is generally agreed that specialized research on relevant science, clinical care, and service use is essential. Serious study of the large group of people with severe functional disabilities due to dementia has only begun in the past few years, and much more information is necessary before public policies, medical practices, and service use can be rationally assessed. Such information can come only from research that focuses on individuals with dementia. Studies need not deal exclusively with persons with dementia to yield useful information. Those that survey long-term care or mental health in elderly people could shed light on the problems of someone with dementia if they include sufficient information to evaluate cognitive function (measured by a standard scale), service use, diagnosis, assessment of lost functions, efficacy of special care, and costs. Diagnosis and Treatment The main policy concern about diagnosis and treatment is rapid dissemination of knowledge to permit accurate diagnosis and appropriate treatment. The primary mechanisms for improving diagnosis and treatment are research and education (discussed in detail later in this section). Also of concern is how to link medical evaluation to long-term care service planning, patient assessment, and social services. Creating new entitlements restricted to those with dementia would, for example, provide strong incentives to widen diagnostic criteria for those conditions, in order for more patients to qualify for public programs. The fragmented nature, complex organization, limited access, and uncertain eligibility criteria for long-term care services cause problems for individuals with dementia and their families. The physician is commonly responsible for coordinating medical services, but there is no analogous person to coordinate long-term care, mental health, social, and aging services. The concern here is for clients to have a person to turn to for information, and to begin planning service needs as soon as possible so that long-term care decisions are not made in a crisis atmosphere. PAGE 45 Ch. 1Dementia: Prospects and Policies 39 One mechanism to begin service planning would be to refer persons who receive the diagnosis of a disorder causing dementia to another professional or organization that can deal with the family and client in planning and coordinating services. This role is variously referred to by such terms as case management, case coordination, or linkage. Having such a professional available for referral from physicians would greatly improve the rational provision of services, but the costs are uncertain. Results from a national demonstration project to study case management and some alternatives (the Channeling project, supported by the Health Care Financing Administration will be available for analysis in late 1986, and information from that analysis will bear directly on policy regarding case management). A third issue related to diagnosis and treatment concerns methods of diagnosis. The National Institute of Neurological and Communicative Disorders and Stroke (NINCDS), NIA, ADRDA, and the American Psychiatric Association each have published general criteria for diagnosis of dementing conditions, but none is specific as to which tests should be ordered and how they should be interpreted, Consensus may not be possible or advisable, but current criteria are not useful for the general practitioner trying to determine the diagnosis of a patient. An NIH consensus conference on diagnosis of dementia will be held in July 1987, and may help address this need. One recent bill passed by Congress and signed by the President (Public Law 99-509) will establish up to 10 centers for diagnosis and treatment of dementing disorders. These would be distinct in function from the existing biomedical research centers, although they might be related geographically and administratively. The State of California has established six such centers, and reports that, even without publicity, the centers cannot meet demand for service (34). The centers are intended to diagnose and treat local cases of dementia, foster research, provide training for health professionals, aid families, and collect and analyze standardized information of use in planning services. California reports that budget cutbacks at the State level have seriously impaired delivery of the expected services at the State-supported centers (34)! Diagnosis and treatment centers could be useful in training, setting standards for care, and focusing clinical research, but they should not be expected to make the diagnosis and treat all cases of dementia in the United States. The cutbacks California has reported could also occur at the national level. Legal and Ethical Concerns Decisions about medical care, family finances, and other important topics are often difficult enough even when all parties are mentally competent. They become even more difficult when someone has dementia. Eventually decisions must be made on behalf of the individualsdecisions about driving an automobile, working, controlling financial assets, or participating in research that may not be of direct benefit. Such decisions are particularly difficult when someones employment involves professional work that is not closely supervised, such as medicine or law, yet these are jobs in which good judgment is essential, State and Federal laws include several ways to appoint someone to make decisions for another person. Guardians and conservators can be appointed by a court following a procedure to decide that an individual is indeed incapable of autonomous choice. Durable powers of attorney allow a person to set certain constraints on finances or medical care and to appoint someone to make decisions before becoming mentally incompetent. Living wills can indicate what types of medical care an individual would wish to receive or refuse. Each of these mechanisms for making decisions raises difficult questions, At what point is someone mentally incompetent? That is not a purely medical or purely legal question, and competence (legally defined) depends not only on the individuals mental ability, but also on the type of decision being made. Other questions include who is to oversee the decisions made by an appointed surrogate and how someone can be protected from conflicts of interest. Few of these questions can be directly addressed by Federal legislation. PAGE 46 40 Losing Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Most are now being decided through the judicial system at both the State and Federal levels. Many States have also passed or considered laws about living wills, powers of attorney, guardianship, and conservatorship. Legal issues related to Federal programs such as Medicare and Medicaid are also important. A family that receives legal advice soon after a diagnosis of progressive dementia is made may transfer the assets of the person with dementia more quickly, and thus establish patient eligibility for Medicaid sooner. Medicaid law stipulates that patient assets cannot be transferred for purposes of establishing Medicaid eligibility, and assets cannot have been transferred more recently than 2 years before becoming eligible. In most cases of dementia, assets would be transferred because of mental incompetence of the patient, but the burden of proof rests with the family. If transfer is completed early in someones illness, the person is more likely to be eligible for Medicaid by the time nursing home care is needed. These considerations make asset transfer a particularly difficult issue for families and State Medicaid administrators. Families benefit from early advice to legally transfer someones assets, but individuals rights to control their possessions must also be protected. And Medicaid is not intended to pay for the care of those who have impoverished themselves only on paper. Medicaid administrators would prefer to target their resources to those who need medical services and cannot afford them. The degree of responsibility of families in this context is unresolved. Idaho attempted to make children financially responsible for the care of their elderly parents in a 1983 law, but the legislation resulted in few recovered funds, was ruled in violation of Federal statutes, and was politically unpopular. No clear legal method can resolve the dilemma, and those with different ideological views differ markedly about the form a remedy would take. The issue might become moot if the incentive to rely exclusively on Medicaid to cover long-term care were reduced significantly. The incentive is strong now because Medicaid is the only public program available, and lower incentives would require a substantially higher rate of private financing (e.g., long-term care insurance, life care communities, or private savings) or availability of alternative publicly financed long-term care services. Another set of legal problems arises in government income support and health care programs. Those entitled to income and health benefits who are deemed mentally incompetent generally have a representative payee designated by the program disbursing funds. The representative payee becomes, in effect, the individuals guardian for social security payments. Yet the legal processes of establishing guardianship are not necessarily recognized by the Social Security Administration, the Veterans Administration, or other government agencies. Legal proceedings may be taken into account, but the agencies own determinations carry more weight, despite being much less formal and providing less protection for the individuals rights. Representative payees receive funds for an estimated 4 million to 5 million Americans. The Department of Health and Human Services has been sued on this issue, in Jordan v. Heckler (U.S. District Court, Western Oklahoma, CIV-79-944-W, Jan. 18, 1985) and the case is pending. Section 16 of the Social Security Disability Benefits Reform Act of 1984 (Public Law 98-460) mandated an annual accounting of representative payees, and sought a report on the proposed accounting system to be prepared for Congress in 1985. A sixpage report was submitted in September 1985 (110), but it contained no data on rates of auditing or details about ascertaining mental competence for purposes of assigning representative payees. Nor did it describe procedures for identifying misuse of funds or special safeguards for those judged mentally incompetent who are cared for outside State mental institutions. Education and Training providing high-quality services for those with dementia presumes the availability of trained people to deliver them. The sudden increase in awareness about dementia has meant that few centers are expert in care and research on this topic. Efforts to correct that deficiency have begun in the last 5 years, but most of those who care for individuals with dementia have never had special training. PAGE 47 Ch. 1Dementia: Prospects and Policies 41 Family members and other informal caregivers need information about the nature of the diseases and how their daily lives might change. That knowledge can improve their ability to plan and anticipate problems. They also need information about how to provide care. Persons with dementia are increasingly receiving special care, yet the results of innovations are not widely disseminated. When they are published, it is frequently in professional journals not readily available to family members. Health professionals can assist by preparing books, pamphlets, videotapes, and other educational materials intended for family caregivers. A few such materials are available: a guide to home care has been prepared (4), and several books have been published in recent years (21, 48,74,84). The care of someone with dementia, as with other chronic illnesses, demands a range of skills and duration of service that no individual can fully supply. That realization has led to the development of interdisciplinary teams consisting of physicians, nurses, psychologists, social workers, and others. Multidisciplinary teams can better coordinate different services and bring their various areas of expertise to bear on the problems of someone with dementia. Physicians now in general practice have had little formal training in geriatrics, although those who graduated from medical schools recently are likely to have had some courses, Attention to dementia has increased dramatically in some specialties, particularly neurology and psychiatry. Other specialties, such as family practice and internal medicine, are also publishing more articles, developing continuing education courses, and modifying medical school and residency curricula to include more material about dementing illness. Physician training in geriatrics should be improved by supportive provisions in the Omnibus Health Act of 1986 (Public Law 99-660). The results of such efforts should be felt over the next decade. The physicians role in dementing illness extends well beyond making a diagnosis and rendering medical treatment. It also involves interacting with the care team and referring patients and their families to support groups, social services, and longterm care agencies. Nurses are the backbone of long-term care, but long-term care is a low prestige and low paying specialty among these professionals. A shortfall of 75,000 nurses in long-term care is projected by 1990 (111). The medical training that nurses receive may not prepare them for the predominantly administrative and supervisory roles they perform in long-term care settings, and coverage of dementia varies among nursing schools even more than among medical schools. Geriatric nurse practitioners, who receive special training in geriatrics, typically learn about the medical needs of older people, including coverage of dementia, and can perform many of the diagnostic, assessment, and treatment functions of physicians. They also generally learn about the service delivery system and how to coordinate services. They can form abridge between the medical and social service systems, and are less costly to use than physicians. Nurses aides provide an estimated 80 to 90 percent of direct patient contact hours in long-term care (1,39). Yet they are poorly paid (usually minimum wage), have low educational levels, and have high turnover rates (45,49). Nurses aides frequently have different socioeconomic and cultural backgrounds than those of their clients. The responsibility to train nurses aides falls to longterm care facilities. Administrators are reluctant to invest heavily in training because aides are unlikely to remain long at the facility, but patient care depends on such training. Even those facilities that do wish to train aides have been hampered by lack of materials on dementia. Materials for training have recently become available through a cooperative effort of ADRDA and the American Health Care Association (44), and through the Hillhaven Corp. (91). Other professionals are also involved in the care of those with dementia. Complete care frequently involves social workers, psychologists, physical and occupational therapists, speech therapists, and administrators who are familiar with the problems faced by individuals with dementia and knowledgeable about available services. The Federal Government could play a critical role in ensuring that health and social service personnel working with persons with dementia receive PAGE 48 ... 42 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias the education and training necessary to deliver high-quality care. This role extends to educational institutions, programs that train professionals, and facilities that provide care. Disseminating information about care to professional networks, family support groups, and the lay press can bean important function. The role of the Federal Government in providing information is most important in those areas in which it predominates (e.g., biomedical research, health services research, and how to use government programs). One example is the Alzheimers Resource Center of New York City, which is preparing a book on nationwide resources about dementia available through the network of Area Agencies on Aging and State Units on Aging. The effort is the result of cooperation between a local chapter of ADRDA, the New York State Department for the Aging, and the Administration on Aging. Accreditation of educational programs that train health and social service professionals is generally performed at the State level, but it is subject to Federal guidelines for those services reimbursed by Federal monies (e.g., Medicare and Medicaid). Licensure of professionals is also largely a State function, subject to Federal standards. Training and staffing requirements for acute, mental health, and long-term care facilities are written by States subject to Federal regulations. Requiring training about the care needs of those with dementia could be incorporated into certification guidelines. Although certification is a State function, the Federal Government could make receipt of Federal funds conditional on certain certification requirements. Direct funding of training programs for physicians, nurses, and other health professionals is supported by the Department of Health and Human Services and the Veterans Administration. Continued support, with increased emphasis on geriatrics and particularly dementia, is likely to result in faculty whose talents are multiplied by teaching others to tackle the problems related to dementia. Delivery of Long-Term Care Formal long-term care services for persons with dementia are provided in nursing homes, board and care facilities, day care centers, mental health facilities, or individuals homes (see table 1-6). Until recently, there has been little study of which services are used or needed by persons with dementia and by their caregivers. Equally little is known about which settings are best suited to deliver many of the needed services. Some studies suggest that 40 to 75 percent of those in nursing homes have dementia; data on prevalence of dementia in other settings are unavailable. Individuals with dementia often need personal care, chore, and homemaker services in addition toand often more thanmedical care. Personal and social services are less widely available and less likely than medical care to be covered by government programs. Families may need temporary respite from continual supervision and care, but few agencies deliver care that is intended to relieve the burden of caregivers rather than patients (although most services do both). Who Delivers Care? Several factors determine who delivers longterm care for persons with dementia, For any one person, care may come from family at home, day care centers, home care providers, or a nursing home. Which provider is most appropriate depends on the extent of family and community informal supports, the quality and range of available services, the individuals symptoms, and the cost of the various options. Families play a predominant role in providing long-term care for older Americans. A General Accounting Office study of the elderly population in Cleveland conducted in 1975 concluded that families were providing more than 50 percent of all long-term care services received, and that as the impairment of the patient increased, so did the proportion of services provided by the family. For the extremely impaired group, families provided 80 percent of needed services (107). The degree of informal support may diminish in coming decades, however, for several reasons. Those most at risk of developing dementia are people in their eighties, and the children and spouses of such individuals are also likely to be older and themselves at risk of disability. At the same time, the declining birth rate in the United States has PAGE 49 Ch. lDementia: Prospects and Policies l 43 reduced the proportion of those who will be available to care for tomorrows older people. The rapid influx of women into the work force also portends reduced availability of family caregivers; although women today report that work is important, one study found that they act as though they give caregiving priority over employment in most cases (12). Rising divorce rates and remarriage rates also complicate determining who will render care to an older relative; a person newly married into a family may feel less obliged to care for the new spouses parent with dementia. Finally, the growing mobility of families increases geographic dispersion, and may make family caregiving Iess likely. Each of these trends weakens the informal care system, and may increase dependence on government services. Caregiver Support The primary needs of informal caregivers are respite care, information about the diseases and care methods, information about services, and a broadened range of services. Family members efforts can be aided by the Federal Government by giving them optimal information (especially that arising from federally supported research), assisting them in finding out about or obtaining services, and extending some benefits to caregivers and the person needing care as a unit, rather than restricting them to the individual with dementia. Range of Services Caregivers believe that more services should be available to care for individuals with dementia. The caregiver survey conducted for OTA found that the majority of those who listed respite care, adult day care, board and care, and nursing home care as (essential either knew these services were not available or did not know if they were available. That finding suggests that there is an unmet need both for services and for information about them. Increasing the number of choices for care of persons with dementia will not necessarily diminish demand for nursing home care or reduce institutional care costs borne by government. Day and home care is much more widely available in the United Kingdom, for example, but rates of nursing home residency are not significantly lower (43). Community-based care has not led to cost savings over nursing home care according to many recent studies (120). Some studies, however, report better patient outcomes with home care, and-of particular importance for persons with dementia who tend to reside for long periods in nursing homes once admittedstudies have not predicted what the benefits of coordinated, expanded home care services might be for older, chronically impaired individuals who do not meet the skilled care requirement but, rather, need ongoing maintenance care (52). Patient Assessment and Eligibility for Services Assessment is the process of identifying, describing, and evaluating patient characteristics associated with illness. While diagnosis of a dementing illness identifies the disease, assessment describes its impact on the individual, quantifies its severity, and is therefore essential in determining longterm care needs. Eligibility for Medicare and Medicaid long-term care services and reimbursement levels for covered services are based primarily on the medical and nursing care needs of the individual. Some States are now using assessment instruments that measure cognitive and behavioral deficits and limitations in activities of daily living to determine Medicaid eligibility or reimbursement levels. These case mix assessments can reduce incentives to discriminate against heavy care patients, but have not been rigorously studied to ascertain their impact on persons with dementia. The RUG-II classification system in New York, for example, places 22 percent of those with diagnoses indicating dementia into the least reimbursed category (32). That placement could be either because these people indeed have only minimal disability (and might be better cared for outside a nursing home), because the diagnosis is incorrect, or because the RUG-II assessment process does not accurately capture the disabilities of such individuals. Other case mix assessments may retain that uncertainty for those with dementia. It is important to determine whether the individuals do not need to be in a nursing home or whether their needs are not being identified by the assessment proce PAGE 50 44 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Demntias dure, because low reimbursement will incline nursing homes against admitting individuals who fall in the minimal disability category. In New York, that has already occurred, with a marked drop in admissions of those showing minimal disability as measured by RUG-II assessment. It will be important to find out if those with dementia constitute a large fraction of that group and if there are alternative methods of care for those not admitted to nursing homes. The assessment process is often the starting point for planning services, educating family members, and referring people to support groups and other community resources. Early engagement of a formal assessment process can thus serve as a focal point for bringing health professionals and families together to determine the prognosis for the individual with dementia, to learn about care options, and to find sources of relevant information. Special Services for Individuals With Dementia An increasing number of long-term care facilities and agencies are developing special services for persons with dementia, but these services are not yet widely available and most such individuals are treated elsewhere. Preliminary data suggest that 1 to 2 percent of nursing home residents with dementia are in special care units. These facilities appear to be raising the standard of care, and are focusing attention on the large subpopulation of nursing home residents who suffer from dementia. Special care involves training of nurses and aides, redesign of rooms and common areas, and activities intended to take advantage of spared mental functions, Adapting the environment to altered needs of those with dementia appears to be useful, but the optimal way to do so is a topic of debate. The number of special care units has increased dramatically in recent years, yet no national body is responsible for identifying them, coordinating studies (to reduce duplication and disseminate results rapidly), or evaluating their efficacy. Several policy issues are raised by special care units and programs. First, there is an apparent shortage of people highly knowledgeable about dementia available to staff such units or evaluate them. Second, evaluation and coordination of different units is currently haphazard. Third, standards for quality are unclear. Fourth, the type of individual eligible for care on special units is not uniform among different units, and optimal care methods may differ according to severity, type of symptoms, or disease. Finally, the costs and fair reimbursement rates for special units merit further inquiry. Do special care units cost more? Should they be paid more to care for those with dementia? Will special reimbursement lead to inequitable treatment of other types of patients, or will failure to pay more for those with dementia diminish their care? Quality Assurance Persons with dementia are at particular risk of receiving substandard care. They cannot communicate effectively, and their complaints may be discounted or ascribed to mental instability or misunderstanding. Reduced intellectual abilities interfere with rational consumer choice, an important component of quality assurance. Family members can act on behalf of individuals with dementia to assess and ensure the quality of care. If they are not available or the family is not cohesive, then ombudsmen, case managers, or designated surrogates must do so. Quality of care in hospitals paid by Medicare is subject to the review of Professional Review Organizations. outpatient and ambulatory acute care are less subject to direct inspection. The threat of malpractice is a strong incentive for providing adequate care in most acute care settings, but it has not been widely applied in long-term care settings. The quality of care in nursing homes is regulated by States, subject to certification standards for Medicare and Medicaid. The system for assessing quality under Medicaid and Medicare is changing from a focus on inspection of facilities and physical plant to one that adds a client-centered assessment. Residents with dementia, however, are unlikely to be able to answer many of the questions about quality; inspection of their physical condition will yield clues as to their physical care, but will not assess overall quality of staff interactions or the residents emotional satisfaction and staff regard for the persons dignity. These con- PAGE 51 Ch. lDementia: Prospects and Policies 45 cerns are difficult to solve through purely regulatory means. Family assessment of a relatives health and happiness is another means of quality assurance. It is not available to residents without families, however, and its efficacy hinges on facilities willingness to attend to suggestions or the availability of alternative care settings if they do not. For Medicare and Medicaid administrators, only limited options exist to ensure compliance with care standards. In many areas, the scarcity of nursing home beds makes moving out of a poorly managed facility an unattractive option for the resident because an alternative one may not be available; that same scarcity makes State agencies reluctant to close down facilities. Less stringent enforcement actions have been successful in some States, and legislation permitting more use of them might be useful (see ch. 10). Professional organizations (e.g., American Health Care Association and the American Association of Homes for the Aging), proprietary and nonprofit nursing home chains, and new programs in teaching nursing homes can also promote higher standards and adherence to existing standards. Day care, home care, board and care, and other community-based settings are licensed and regulated much less than nursing homes. Information about quality in such settings is sparse and much less thoroughly analyzed than information regarding quality of care in hospitals or nursing homes, Payment levels are generally lower and tend to be direct rather than through public subsidy, making any government regulation beyond licensing unlikely. Family or case manager assessment of quality is thus the main assurance of quality, perhaps supplemented by final resort to the legal system. Organizations (e.g., the National Association for Home Care and the National Council on the Aging) can help develop guidelines for care and suggest means of quality assurance. Federal and State Governments could also choose to have a direct role. If the range of services is expanded, examination of the quality of care in day care, home care, and board and care settings would bean important topic for health services research to identify innovative ways to ensure that individuals have quality care that respects their rights and preserves their dignity. Financing Long-Term Care Financing long-term care for persons with dementia is one of the policy issues of greatest concern to caregivers and policymakers, and about which there is the least consensus. Policy options fall into several groups, according to the range of services reimbursed; the source of payment (individual, Medicaid, Medicare, insurance); and the relative responsibility of individuals and government. These factors are woven together in a confusingly complex fabric of existing policies and priorities. Caregivers would prefer to see an expanded range of services available, whatever the source of payment. Government program administrators, legislators, and insurers also wish to fund the broadest number of options, but they do not want to leave commitments open-ended or to pay for services used by those who do not need them. The extremely complex set of laws, regulations, and contract arrangements for long-term care services reflects that concern for overutilization. Restricting payment to institutional settings has been one way to discourage illegitimate use and to attempt to concentrate resources on those who most obviously need them. The source of payment determines not only who pays but also which services are covered and how those services are regulated and financed. Acute care under Medicare, for example, is paid under the diagnosis-related group payment system in most States, covers only some medically necessary services, and is relatively uniformfrom the point of view of the individualthroughout the United States. Medicaid, in contrast, varies tremendously among the States in its eligibility criteria, funding levels, extent of coverage of nonmedical services, access to home services, method of payment, and enforcement of quality standardsfor both acute and long-term care (19). Options for financing long-term care also differ in degree of public subsidy, ranging from complete private financing to heavy public subsidy. At one end of the scale, private financing would include: l direct individual or family payments not derived from government income programs, PAGE 52 46 l Losing a Million Minds: Confronting the Tragedy of A/zheimers Disease and Other Dementias l l l group cooperatives (for bargaining reduced rates with providers and insurers), charities, and conversion of home equity or other illiquid assets. Numerous options that combine private financing with indirect public subsidy have been suggested: l l l l l l l l direct payments derived in part from government income programs; volunteer programs (generally by tax-subsidized nonprofit organizations, but also including government aid as in ACTIONs Senior Companion programs); social/lhealth maintenance organizations (S/HMOs); cooperatives (composed of groups of individuals with similar needs either directly providing care on a mutual help basis, directly financing services, or sharing information about services and financing options); private long-term care insurance (tax-subsidized); life care communities (tax-subsidized); dependent care tax deductions or tax credits; and individual medical or retirement accounts (tax-subsidized). Finally, financing could involve increased direct public subsidy, with individuals contributing partial costs through expanded Medicaid eligibility, range of services, or level of payment, and through Medicare coverage of long-term care services. Policy changes affecting Medicaid and Medicare could involve either small incremental changes in eligibility, scope of services, or reimbursement mechanisms or major long-term care reform. Major reform might entail private options dovetailed to public programs, publicly managed voluntary insurance options, or mandatory long-term care coverage. Options that extend complete public subsidy of all costs have not been discussed because proposals for such programs are not before the U.S. Congress. The full range of policy options is more fully discussed in chapter 12, with brief discussions of some of the advantages and disadvantages of each. They are also covered in the report of the OTA workshop held in May 1986, to be released by the Senate Committee on Labor and Human Resources and the House Select Committee on Aging. In addition, reports on long-term care financing are expected from the Brookings Institution and the Congressional Budget Office. Secretary of Health and Human Services Otis Bowen transmitted a report on catastrophic illness to the President in November 1986. That report discussed acute medical care and also recommended several changes to improve long-term care financing, noting that long-term care is the most likely catastrophic illness risk faced by individuals and families. Long-term care recommendations included: 1) Federal and private support for a broad educational effort regarding risks, costs, and options; 2) establishment of Individual Medical Accounts and withdrawal provisions for Individual Retirement Accounts (see ch. 12); and 3) support for private long-term insurance through tax provisions and removal of employer disincentives to cover long-term care in health insurance plans. Preparation of the report involved several public hearings in different regions, deliberations by three committees, and is based in part on a report to the Secretary by the Private/public Sector Advisory Committee on Catastrophic Illness (86). Financing of long-term care is one of the issues affecting individuals with dementia (and their families) that is most sensitive to public policies. Through Medicaid, Federal and State Governments are important payers of long-term care, covering the majority of those in nursing homes. The amounts paid by State and Federal Governments for nursing home care are roughly equal to total payments by individuals. The American Health Care Association estimates that 70 percent of nursing home residents are covered by Medicaid, and the figure is well over 80 percent for some States (58). The proportion of patients covered by Medicaid is higher than its fraction of payments for two reasons: 1. some patients on Medicaid also receive some income (from social security or other sources) that is paid to the facility to reduce Medicaid payments, and PAGE 53 Ch. 1Dementia: Prospects and Policies 47 2. levels of reimbursement per person are generally lower through Medicaid than other sources of payment. The dominance of Medicaid means that decisions about the Medicaid program have a great effect on how nursing homes operate. Policies affecting nursing home coverage under Medicare affect a smaller, but still significant, fraction of nursing homes. Because of the absence of private insurers in long-term care, Federal and State Government decisions about financing are pivotal in determining access to and availability of day care, home care, respite care, and other services outside nursing homes. Biomedical Research Biomedical research includes basic biological, clinical, and public health research. It roughly corresponds to the type of research conducted under the auspices of the National Institutes of Health (either directly or through universities and medical centers). Basic research is conducted in the pursuit of scientific knowledge without primary regard for the applications of such knowledge. Clinical research applies basic knowledge in the search for preventive measures, treatments, and methods of diagnosis. Public health research builds on both basic and clinical research and applies it to population aggregates. The most common type of dementia, Alzheimers disease, cannot be prevented or its symptoms reversed with current knowledge and techniques. The severity of future medical and social problems could be dramatically reduced if an effective drug or surgical treatment were found to significantly reduce symptoms or arrest the disease. Only a small proportion of those expected to develop dementia now have it, so finding a means of prevention could drastically reduce the projected number of people affected. NIA, NIMH, and NINCDS are the three primary agencies supporting biomedical research (see table 1-8). Federal support for biomedical research (excluding funding for the Administration on Aging (AOA) and the Health Care Financing Administrati o n ( HCFA ), whose research is primarily on health service delivery) has gone from less than $4 million in 1976 to over $65 million estimated for 1987. The number of publications on Alzheimers disease, dementia, and senility leapt from 30 in 1972 to 87 in 1976, and then to 548 in 1985, reflecting the importance of increased Federal support. Nongovernment organizations such as ADRDA, the John Douglas French Foundation on Alzheimers Disease, the American Federation for Aging Research, and the Howard Hughes Medical Institute are also contributing research funds, at levels corresponding to 5 to 10 percent of Federal funding, Private pharmaceutical and medical products companies are supporting applied research to find effective drugs and diagnostic devices, but their work builds on the basic research supported by the Federal Government. Biomedical research on dementing conditions is likely to yield benefits in addition to its clinical Table l-8.Federal Funding for Research on Dementia, 1976-87 (thousand dollars) Agenc v a 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986b 1986C 198 7 d NIA . . . 857 1,500 1,960 4,142 4,211 5,196 8,054 11,848 21,456 28,830 34,048 32,691 40,760 NINCDS . . .2,314 2,333 2,422 2,844 4,960 5,427 6,243 8,678 11,700 12,826 14,030 13,427 15,900 NIMH . . 728 815 790 1,315 2,151 4,700 4,800 5,000 5,600 5,750 6,000 5,750 6,000 NIAID . . 1,381 1,775 1,394 1,256 1,041 1,336 1,211 1,247 1,192 1,412 DRR . . . 604 709 1,034 1,055 1,010 1,062 AOA . . . 164 1,128 900 627 600 HCFA . . 1,200 Total DHHS .3,899 4,648 5,172 9,682 13,097 16,717 20,353 27,171 40,965 50,779 57,280 54,697 66,93 4 aNIA (f.Jatk~nal Institute on Aging), NINCDS (f.Jational Institute on Neurological and Communicative Disorders and Stroke), NIMH (National Institute Of Mental Health), NIAID (National Institute on Allergy and Infectious Diseases), DRR (Division of Research Resources, National Institutes of Health), AOA (Administration on Aging), and HCFA (Health Care Financing Administration), All agencies are in the U.S Department of Health and Human Services. bAPProPriated by Congress in Public Law 99-ITfJ CEStlrnateS following sequestration of funding under the Deficit Reduction Act of 1985. dEstimates based on Continuing Resolution appropriations for Fiscal Year 1987 (P, L, 99.500), with individual figures taken from agency budget Off iCeS and direct appropriations. SOURCE National Institute on Aging Budget Office, 1988; National Institute of Mental Health Budget Office, 1986; and Progress Report on A/zheirners Disease: Vo/urrre //, NIH Publication 84-2500, July 1984; modified by the Office of Technology Assessment in light of fiscal year 1987 appropriations, Estimates obtained from individual agency budget offices for years 1988 and 1987. PAGE 54 48 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias applications. Knowledge of the brain is still scant in comparison to the size of the task, and the study of the nervous systemneuroscienceis one of the most exciting areas in biology today. Support for research on dementing conditions will likely support work that will increase such knowledge in these disciplines. Research on dementia could, in fact, become a focus for neuroscience, just as cancer research led to many important advances in molecular biology and the spawning of biotechnology. Major successes in biomedical research could also substantially reduce the costs and projected social and personal burdens of dementia. In other areas of research, successful prevention or treatment may actually lead to increased health care costs (e.g., a death prevented in middle age can increase aggregate costs because the person lives longer to have more episodes of ill health, each of which involves costs). Prevention or effective treatment of dementing disorders is likely to be highly cost-effective in the long term because the financial impact is severe, chronic, and occurs at the end of life. An effective means of preventing Alzheimers disease would, for example, dramatically reduce the need for nursing homes and costly medical care without necessarily leading to substantially longer life or new medical problems. Other medical problems would likely cost less, rather than more. An exclusive focus on biomedical research is unwise, however. Although increased funding makes scientific discoveries more likely, such discoveries will not necessarily lead to a means of prevention or cure, diagnostic tests, or even effective treatments. The consequences of new scientific findings may not be known for several decades, and may only much later improve clinical care. Scientific problems posed by disorders causing dementia are likely to yield to scientific inquiry, but public policy that presumes a revolution in care methodsbased on discoveries not yet made is not advisable. Health Services Research Health services research, as it applies to the subject of this report, is the multidisciplinary study of those with dementia and of the systems that serve them. It includes the community and family, but excludes biomedical research. Some types of research, such as epidemiology and patient assessment, bridge the gap between health services and biomedical research. Study of how to care for individuals, especially evaluation of methods that do not employ drugs or medical devices, is included in health services research, although some elements are also clinical. Topics range from studying how best to care for persons with dementia (at home, in nursing homes, or in day care centers) to evaluating different methods of paying for long-term care services. Health services research tends to be supported by different agencies than biomedical research, although there is some overlap (NIMH and NIA, for example, mainly support biomedical research but are also among the agencies providing the most support for health services research on dementia). The type of information derived from health services research is crucial to rational planning of public policy and informed consumer choice. One analyst has observed, however, that public policy is hampered by the woeful state of information about almost all social aspects of senile dementia and the deplorable quality of studies of intervention effects (58). Health services research related to dementia was the topic of an OTA workshop held in February 1986, cosponsored by the Subcommittee on Aging of the Senate Committee on Labor and Human Resources, the Human Services Subcommittee of the House Select Committee on Aging, and ADRDA. Results of that workshop are summarized here, and are discussed more fully in another document available through the Senate Committee on Labor and Human Resources and the House Select Committee on Aging. Discussions at that workshop revolved around six general topics: 1. epidemiology, 2. patient assessment, 3. service needs, 4. availability of and access to services, 5. cost of care, and 6. quality assurance and measurements of outcome. Several points of consensus emerged at the workshop. First, dementing disorders are a sub- PAGE 55 Ch. lDementia: Prospects and Policies 49 stantial problem for the health care system, particularly in long-term care. Second, little is known about them in any setting. Third, data have been gathered that might shed light on current policies, but the data have not been analyzed with a view to discerning the needs of the large number of individuals who have dementia (71). Finally, there is a need to intensify the study of health care delivery to individuals with dementia and their families. The few studies of health services that have focused specifically on the needs of individuals with dementia stand in stark contrast to the amount of information about treatment of specific groups of comparable size in acute care (e.g., persons with diabetes). That lack reflects both a general paucity of information about long-term care services, and a failure of long-term care studies to focus on the large subpopulation with dementia. Many recent and ongoing efforts to gather data about long-term care do contain information about individuals with dementia. No single survey is ideal in assessing needs, disabilities, severity of cognitive impairment, and availability of informal supports, but the breadth and depth of the information collected across the data sources suggest that a substantial understanding of health service questions could be acquired by analysis of the data sets (73). Efforts to analyze such data sets would be much less costly than beginning extensive new surveys, and could answer some important questions and identify other key ones to address in future demonstrations, Some questions are not addressed, however, in available data sets (e.g., whether special care is effective or economical, or the long-term impact of respite care on family stress, functional disability, and costs). Analysis of such questions will require new demonstrations, but these should start from the most sophisticated understanding of current data available. Several important questions about long-term care need to be resolved before prudent public policy on health services can be enacted. It is frequently argued, for example, that in-home services can help physically and cognitively impaired people to remain in their homes. Yet a growing body of evidence indicates that expanded use of in-home services does not generally reduce the need for nursing home beds (120). Such research has failed to separately analyze those with and without dementia, to focus on specific target groups (99), or to concentrate on long-stay patients whose needs are more supervisory than medical (52). Persons with dementia fall into the groups about which there is the least informationthose needing supervisory care for long periods rather than skilled care for short periods. It is thus unclear whether in-home and other respite services will supplement, supplant, or increase nursing home care for those with dementia. Special attention to this group may prove crucial to designing long-term care services in general. A large proportion of nursing home residents, particularly long-stay residents, are individuals with dementia who require 24-hour supervision, a service that is not generally offered in the home. Conversely, persons needing long-term care but not 24-hour supervision (e.g., those with arthritis or paralysis due to stroke) may benefit greatly from home care services but are less likely to be in a nursing home. The lack of correlation between availability of home services and reduction of nursing home care may thus be explained, at least in part, as use by different types of individuals. Only further study of long-term care service delivery in various settings can resolve that and other questions of interest to providers and policy makers. Research on delivery of care can build on efforts by States, long-term care providers, and family support groups, but Federal coordination would be useful to reduce needless duplication of effort, to ensure wide dissemination of relevant results (a clearinghouse function), and to maintain sufficient focus on Federal issues (e.g., quality assurance, cost containment, and payment). Health services research will determine the future basis for public and private activities in financing, quality assurance, training, and service delivery to persons with dementia. Research in this field does not necessarily depend on projects including only individuals with dementia. Evaluation of more general long-term care demonstrations can shed light on how those with dementia use such care. HCFA is supporting a study of reimbursement in the State of Texas, for example, that covers a sample of all nursing home patients, not just those with dementia. A part of the informa- PAGE 56 50 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias tion gathered will include assessment of cognitive status that can be compared with existing studies on those with dementia in the community. That study should permit an evaluation of the influence of cognitive impairment per se, which has not been previously possible. Federal spending for health services research in 1984 reached $200 million. That was onetwentieth of 1 percent of total health care spending that year ($387 billion), one-fifth of 1 percent of Federal health care spending ($111.9 billion), and 3.2 percent of the Federal budget for biomedical research ($6.15 billion). A survey of Federal agencies supporting health services research on dementia was conducted in April 1986 by the Congressional Research Service (81, cited in 119). The survey found that AOA was funding 12 projects, with the following spending history: $163,817 for two projects in fiscal year 1984; $1,127,618 for 12 projects in fiscal year 1985; and $431,400 continuing and $500,000 planned new spending in fiscal year 1986. NIA was planning $426,000 for fiscal year 1986. NIMH was funding three health service research projects that would include a component focused on dementia in fiscal year 1983, four in fiscal year 1984, seven in fiscal year 1985, and seven in fiscal year 1986, but the budget specific to dementia was not estimated. AOA, NIMH, and HCFA were each soliciting proposals for research that included analysis of health services for those with dementia. The National Center for Health Services Research (NCHSR) and Health Care Technology Assessment had not funded specific research and was not soliciting projects. Estimated Federal spending on health services research related to dementia was thus in the range of $1.3 million to $2 million in 1986. That corresponds to roughly one-two-hundredth of 1 percent of the estimated national costs of dementing illness ($24 billion to $48 billion), one-thirtieth of 1 percent of Federal payments for long-term care of those with dementia ($4.4 billion), and 3 percent of biomedical research on dementia ($54 million). The need for information about long-term care of those with dementia in order to plan national health policy has prompted Congress to fund research in this area. The final column in table 1-8 shows the estimated levels of research funding provided by the Continuing Appropriations for fiscal year 1987 (called the continuing resolution Public Law 99-500). The bulk of funding is for basic and clinical research, but also includes $1.2 million for HCFA to develop and fund three demonstration projects on respite care for families of those with Alzheimers disease and related disorders. The omnibus Budget Reconciliation Act of 1986 (OBRA-Public Law 99-509) authorizes up to $40 million to create 5 to 10 regional centers to diagnose and treat individuals with Alzheimers disease and related disorders. Funding will come from Medicare payments for those already Medicare eligible. (The continuing resolution limits funding for demonstration projects under Medicare, and a few experts contacted by OTA believe that this limit might apply to the Alzheimers disease diagnosis and treatment centers. Most consulted, however, believed that the restrictive language would not apply, and the centers would be funded as specified in OBRA.) OBRA also authorized $1 million for fiscal year 1987, and $2 million in each of the three following years, to develop a respite care demonstration program in New Jersey under the States Medicaid program. HCFA funding for health services research will be supplemented by a group of projects supported by a combination of private and government sources. The Robert Wood Johnson Foundation, Administration on Aging, and ADRDA are jointly planning a competitive grants program. They intend to support the development of dementia service delivery demonstration projects in a number of communities throughout the Nation. The last piece of legislation passed by the 99th Congress (Public Law 99-660) includes the Alzheimers Disease and Related Dementias Services Research Act. This law establishes a Council on Alzheimers Disease within the Department of Health and Human Services (making permanent the Task Force on Alzheimers Disease), an Advisory Panel on Alzheimers Disease (composed of 15 citizens appointed by the Director of the Office of Technology Assessment), a new group of awards for achievement in research to be bestowed by the Director of NIA, and an information clearinghouse to disseminate information about Alzheimers PAGE 57 Ch. 1Dementia: Prospects and Policies l 51 disease-also administered by NIA. The act authorizes health services research to be conducted by NIA, NIMH, NCHSR/HCTA, and HCFA (beginning in October 1987) and mandates educational programs for the Social Security Administration (regarding disability policies related to dementia) and training of safety and transportation personnel about special problems in dealing with individuals who have dementia. It also authorizes increased support for training in geriatrics. Several of the provisions of the new law can go into effect without further action. The research programs and other activities authorized by the act will, however, depend on new appropriations in the 100th Congress. CHAPTER 1 REFERENCES 1. Almquist, E., and Bates, D., Training Program for Nursing Assistants and LVNs in Nursing Homes, Journal of Gerontological Nursing 6:622-627, 1980. 2. Alzheimer Task Force, Alzheimer Task Force Report Long-Term Care Coordinating Council for the Elderly, Austin, Texas, Oct. 31, 1985. 3. Alzheimers Disease and Related Disorders Association, Advocacy Update, July 31, 1985. 4. Alzheimers Disease and Related Disorders Association, Ad Hoc Committee on Planning, Jan. 9 and 10, 1986 report, 5. Alzheimers Resource Center, Caring: A Family Guide To Managing the Alzheimers Patient at Home, New York City Alzheimers Resource Center, 1986. 6. American Association of Retired Persons, ( AARP Long-Term Care Research Study, survey conducted by the Gallup Organization, Jan. 30, 1986. 7. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 3d ed. (Washington, DC: 1980). 8. Arnett, R. H., McKusick, D. R., Sonnefeld, S. T., et al., ( Projections of Health Care Spending to 1990, Health Care Financing Review 7:1-36, spring 1986. 9. Barclay, L. L., Zemcov, A., Blass, J. P., et al., Survival in Alzheimers Disease and Vascular Dementia, Neurology 35:834-840, 1985. 10. Battelle Memorial Institute, The Economics of Dementia) contract report prepared for the Office of Technology Assessment, U.S. Congress, 1984. 11. Bloom, D. E., and Korenman, SD., The Spending Habits of American Consumers, American Demographics 8:23-25, 51-54, March 1986. 12. Brody, E. M., Parent Care as a Normative Family Stress, Donald P. Kent Memorial Lecture, Gerontological Society of America, San Antonio, TX, Nov. 18, 1984. Reprinted in The Gerontologist 25: 1929, 1985. 13. Brody, E. M., Lawton, M. P., and Liebowitz, B., Senile Dementia: Public Policy and Adequate Institutional Care, American Journal of Public Health 74:1381-1383, 1984. 14. Brody, E. M., and Brody, S. J., Service Systems for the Aged, prepared for the Encyclopedia of Social Work, in press. 15. Brody, S. J., The Thirty-to-One Paradox: Health Needs and Medical Solutions National Journal 11:1869-1873, 1979. 16. Brody, S. J., and Magel, J. S., LTC: The Long and Short of It, Long-Term Care, C. Eisdorfer (cd.) (Baltimore: Johns Hopkins Press, in press). 17. Chandra, V., Bharucha, N. E., and Schoenberg, B. S., Conditions Associated With Alzheimers Disease at Death: Case Control Study, Neurology 36:209-211, 1986. 18. Chandra, V., Bharucha, N. E., and Schoenberg, B. S., Patterns of Mortality From Types of Dementia in the United States, 1971 and 1973 -1978, Neurologv 36:204-208, 1986. 19. Chavkin, D., Interstate Lamiability in Medicaid Eligibility and Reimbursement for Dementia Patients, contract report prepared for the Office of Technology Assessment, U.S. Congress, March 1986. 20. Cicirelli, Family Relationships and the Care/Management of the Dementing Elderly, The Demen tias: Policy and Management, M .L.M. Gilhooly, S.H. Zarit, and J.E. Birren (eds.) (Englewood Cliffs, NJ: Prentice-Hall, 1986). 21. Cohen, D., and Eisdorfer, C., The Loss of Self; A Family Resource for the Care of Alzheimers Disease and Related Disorders (New York: W.W. Norton, 1986). 22. Cohen, J., Holahan, J., and Liu, K., Financing Long-Term Care for the Mentally Ill: Issues and Options, working paper # 3546-01, Urban Institute, Washington, DC, May 1986. 23. Colerick, E. J., and George, L. K., Predictors of Institutionalization Among Caregivers of Patients With Alzheimers Disease, Journal of the American Geriatrics Society 34:493-498, 1986. 24. ( Coolfont Report: A PHS Plan for Prevention and Control of AIDS and the AIDS Virus, report of a Public Health Service meeting in Berkeley PAGE 58 52 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Springs, WV, June 4-6, 1986, Public Health Reports 101:341-348, 1986. 25. Coons, D. H., A Residential Care Unit for Persons With Dementia, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986, 26. Cornelius, E., Health Care Financing Administration, personal communication, April 1986. 27. Cross, P. S., and Gurland, B. J., The Epidemiology of Dementing Disorders, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. 28. Danish Medical Bulletin, Special Issue on Alzheimers Disease, vol. 32, Gerontology Special Supplement No. 1, February 1985, pp. 1-111. 29. Doty, P., Liu, K,, and Wiener, J., Special Report: 30 < 31, 32. 33. An Overview of Long-Term Care, Health Care Financing Review 6:69-78, 1985. Dunn, L., The Senior Respite Care Program, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986, Fields, S. D., MacKenzie, C. R., Charlson, M. E., et al., Cognitive Impairment: Can It Predict the Course of Hospitalized Patients? Journal of the American Geriatrics Society 34:579-585, 1986, Foley, W .J., Dementia Among Nursing Home Patients: Defining the Condition, Characteristics of the Demented, and Dementia on the RUG-II Classification System, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. Folstein, M., Anthony, J. C., Parhad, I., et al., The Meaning of Cognitive Impairment in the Elderly, Journal of the American Geriatrics Society 33:228235, 1985. 34. Fox, P.J., Lindeman, D.A., and Benjamin, A.E., Status of Alzheimers Disease Diagnostic and Treatment Centers and Alzheimers Disease Research Grants in California, Institute for Health and Aging, University of California, San Francisco, January 1986. 35. French, C.J., Experiences in the Development and 36 37 Management of the Community Services Program of the Atlanta Area Chapter of Alzheimers Disease and Related Disorders Association, Inc., contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. Garfield, A., Alzheimers Disease and Related Disorders Association, Chicago, IL, personal communication, April 1986. George, L. K,, The Dynamics of Caregiver Burden, final report submitted to the American Association of Retired PersonsAndrus Foundation, Washington, DC, 1984. 38. Georgia Department of Human Resources, Office of Aging, Study Committee Report, Alzheimers Disease, Atlanta, GA, December 1985. 39. Geriatric Nursing Assistant Training Task Force, Geriatric Nursing Assistant Training in Virginia, Final Report, Department of Education of the Commonwealth of Virginia, Richmond, VA, January 1982. 40. Gordon, N. M., Assistant Director for Human Re41 42, 43. 44. 45. 46. 47. 48. 49. 50. 51. sources and Community Development, Congressional Budget Office, statement before the U.S. House of Representatives, Committee on Energy and Commerce, Subcommittee on Health and the Environment, prepared by S.H. Long, J. Rodgers, and B. Vavrichek, Congressional Budget Office, Mar. 26, 1986. Governors Committee on Alzheimers Disease, Commonwealth of Massachusetts, Boston, MA, 1985. Governors Task Force on Alzheimers Disease and Related Disorders, The Maryland Report on Alzheimers Disease and Related Disorders, State of Maryland, Annapolis, MD, June 30, 1985. Gurland, B.J., Public Health Aspects of Alzheimers Disease and Related Dementia, Alzheimer's Disease and Related Disorders: Research and Management, W.E. Kelley (cd.) (Springfield, IL: Charles C. Thomas, 1985). Gwyther, L. P., Care of Alzheimers Patients: A Manual for Nursing Home Staff (Chicago, IL: Alz heimers Disease and Related Disorders Association, 1985). Handschu, S. S., Profile of the Nurses Aide, The Gerontologist Part I, pp. 315-317, autumn 1973. Heckler, M.M., The Fight Against Alzheimers Disease) American Psychologist 40:1240-1244, 1985. Henderson, J. N., Mental Disorders Among the Elderly: Dementia and its Sociocultural Correlates, Modern Pioneers: An Interdisciplinary View of the Aged, P. Silverman (cd.) (Bloomington, IN: Indiana University Press, 1986). Heston, L. L., and White, J. A., Dementia: A Practical Guide to Alzheimer's Disease and Related Disorders (New York: W.H. Freeman, 1983). Hogstel, M, O., Auxiliary Nursing Personnel, Management of Personnel in Long-Term Care, M.O. Hogstel (cd.) (Bowie, MD: Robert J. Brady Co,, 1983). Hu, T. W., Huang, L. F., and Cartwright, W. S., Evaluation of the Costs of Caring for the Senile Demented Elderly: A Pilot Study) The Gerontologist 26:158-163, 1986. Huang, L.-F., Hu, T.-W., and Cartwright, W. S., The Economic Cost of Senile Dementia in the PAGE 59 Ch, lDementia: Prospects and Policies l 5 3 52. 53, 54. 55 < 56 57, 58, 59, 60, 61. 62< 63. 64. United States, 1983) contract report prepared for the National Institute on Aging, No. 1-AG-3-2123, 1986. Hughes, S. L., (Apples and Oranges? A Review of Evaluations of Community-Based Long-Term Care, Health Services Research 20:461-488, 1985. ICF, Inc., Private Financing of Long-Term Care: Current Methods and Resources, final report submitted to the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, January 1985. ICF, Inc., The Role of Medicare in Financing the Health Care of Older Americans, submitted to American Association of Retired Persons, Washington, DC, July 1985. Intergovernmental Health Policy Project, Alzheimers Initiatives Advance, State Health Notes, No. 56, September 1985, pp. 1-3. International Classification of Diseases, 9th Revision Conference, 1975, (Geneva: World Health Organization), vol. 1, 1977 and vol. 2, 1978; modified by Coding Clinics for ICD-9 CM, American Hospital Association, various issues, Jazwiecki, T., Director, Office of Reimbursement and Financing, American Health Care Association, Washington, DC, personal communication, April 1986. Kane, R. A., Senile Dementia and Public Policy, The Dementias: Policy and Management, M.L. Gilhooly, S.H. Zarit, and J.E. Birren (eds.) (Englewood Cliffs, NJ: Prentice-Hall, 1986). Kane, R.L., Acute and Long-Term Care: Decisions and Decisionmakers, paper prepared for the Conference on the Impact of Technology on LongTerm Care, Feb. 16-18, 1983, sponsored by the Office of Technology Assessment, U.S. Congress, Project HOPE, the George Washington University Health Policy Forum, and the Institute of Medicine, National Academy of Sciences, 1983. Kansas Alzheimers and Related Diseases Task Force, Final Report to the Kansas Department on Aging, Topeka, KS, 1986. Katzman, R., The Prevalence and Malignancy of Alzheimers Disease: A Major Killer, Archives of Neurology 33:217-218, 304, 1976. Katzman, R., Aging and Age-Dependent Disease: Cognition and Dementia, America's Aging: Health in an Older Society, Committee on an Aging Society, Institute of Medicine and National Research Council (Washington, DC: National Academy Press, 1985). Katzman, R., Alzheimers Disease, New England Journal of Medicine 314:964-973, 1986. Katzman, R., Lasker, B., and Bernstein, N., Ac65 66 67. 68. 69. 70. 71 72 73 74 75 76 curacy of Diagnosis and Consequences of Misdiagnosis of Disorders Causing Dementia, contract report prepared for the Office of Technology Assessment, U.S. Congress, submitted for publication, 1986. Larson, E. B., Reifier, B. V., Sumi, S. M., et al., ( Diagnostic Tests in the Evaluation of Dementia: A Prospective Study of 200 Elderly Outpatients, Department of Medicine, University of Washington Medical Center, Seattle, WA, in press. Levit, K. R., Personal Health Care Expenditures by State: 1966 -1982, Health Care Financing Review 6:1-49, 1985. Lidoff, L., Mobilizing Community Outreach to the High-Risk Elderly: The Gatekeepers Approach, (Washington, DC: National Council on the Aging, Inc., 1984). Light, Enid, U.S. Department of Health and Human Services, National Institute of Mental Health, Program on Aging, personal communication, Apr. 19, 1986. Light, E., Lebowitz, B., and Bailey, F., CMHCs and Elderly Services: An Analysis of Direct and Indirect Services and Services Delivery Sites) submitted for publication by the U.S. Department of Health and Human Services, National Institute of Mental Health, 1986. Lindeman, D. A., Bliwise, N. G., Berkowitz, G., et al,, Development of a Uniform, Comprehensive Nomenclature and Data Collection Protocol for Brain Disorders, Institute for Health and Aging, University of California, San Francisco, June 1986. Liu, K., Analysis of Data Bases for Health Services Research on Dementia, contract report prepared for the Office of Technology Assessment, US. Congress, 1986. Liu, K., and Manton, K. G., The Length-of-Stay Pattern of Nursing Home Admissions, Medical Care 21:1211-1222, 1983. Lockery, S.A., Impact of Dementia Within Minority Groups, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. Mace, N., and Rabins, P., The 36-Hour Day: A Family Guide To Caring for Persons With Alzheimer's Disease, Related Dementing Illnesses, and Memory Loss in Later Life (Baltimore, MD: Johns Hopkins University Press; and New York: Warner, 1981). Max, W., Lindeman, D.A., Segura, T.G., et al., Estimating the Utilization and Costs of Formal and Informal Care Provided to Brain-Impaired Adults: A Briefing Paper, Institute for Health and Aging, University of California, San Francisco, June 1986. McCall, N., Rice, T., and Sangl, J., Consumer PAGE 60 54 Los/rig a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Knowledge of Medicare and Supplemental Health Insurance Benefits, Health Services Research 20:633-657, 1981. 77. Minnesota Task Force on the Needs of Persons 78 79, 80. 81. 82. 83. 84. 85. 86. 87. 88. With Brain Impairment, Final Report, submitted to the Commissioner of the Department of Human Services, State of Minnesota, December 1985. Mortimer, J. A., Epidemiology of Dementia International Comparisons, Epidemiology and Aging, G. Maddox and J. Brody (eds.) (New York: Springer, 1986). Mortimer, J. A., and Hutton, J.T., Epidemiology and Etiology of Alzheimers Disease, Senile Dementia of the Alzheimer Type, J.T. Hutton and A.D. Kenny (eds.) (New York: A.R. Liss 1985). Mulley, G .P., Differential Diagnosis of Dementia, British Medical Journal 292:1416-1418, 1986. OShaughnessy, C., Survey of Agencies Performing Health Services Research on Long-Term Care of Patients with Dementia, Congressional Research Service, Library of Congress, U.S. Congress, April 1986. Ouslander, J .G., and Kane, R. L., The Costs of Urinary Incontinence in Nursing Homes, Medical Care 22:69-79, 1984. Petty, D., The Family Survival Project, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. Powell, L. S., and Courtice, K., Alzheimer's Disease: A Guide for Families (Reading, MA: AddisonWesley, 1983). Price, D. L., Basic Neuroscience and Disorders Causing Dementia, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. Private/Public Sector Advisory Committee on Catastrophic Illness, Report to the Secretary of Health and Human Services, Aug. 19, 1986. Prospective Payment Assessment Commission, personal communication, Apr. 17 and 18, 1986. Radebaugh, T. S., Hooper, F.J., and Gruenberg, E. M., The Social Breakdown Syndrome in a Community Residing Elderly Population, British Journal of Psychiatry, in press. 89. Raschko, R,, Systems Integration at the Program Level: Aging and Mental Health, Spokane Community Mental Health Center, Spokane, WA, in press. 90. Rees, K.C., Legislative Advocacy and Alzheimers Disease: The California Experience, presented at the National Conference on Alzheimers Disease and Dementia, Detroit, MI, Apr. 10-12, 1986. 91. Reifier, B. V., and Orr, N., Alzheimer's Disease and the Nursing Home: A Staff Training Manual, (Tacoma, WA: Westprint Division of Hillhaven Corp., 1985). 92. Rhode Island Legislative Commission, Dementias Related to Aging, Providence, RI, May 1, 1984. 93. Risse, S. C., and Barnes, R., Pharmacologic Treatment of Agitation Associated With Dementia, Journal of the American Geriatrics Society 34:368376, 1986. 94. Ron, M. A., Toone, B. K., Garralda, M. E,, et al., 95 96 Diagnostic Accuracy in Presenile Dementia, British Journal of Psychiatry 134:161-168, 1979. Rovner, B.W., Kafonek, S., Filipp, L., et al., Prevalence of Mental Illness in a Community Nursing Home, American Journal of Psychiatry, in press. Rubenstein, L.Z., Josephson, K. R., Wieland, G. D., et al., Differential Prognosis and Utilization Patterns Among Clinical Subgroups of Hospitalized Geriatric Patients, Health Services Research 20:881-895, 1986. 97. Sayetta, R. B., Rates of Senile DementiaAlzheimers Type in the Baltimore Longitudinal Study, Journal of Chronic Diseases 39:271-286, 1986. 98. Schneider, D., Desmond, M., Foley, W., et al., 99. 100, 101, 102, 103. 104. 105. 106. Long-Term Care Case Mix Reimbursement Using RUG-II (Albany, NY: New York State Department of Health, December 1985). Shaughnessy, P. W., Long-Term Care Research and Public Policy, Health Services Research 20:489-499, 1985. Stone, R., Cafferata, G.L., and Sangl, J., Caregivers of the Frail Elderly: A National Profile, National Center for Health Services Research and Health Care Technology Assessment, US. Department of Health and Human Services, 1986. Study Committee Report, 1985, Alzheimers Disease) Georgia Department of Human Resources, Office of Aging, December 1985. Sulvetta, M. B., and Holahan, J., Cost and CaseMix Differences Between Hospital-Based and Freestanding Nursing Homes, Health Care Financing Review 7:75-84, spring 1986. Texas Department of Health, Alzheimer's Disease Initiative: Nursing Home Study (Austin, TX, 1985). U.S. Congress, House Select Committee on Aging, Twentieth Anniversary of Medicare and Medicaid: Americans Still at Risk, Hearing Before the U.S. House of Representatives, 99th Congress, July 30, 1985, Comm. Pub. No. 99-538 (Washington, DC: U.S. Government Printing Office, 1986). U.S. Congress, Office of Technology Assessment, Technology and Aging in America, OTA-BA-264 (Washington, DC: U.S. Government Printing Office, 1985). U.S. Congress, General Accounting Office, Con- PAGE 61 Ch. 1Dementia: Prospects and Policies l 55 straining National Health Care Expenditures: Achieving Quality Care at an Affordable Cost, No. HRD-85-105 (Washington, DC: U.S. General Accounting Office, 1985). 107. U.S. Congress, General Accounting Office, The Well-Being of Older People in Cleveland, Ohio, No. HRD-77-70 (Washington, DC: U.S. General Accounting Office, 1977). 108. U.S. Department of Health and Human Services, Alzheimers Disease, vol. 32, Gerontology Special Supplement, No. 1, February 1985, pp. 1-111. 109. U.S. Department of Health and Human Services, Report of the Secretary as Required by Section 16, Public Law 98-460, September 1985. 110. U.S. Department of Health and Human Services, Alzheimer's Disease: Report on Secretarys Task Force on Alzheimers Disease, DHHS Pub. No. ADM 84-1323, (Washington, DC: U.S. Government Printing Office, 1984). 111. U.S. Department of Health and Human Services, Health Care Financing Administration, LongTerm Care: Background and Future Directions, 1981. 112. U.S. Department of Health and Human Services, National Center for Health Statistics, Characteristics of Nursing Home Residents, Health Status, and Care Received: National Nursing Home Survey United States, May-December 1977, Vital Health Statistics Series 13, No. 51, DHHS Pub. No. (PHS) 81-1712, 1981. 113. U.S. Department of Health and Human Services, Task Force Report on Long-Term Care, Report of the Under Secretary, April 1981. 114. U.S. Department of Health and Human Services, Catastrophic Illness Expenses, Report to the President, November 1986. 115. U.S. Veterans Administration, Caring for the Older Veteran, (Washington, DC: U.S. Government Printing Office, 1984). 116. U.S. Veterans Administration, International Work Group, The Veterans Administration and Dementia, Recommendations for Patient Care, Research, and Training, Office of Geriatrics and Extended Care, Veterans Administration Central Office, Kellogg International Scholarship Program on Health and Aging, Institute of Gerontology of the University of Michigan, and Institute of Social Medicine, University of Copenhagen (Washington, DC: October 1985). 117. U.S. Veterans Administration, Office of Geriatrics and Extended Care, Department of Medicine and Surgery, Veterans Administration Central Office, Dementia: Guidelines for Diagnosis and Treatment (Washington, DC, 1986). 118. Vane) R., Natural Support Systems, Minority Groups, and the Late Life Dementias: Implications for Service Delivery, Research, and Policy, Clinical Aspects of Alzheimers Disease and Senile Dementia (Aging, vol. 15), N.E. Miller and G.D. Cohen (eds.) (New York: Raven Press, 1981). 119. Vierck, E., Health Services Research Related to Dementia, a report by the Subcommittee on Aging, U.S. Senate Committee on Labor and Human Resources, draft report, June 1986. 120. Weissert, W G., Seven Reasons Why It Is So Difficult to Make Community-Based Long-Term Care Cost-Effective, Health Services Research 20:423433, 1985. 121. Whitehouse, P. J., Alzheimers Disease, Current Therapy in Neurologic Disease, 1985-1986, R.T. Johnson (cd.) (Philadelphia, PA: B.C. Decker, 1985). 122. Winograd, C. H., and Jarvik, L. F., Physician Management of the Demented Patient, Journal of the American Geriatrics Society 34:295-308, 1986. 123. Yankelovich, Skelly, and White, Inc., Caregivers of Patients With Dementia, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. 124. Zarit, S. H., and Anthony, C. R., Interventions With Dementia Patients and Their Families, The Dementias: Policy and Management, M.L.M. Gilhooly, S.H. Zarit, and J.E. Birren (eds.) (Englewood Cliffs, NJ: Prentice-Hall, 1986). 125. Zarit, S. H., Reever, K. E., and Back-Peterson, J., ( Relatives of the Impaired Elderly: Correlates of Feelings of Burden, The Gerontologist 20:649655, 1980. PAGE 62 Chapter 2 Characteristics of Persons With Dementia PAGE 63 CONTENTS Page Definition of Dementia . . . . . . . . . . . . 60 other Diagnostic Criteria . . . . . . . . . . . 61 Variation in Symptoms . . . . . . . . . . . 61 Stages of the Disease . . . . . . . . . . . ., 62 Theoretical Advantages of Staging or Measures of Severity . . . . 63 Staging Instruments . . . . . . ., . . . . . 63 Use of Assessment Tools for Staging . . . . ..., . . . 63 Problems in the Use of Scales and Stages . . . . . . . 63 Symptoms of Dementia . . . . . . . . . . . . 68 Cognitive/Neurological Symptoms . . . . . . . . . 68 Ability To Do Normal Daily Activities. . . . . . . . . 70 Behavioral or PsychiatricSymptoms . . . . . . . . 72 Excess Disability Brought About by outside Factors . . . . . 77 Conceptual Issues Raised by the Characteristics of Persons With Dementia . 79 Is Dementia a Disease or Normal Aging? . . . . . . . . 79 Are Persons Eligible for Services on the Basis of Age or Disability? . . 79 Is Dementia a Mental Disorder, an Organic Disease, or Something In-Between? . . . . . . . . . . . . 79 What Share of Funds Should Be Allocated to Research Into Patient Care? . 80 Chapter 2 References. . . . . . . . . . . . . 81 Tables Table No. Page 2-1. Brief Cognitive Rating Scale . . . . . ..., . . . . 64 2-2.The Global Deterioration Scale for Age-Associated Cognitive Decline and Alzheimers Disease. . . . . . . . . . . . 6.5 2-3. Clinical Dementia Rating Scale. . . . . . . . . . 66 2-4. Ability of Dementia Patients To Do Basic Tasks . . . . . . 71 2-5. Assessment of Dementia Patients Eating SkiIls ,..,., . . . . 71 2-6. Assessment of Dementia Patients Toilet Skills. .,., . . . . . 71 2-7. Frequency of Dementia Patients Engagement in Certain Behaviors . . 73 Boxes B OX NO. Page A.The Experience of the Victim . . . . . . . ., . . 59 B. Progression of Dementia. . . . . . . . . . . 67 PAGE 64 Chapter 2 Characteristics of Persons With Dementia* What happens to the mind when a dementing illness strikes? Families and professionals alike struggle to understand why persons with dementing illnesses act as they do, and what, if anything, can be done to modify the persons strange behaviors or support lost skills. The burden of caring for individuals with dementia arises as much out of the need to protect them from their own lack of judgment and to restrain them from dangerous behaviors as it does from providing personal or medical care (22). The difficult behaviors, poor judgment, profound memory loss, and changes in cognition as the diseases progress significantly affect both family caregivers and those working in formal support systems (see box A and chs. 4 and 7). l This chapter is a contract report by Nancy Mace, Consultant in Gerontolo~, Towson, MD. This chapter will describe persons with dementia: the abilities they are losing, those that remain, and the ways in which these changing impairments affect the care these individuals need. The chapter: l outlines the stages of decline of chronic dementing illnesses and discusses the usefulness of documenting stages in the illness; l describes the symptoms of dementia and the impairments individuals experience; l identifies the symptoms that are most read ily alleviated; and l considers the care needs of victims of dementia that arise from these symptoms. while some causes of dementia are treatable (see Ch, 3), only chronic and irreversible illnesses are discussed here. 59 63-218 0 87 3 QL : 3 PAGE 65 60 Losing a Milliion Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Although most physicians and researchers agree among dementing diseases, and with patients on the definition of dementia, there is disagreethought to have the same disease. These variament over the stages of an individuals decline, tions, both in medical opinion and in knowledge on the causes of behaviors, and on the treatabilof the diseases, have a significant impact on policy. ity of symptoms. The course and symptoms vary DEFINITION OF DEMENTIA Several different methods are used to determine whether an individual has dementia. Clinicians increasingly use the criteria specified by the American Psychiatric Association in the third edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-III) (l). Many of the epidemiologic and clinical studies done since 1980 have also used these criteria. The DSM-III diagnostic classification provides a method for systematically grouping symptoms that affect mental function. A similar set of criteria was developed in 1983 in a joint effort between the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimers Disease and Related Disorders Association (ADRDA) (17,27). Based on these two sets of criteria, dementia is defined as: l a decline in intellectual function; l global cognitive impairment, that is, memory impairment and at least one of the following: impairment of abstract thinking; impairment of judgment; impairment of other complex capabilities such as language use, ability to perform complex physical tasks, ability to recognize objects or people, or to construct objects; and personality change; and l being in clear consciousness (i.e., awake and alert). The definition differentiates dementia from mental retardation, in which there is no decline from a previous level. Thus a person with exceptional intelligence might have dementia if his or her intellectual ability declined to average. Similarly, a mentally retarded person can suffer from dementia when his or her intellectual limitations worsen. That qualification requires that the individuals previous level of function be known. If no one can give a clear account of the persons past, the only way to determine if abilities are declining is to observe the individual over time. That necessity has implications for both epidemiology (7) and policy. If criteria for eligibility for services were to include documentation of change over time, individuals who require immediate assistance might be excluded. If, on the other hand, documentation of decline is not required, persons with lifelong impaired capacity might use limited services intended for persons with dementia. It is usually easy to document decline, based on the familys report. When someone has no close family, it is more difficult. The next part of the definition, global, means that more than one area of intellectual function is impaired. Thus a person suffering only a memory impairment (e.g., caused by Korsakoffs syndrome) or only an impairment in the ability to speak (e.g., caused by some strokes) is usually not said to be suffering from a dementia (26). In practice, these individuals are often similarly handicapped and limited in their ability to function independently. They will need services and resources like those for persons with a dementing illness. In addition, many people with Alzheimers disease suffer only memory loss at first. It is the expectation that other abilities will be lost that differentiates them from persons with pure amnesia. The definition also distinguishes dementia from other mental states such as delirium, sleep, coma, stupor, and intoxication. The third major qualification, in clear consciousness, means that in contrast to delirium, the person is mentally impaired even when awake and alert. Several criteria distinguish delirium from dementia. State of consciousness: Persons with delirium have fluctuating or clouded conscious- PAGE 66 Ch. 2Characteristics of Persons With Dementia l 6 1 l l l l ness, while those with dementia areas attentive as they can be. Stability: With delirium, the individuals ability to pay attention and respond varies over short periods, only minutes or hours, while dementia is relatively stable in comparison. Duration: Delirium is usually short-lived, while dementia has a more prolonged course. Rate of onset: Delirium usually appears abruptly, over days or weeks, while dementia, except for some vascular dementia, usually develops insidiously. Cause: Delirium usually can be traced to a recent sourcehead trauma, drugs, fever, infectionwhile dementia may not be linked to another cause. These distinctions are usually easy to make in young persons, but the borders between dementia and delirium blur with age. Elderly people can remain delirious for prolonged periods and the cause can be obscure. Many of the physical insults that cause delirium in the young can produce symptoms that look very much like dementia in older people. The elderly delirious patient can exhibit a full spectrum of psychiatric symptoms including delusions, hallucinations, depression, excitement, agitation, fear, anger, and apathy. A cognitive examination reveals disorientation, memory impairment, problems in writing, and inability to sustain a conversation (9). Thus delirious persons can easily be misdiagnosed as having a dementing illness, and the underlying cause of the delirium may be left untreated. Elderly people are especially vulnerable to delirium caused by illness or reactions to medication. Some may have only a delirium; others may suffer from both a delirium and a dementia. Persons with dementing illnesses are prone to develop additional delirium when they develop any other illness (42). In such cases, the delirium may cause a further decline in the individuals cognitive abilities. Therefore, the presence of an underlying dementia cannot be determined until any concurrent delirium has disappeared (39). Thus, eligibility for services based on the presence of dementia requires a careful search to exclude delirium. Any assessment of need for services would be difficult to determine for elderly persons who are acutely ill and confused. That is a particularly significant problem when such persons have been hospitalized. In order to avoid delays, plans for a patients discharge are begun soon after admission, when the presence and severity of dementia maybe difficult to determine. Other Diagnostic Criteria Several criteria that have been used in defining dementia are omitted from the DSM-III definition. DSM-III does not include any statement regarding the course of the illness (i.e., chronic or acute) or prospects for treatment (i.e., reversible or irreversible). It makes no statement regarding the cause of the dementia (e.g., Alzheimers disease or stroke) (26). Nor does it require the presence of specific behaviors such as agitation or wandering. Its great advantage is that it allows the description of disabilities along several axes without using unproved assumptions about cause or classification to label an individual. The absence of such labels has policy implications. In the past, elderly persons with memory loss or changed behaviors were said to be suffering from (chronic organic brain syndrome -a label that consigned them to a hopeless category before their condition had been diagnosed, and that discouraged the search for treatable causes of the dementia. Although the most common disorders causing dementia Alzheimers disease and multi-infarct dementia-are not curable, that may not always be so. Therefore, a definition that includes irreversibility would be inappropriate. Excluding the cause of the dementia from the diagnosis also permits identification of an individuals characteristics and needs in the absence of a causal diagnosis. Behaviors such as wandering are not necessary for the diagnosis because they may disappear as the persons condition declines or when under treatment. Variation in Symptoms The specific cognitive functions that are lost and those that remain can vary from time to time and from person to person (17). These variations may be due to several factors: l The progression (stage) of the disease or the length of time the person has had the disease PAGE 67 62 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias (18): Over time individuals gradually lose more and more cognitive ability. Because the speed at which these changes occur varies from person to person (from 1 to 20 years) (18), services need to be flexible if they are to meet changing impairments. (The limitations inherent in describing the course of the disease by stages are described later in this chapter.) The underlying disease causing the dementia (14): Some dementing illnesses affect gait, bladder control, or mood to a greater or lesser extent; other dementias affect reason, judgment, mathematical ability, and complex thought (26). These variations can affect the equitable distribution of resources. For example, eligibility criteria for Old Age Survivors Disability Insurance include evidence of deterioration of personal habits. One persons coherent speech and appearance of wellbeing may conceal very poor judgment and inability to hold a job, while anothers apathetic and disheveled appearance may make him or her appear much more impaired. Furthermore, Alzheimers disease and multi-infarct dementia can be difficult to distinguish, making the course of an individuals illness hard to predict. The presence of other illnesses or reactions to medication (18): As noted earlier, persons with dementia often experience a further impairment in their intellectual function when they also develop other illnesses or drug reactions. Even minor illness can temporarily cause worsened behavior or greater confusion (20). The idiosyncratic characteristics of the individual (19): One person with Alzheimers disease may be agitated and combative, while another may be amiable and easily managed. The causes of these differences are not understood. The difference affects the services l l needed and the individuals ability to use services, The uneven impact of the illness on different areas of intellect (19): The ill person will be able to do some things better than others. This seeming paradox of intellectual function often leads to misunderstandings of a persons abilities. Families often mistakenly believe that ability to do one task indicates an ability to do an apparently similar task. For example, one woman could load her elder daughters dishwasher but not the younger ones. The daughters attributed this to the mothers longstanding preference for the elder daughter, but an occupational therapist found that the elder daughters dishwasher was old, and the mother had learned to operate it before she became ill. The younger daughters dishwasher was new and the mother was unable to learn even the simple skill of opening it (19). The varied response of different symptoms to intervention: Symptoms vary in their responsiveness to treatment, regardless of whether the underlying disease is treatable. Angry outbursts or hallucinations maybe controlled or prevented, for example, but an increasing memory loss may not be stopped. Because of these variations, the ability and behavior of individuals with the same disease may differ widely, and the ability of one individual may vary through the day, or from week to week. Neu ropsychological tests are being designed that more accurately measure these varied disabilities and changes over time. However, the relationship between the test results and the persons actual ability to function in familiar surroundings has not been standardized. Although useful in research, such tests are not sufficient by themselves to determine eligibility for services (see ch. 8), STAGES OF THE DISEASE The most common cause of dementia, Alzheimers disease, is a chronic, progressive disorder. Its worsening course has been described in terms of stages of increasing severity. The course of the disease differs from that of multi-infarct dementia or other diseases, but the problems in accurately diagnosing Alzheimers disease and multi-infarct dementia make it difficult to develop ways to de- PAGE 68 Ch. 2Characteristics of Persons VVith Dementia l 63 scribe these stages. This section will discuss the concept of identifying stages only for Alzheimers disease. Theoretical Advantages of Staging or Measures of Severity The successful definition of a series of discrete and reliable stages describing Alzheimers disease would have several advantages. Staging would enable a family to plan ahead for an individuals needs. It would enable researchers to compare different individuals at similar points in their illnesses. It would allow researchers to measure the effect of experimental interventions in postponing the next stage. Researchers could test the effects of experimental drugs by comparing treated persons with untreated persons at the same stage. Staging would also allow planning for appropriate levels of service needed as individuals decline. Average lengths of time in each stage would allow planners to estimate costs of care. The stage of the individuals illness could be used as a criterion of eligibility for specific services, Staging Instruments The effort to develop accurate measures of stages has only begun. One of the classic descriptions of Alzheimers disease, which has been used by many clinicians, has three stages. The first stage is marked by the onset of memory loss. The second stage is marked by problems in language, motor ability, and recognition of objects. The third or terminal stage shows profound dementia with loss of continence, loss of the ability to walk, and nearly complete loss of language (38). Several more detailed theories of stages have been developed recently in an effort to characterize more specifically the predictable changes during the course of the disease. Although the validity of scales remains controversial, two examples are included here. Table 2-1 shows the Brief Cognitive Rating Scale (32), which describes seven stages of the patients illness on 10 axes: concentration, recent memory, past memory, orientation, functioning and selfcare, speech, motor functioning, mood and behavior, practice of an art or skill, and calculation ability. This scale has the advantage of describing declines in several areas of function. Also it is more detailed and specific than the three-stage model. Table 2-2 shows the Global Deterioration Scale, which defines seven stages of deterioration, ranging from no cognitive decline to very severe cognitive decline, and their associated clinical phases and characteristics. The Clinical Dementia Rating Scale (15) (table 2-3) uses five stages and six axes and is designed to measure the severity of major areas of cognition. Use of Assessment Tools for Staging Tests intended to diagnose the presence of dementia, to assess those areas of cognition that are more impaired than others, or to track the decline of individuals can be used to describe stages. These scales may rate persons abilities to perform familiar tasks (3), or several general kinds of functioning (10). Researchers have examined many other specific characteristics of intellect in search of those that show a consistent and reliable pattern of change in dementia (18). Problems in the Use of Scales and Stages Researchers do not agree about the validity of the scales. While some report consistent similarities in persons with dementia, others are struck by the degree of variability. Although one researcher states, present investigations indicate that seven stages of progressive deterioration in normal aging and Alzheimers disease can readily be described (33), another maintains that: although the patient with Alzheimers disease or a related disorder undergoes a series of behavioral changes and losses, empirical data are still not available to describe the course of the illness. Cognitive skills and competency in life tasks appear to deteriorate at different rates in different people, but the losses are progressive until the individual ultimately dies (4). Alzheimers disease is a gradually progressive disorder with no noticeable hallmarks that mark a persons passage from one stage to the next. Observers note that some individuals remain un- PAGE 69 64 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Table 2-1.Brief Cognitive Rating Scale Part 1 Axis 1: Concentration 1. 2. 3. 4. 5. 6. 7. No objective or subjective evidence of deficit in concentration. Subjective decrement in concentration ability. Minor signs of poor concentration (e.g., subtraction of serials 7s from 100). Definite concentration deficit for persons of their background (e.g., marked deficit on serial 7s; frequent deficit in subtraction of serial 4s from 40). Marked concentration deficit (e.g., giving months backwards or serials 2s from 20). Forgets the concentration task. Frequently begins to count forward when asked to count backwards from 10 by 1s. Marked difficulty counting forward to 10 by 1s. Axis //: Recent memory 1. No objective or subjective evidence of deficit in recent memory. 2. Subjective impairment only (e.g., forgetting names more than formerly). 3. Deficit in recall of specific events evident upon detailed questioning. No deficit in the recall of major recent events. 4. Cannot recall major events of previous weekend or week. Scanty knowledge (not detailed) of current events, favorite TV shows, etc. 5. Unsure of weather; may not know current president or current address. 6. Occasional knowledge of some recent events. Little or no idea of current address. 7. No knowledge of recent events. Axis Ill: Past memory 1. No subjective or objective impairment in past memory. 2. Subjective impairment only, can recall two or more primary school teachers. 3. Some gaps in past memory upon detailed questioning. Able to recall at least one childhood teacher and/or childhood friend. 4. Clear-cut deficit, the spouse recalls more of the patients past than the patient. Cannot recall childhood friends and/or teachers but knows the names of schools attended. Confuses chronology in reciting personal history. 5. Major past events sometimes not recalled (e.g., names of schools attended). 6. Some residual memory of past (e.g., may recall country of birth or former occupation; may or may not recall mothers name; may or may not recall fathers name). 7. No memory of past (cannot recall country, State, or town of origin; cannot recall names of parents, etc.). Axis IV: Orientation 1. No deficit in memory for time, place, identity of self or others. 2. Subjective impairment only, knows time to nearest hour, location. 3. Any mistake in time of 2 hours or more; day of the week of 1 day or more; date of 3 days or more. 4. Mistakes in month of 10 days or more; or year of 1 month or more. 5. Unsure of month and/or year and/or season; unsure of locale. 6. No idea of date. Identifies spouse but may not recall name. Knows own name. 7. Cannot identify spouse. May be unsure of personal identity. Axis V: Functioning and self-care 1. No difficulty, either subjectively or objectively. 2. Complains of forgetting location of objects. Subjective work difficulties. 3. Decreased job functioning evident to co-workers, difficulty in traveling to new locations. 4. Decreased ability to perform complex tasks (e.g., planning dinner for guests, handling finances, marketing, etc.). 5. Requires assistance in choosing proper clothing. 6. Requires assistance in feeding, and/or toileting, and/or bathing, and/or ambulating. 7. Requires constant assistance in all activities of daily life. SOURCE: B. Reisberg, S. Ferris, and M.J. deLeon, Senile Dementia of the Alzheimers Type: Diagnostic and Differential Diagnostic Features With Special Reference to Functional Assessment Staging, FYoceed/ngs, Second International Tropon-Bayer Symposium, 1984. PAGE 70 Ch. 2Characteristics of Persons With Dementia 6 5 Table 2-2.The Global Deterioration Scale (GDS) for Age-Associated Cognitive Decline and Alzheimers Disease GDS stage Clinical phase Clinical characteristic 1 Normal No cognitive decline 2 Forgetfulness Very mild cognitive decline 3 Early confusional Mild cognitive decline 4 Late confusional Moderate cognitive decline 5 Moderately severe decline Early dementia 6 Middle dementia Severe cognitive decline 7 Late dementia Very severe cognitive decline No subjective complaints of memory deficit. No memory deficit evident on clinical interview. Subjective complaints of memory deficit, most frequently in following areas: a) forgetting where one has placed familiar objects; b) forgetting names one formerly knew well. No objective evidence of memory deficit on clinical interview. No objective deficits in employment or social situations. Appropriate concern with respect to symptomatology. Earliest clear-cut deficits. Manifestations in more than one of the following areas: a) patient may have gotten lost when traveling to an unfamiliar location; b) co-workers become aware of patients relatively poor performance; c) word and name finding deficits become evident to intimates; d) patient may read a passage or a book and retain relatively little material; e) patient may demonstrate decreased facility in remembering names upon introduction to new people; f) patient may have lost or misplaced an object of value; g) concentration deficit may be evident on clinical testing. Objective evidence of memory deficit obtained only with an intensive interview conducted by a trained geriatric psychiatrist. Decreased performance in demanding employment and social settings. Denial begins to become manifest in patient. Mild to moderate anxiety accompanies symptoms. Clear-cut deficit on careful clinical interview. Deficits manifest in following areas: a) decreased knowledge of current and recent events; b) may exhibit some deficit in memory of personal history; c) concentration deficit elicited on serial subtractions; d) decreased ability to travel, handle finances, etc. Frequently no deficit in following areas: a) orientation to time and person; b) recognition of familiar persons and faces; c) ability to travel to familiar areas. Inability to perform complex tasks. Denial is dominant defense mechanism. Flattening of affect and withdrawal from challenging situations occur. Patients can no longer survive without some assistance. Patients are unable during interview to recall a major relevant aspect of their current lives: e.g., the names of close members of their family (such as grandchildren), the name of the high school or college from which they graduated. Frequently some disorientation to time (date, day of week, season, etc.) or to place. An educated person may have difficulty counting back from 40 by 4s or from 20 by 2s. Persons at this stage retain knowledge of many major facts regarding themselves and others. They invariably know their own names and generally know their spouses and childrens names. They require no assistance with toileting or eating, but may have some difficulty choosing the proper clothing to wear. May occasionally forget the name of the spouse upon whom they are entirely dependent for survival. Will be largely unaware of all recent events and experiences in their lives. Retain some knowledge of their past lives, but this is very sketchy. Generally unaware of their surroundings, the year, the season, etc. May have difficulty counting from 10, both backward and sometimes forward. Will require some assistance with activities of daily living, e.g., may become incontinent, will require travel assistance, but occasionally will display ability to travel to familiar locations. Diurnal rhythm frequently disturbed. Almost always recall their own name. Frequently continue to be able to distinguish familiar from unfamiliar persons in their environment. Personality and emotional changes occur. These are quite variable and include: a) delusional behavior, e.g., patients may accuse their spouse of being an impostor, may talk to imaginary figures in the environment, or to their own reflection in the mirror; b) obsessive symptoms, e.g., person may continually repeat simple cleaning activities; c) anxiety symptoms, agitation, and even previously nonexistent violent behavior may occur; d) cognitive abulia, i.e., loss of willpower because an individual cannot carry a thought long enough to determine a purposeful course of action. All verbal abilities are lost. Frequently there is no speech at all only grunting. incontinent of urine; requires assistance toileting and feeding. Lose basic psychomotor skills, e.g., ability to walk. The brain appears to no longer be able to tell the body what to do. Generalized and cortical neurologic sign and symptoms are frequently present. SOURCE: B. Reisberg, Clinical Presentation, Diagnosis, and Symptomatology of Age-Associated Cognitive Decline and Alzheimers Disease, Alzheirners Disease: The Standard Reference (New York: Free Press, 1983 ), pp. 173-187 changed for long periods while others follow an fulness of staging instruments. Further, as noted, atypical course (17). It can be difficult to clinically there are many reasons why persons with Alzdistinguish this disease from other dementing illheimers disease can show worsened symptoms: nesses with slightly different courses; indeed, the other illnesses, fatigue, delirium, or an inappropri term Alzheimers disease may actually include ate environment. The stage of a persons illness several diseases, each with a slightly different patcannot be determined until these factors have tern (see ch. 3). All of these factors limit the usebeen ruled out. PAGE 71 Table 2-3.Clinical Dementia Rating (CDR) Scale Healthy Questionable dementia Mild dementia Moderate dementia Severe dementia CDR O COR 0.5 CDR 1 CDR 2 CDR 3 Memory No memory loss or slight Mild consistent forgetfulness; Moderate memory loss, more Severe memory loss; only highly Severe memory loss; only inconsistent forgetfulness partial recollection of events; marked for recent events; defect learned material retained; new fragments remain benign forgetfulness interferes with everyday activities material rapidly lost Orientation Fully oriented Some difficulty with time Usually disoriented in time, often Orientation to person only relationships; oriented for place to place and person at examination but may have geographic disorientation Judgment and problem-solving Solves everyday problems well; Only doubtful impairment in Moderate difficulty in handling Severely impaired in handling Unable to make judgments or judgment good in relation to solving problems, similarities, complex problems; social problems, similarities, differences; solve problems past performance differences judgment usually maintained social judgment usually impaired Community affairs Independent function at usual Only doubtful or mild impairment Unable to function independently No pretense of independent function outside home level in job, shopping, business in these activities at these activities though may Appears well enough to be taken Appears too ill to be taken to and financial affairs, volunteer still be engaged in some; may to functions outside a family functions outside a family home and social groups still appear normal to casual home inspection Home and hobbies Life at home, hobbies, intellectual Life at home, hobbies, intellectual Mild but definite impairment of Only simple chores presemed; No significant function in home interests well maintained interests slightly impaired function at home; more difficult very restricted interests, poorly outside of own room chores abandoned; more sustained complicated hobbies and interests abandoned Personal care Fully capable of self-care Needs prompting Requires assistance in dressing, Requires much help with hygiene, keeping of personal personal care; often incontinent effects SOURCE C P Hughes, L Berg, W L Oonzger, et al., New Clinical Scale for the Staging of Dementia, Brfllsh Journal of Psychutry 140 -572, 1982 PAGE 72 Ch. 2Characteristics of Persons With Dementia 67 Concepts of staging can be used for different purposes: research, family education, understanding an individual patient, or measuring disability to enable eligibility for services. Scales used for eligibility must correctly screen out those who should not be eligible while not excluding some whose symptoms are atypical. They should be replicable and they should produce the same results as other reliable tests. They should produce accurate scores regardless of the sociocultural background of the person being tested; they should detect dementia early in the illness and give accurate scores of disability through the full course of the illness. They should be easy to administer and not upsetting to the individual. None of the scales or theories of staging yet meets these criteria. PAGE 73 68 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias SYMPTOMS persons suffering from a dementing illness lose cognitive abilities, as manifested in changes in behavior and losses of function (35). These symptoms can be loosely grouped into four categories: cognitive or neurological symptoms; functional symptoms or impairment of the ability to carry out normal daily activities; behavioral or (psychiatric symptoms; and the excess disabilities brought about by outside factors (18). Categorizing symptoms is somewhat arbitrary: Many could as easily fit into one group as into another. Nevertheless, grouping symptoms is useful in describing the kind of care these individuals need. An understanding of which of the individuals cognitive functions have been spared or impaired can be used by the clinician to explain specific behaviors to the family and is useful in devising ways to assist the person with dementia (30,&I). As noted, social skills, judgment, ability to do mathematics, ability to remember things, or ability to pay attention may all vary independently. One person may still seem gracious and friendly but be unable to remember the context of a conversation from moment to moment. Another may be able to remember how to dismantle a sink but be unable to realize that the sink being taken apart is in someone elses room, The loss of intellectual function, often combined with the false appearance of normal capability, confuses family members and professional caregivers. Demented individuals may still be able to walk or drive but may get lost or have accidents. That is one way in which these individuals differ from other frail, elderly, or ill persons. They may have no awareness of their impairments and therefore resist assistance. They may argue with caregivers or accuse them of abuse (22). Cognitive/Neurological Symptoms In the early part of the illness, person with dementias typically experience memory loss and aphasia (language problems). That is often followed by apraxia (inability to carry out purposeful movement in the absence of motor or sensory impairment), agnosia (failure to recognize things or people), loss of the ability to learn, and disorienOF DEMENTIA tation (41). Other possible neurological symptoms include seizures, shocklike contractions of a group of muscles, changes in reflexes, tremors, and failure of muscle coordination. There is considerable overlap between some symptoms. Symptoms are thought to correlate with specific areas of brain damage or systems of neurotransmitters (26). In disorders for which medicine now has no cure, such as Alzheimers disease, these symptoms are quite stable within a given individual at a given time, despite efforts to modify them. That is, when other factors (delirium, nonsupportive environment, unnecessary stress) are removed, most efforts to bring about improvement in these functions have been unsuccessful (29). Cognitive symptoms can be measured with neuropsychological tests and some can be reliably replicated in the same person. Therefore they are frequently selected as markers to measure change brought about by experimental therapy. There is more general agreement about the sequence or stages in which these cognitive symptoms appear in Alzheimers disease than there is about other symptoms. Disorders affecting rapid and complex hand movements also may begin early in Alzheimers disease. Cognitive impairments profoundly affect the way in which a person perceives his or her world and therefore significantly affect behavior. Memory Impairment The hallmark of dementia is impairment of memory, which differs from the normal forgetfulness of healthy individuals, In dementia, memory of important information such as the names of close family members or the way to get home from a familiar place may be lost. At the beginning of the illness it can be difficult to distinguish between normal forgetfulness and the first signs of a dementing illness. That can cause anxiety among elderly persons who fear they are developing dementia. However, as the disease progresses, the severity of the memory impairment becomes evident, and is clearly different from absentmindedness. PAGE 74 Ch. 2Characteristics of Persons With Dementia l 6 9 There are several different forms of memory: immediate (remembering for a few seconds), short-term (remembering for a few minutes), and long-term (remembering material learned from year to year). Neuropsychological testing can delineate the types of memory that are spared and impaired in a given person. Most persons with Alzheimers disease have impaired short-term memory (35), but many retain some long-term memory. It is difficult to imagine life without a short-term memory. One could not learn from experience. Following a conversation would become impossible. Television would become a meaningless jumble, Individuals who have lost short-term memory cannot remember the question just asked or the answer just given, or even that they have forgotten, These individuals often become fearful and anxious and cling to a trusted caregiver. They may ask the same question many times or fail to do something because they cannot remember what they were asked to do. Such problems often begin before a person looks or acts ill, so that others are not sensitive to the disability. Aphasia Aphasia is impairment in the use of language. In some persons, it is the first symptom of dementia; it eventually occurs in persons with Alzheimers disease (25). Expressive aphasia is an impairment in the ability to use language, speak, or write, while receptive aphasia is an impairment in the ability to understand spoken or written language. Unlike persons who are deaf, persons whose brains cannot process language cannot use symbols, pictures, or sign language. Aphasias are further classified by precise types of language impairment, such as the loss of the ability to name items, to put together sentences, to understand and act on what is heard, or to read or write. A person may experience quite selective losses of language. For example, an individual may be able to read aloud a note on the refrigerator to take your pills at noon, but be unable to carry out those instructions. Such highly specific impairments frustrate caregivers who reason that a person who can read ought to be able to act on instructions, or that a person who can hold reasonable social conversation ought to be able to remember a spouses name. But reading and comprehending instructions, participating in casual conversation, and recalling nouns are all different skills, and one can be lost before another. As dementia progresses, the person loses more language skills. Eventually, these individuals become nearly mute and it is no longer possible to differentiate types of language loss. Loss of communication often means that a person cannot ask for help when his or her memory has failed, and caregivers must then guess at needs. As the disease progresses, individuals become unable to tell caregivers when they are in pain, cold, or hungry. Apraxia Apraxia is the inability to carry out purposeful movement or motor actsbuttoning buttons, walking, dressing, eating a meal, or maintaining a sitting positionin the absence of motor or sensory impairment. Unlike the person who is paralyzed or injured, the person with apraxia has forgotten a skill. In Alzheimers disease, apraxia is progressive, beginning with a slight clumsiness and progressing to a dramatic lack of coordination, frequent falls, or the loss of the ability to walk. At first a person may have difficulty with clothing fasteners, whereas later the problem may be getting feet into trousers. Eventually, the person will be unable to participate at all in getting dressed. Although someone who has lost a hand in an accident can learn to use a prosthesis, and a person who has suffered a paralyzing spinal cord injury may learn to use crutches, individuals with dementia have lost the ability to remember and learn. Therefore, they may be unable to learn to use a walker or other assistive device, The methods of helping a person with a dementia to compensate for a disability are thus different from those used to assist a physically handicapped person. Yet the persons disability is as real as an amputees (24). Research may lead to the development of devices persons with dementia can use. Agnosia Agnosia is a disorder of perceptionthat is, the loss of the ability to comprehend the meaning or PAGE 75 70 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias recognize the importance of various types of sensory stimulation. That loss is different from the loss of memory, and might be described as an inability to use sensory information to recognize something. Individuals with agnosia may run into the mantlepiece because they do not recognize it as protruding before them. They may urinate in the wastebasket or put their dentures in the refrigerator because they do not correctly recognize the function of the wastebasket or refrigerator. Some individuals with agnosia insist that the spouse who is caring for them is not their spouse. Such a person may agree that the caregiver looks just like the spouse, but will insist that this caregiver is an imposter. A woman may cease to recognize a mirror image and begin to talk to the woman in the bathroom In some cases, she may regard the woman in the bathroom as a rival or intruder and act on this belief. Such impairments can be terribly distressing to family members, and the peculiarly circumscribed nature of some agnosias can make it difficult for family members to accept agnosia as a symptom of neurological damage (22). Persons with agnosia maybe unable to put together the various elements of a situation or object. In neurological examination, a person may be asked to copy a simple diagram but be unable to reproduce more than a section of it. At home that individual may be unable to set the table because he or she cannot think of all the elements china, cloth, and silverwareat one time. The individual may be able to pay attention to only two of four people in a room, and appear to ignore the others. Impaired Ability To Learn New Material Persons with a dementia usually experience a profound impairment in the ability to learn. They may be unable to learn a list of numbers in a test situation or unable to learn information as important as the location of the bathroom in a new residence. (That inability is closely related to other impairments such as loss of short-term memory.) Someone suffering from a dementia may superficially appear capable in other areas of intellectual function, but at the same time may be unable to learn even basic new material. That impairment can be disabling to the person who must move to a new residence or who is expected to learn a new, although less difficult, job skill. Some victims of dementia have been disqualified for payments under Social Security Disability Insurance (OASDI) because they are assumed to be able to work at less demanding jobs (6). However, not only are these individuals unable to learn simple new skills, but they cannot even learn that they are not doing their old job. Thus a former engineer whose intelligence score indicates an ability to work as a janitor may be unable to learn where the brooms are kept but insist that he or she is still an engineer. At the same time, persons with Alzheimers disease have not lost all ability to learn. Especially early in the disease, some individuals have learned compensatory techniques or ways to signal the caregiver, Although these are eventually lost, research to clarify the circumstances under which such technique? can be learned would greatly assist care providers. Disorientation Disorientation is the lack of correct knowledge of person, place, or timewhere a person is, who the people around you are, or what time of day, day of the week, or month it is. Persons with dementia develop these limitations from disorientation gradually. Some may not be disoriented, especially if the person is in a familiar setting or in the early stages of illness. Ability To Do Normal Daily Activities Persons with dementing illnesses gradually lose the ability to do the tasks of normal daily living. These skills include ones known as the activities of daily living (ADLs), which include basic skills such as dressing or eating, and those known as instrumental activities of daily living (IADLs) such as answering the telephone or making change. (For a full discussion of ADLs and IADLs, see ch. 8.) Checklists provide a score that describes the extent of the persons dependence or independence. Tables 2-4, 2-5, and 2-6 show the percentage of respondents in a survey, done for OTA, of caregivers who reported that persons with dementia PAGE 76 Ch. 2Characteristics of Persons With Dementia 71 Table 2-4.-Ability of Dementia Patient To Do Basic Tasks Percent of total respondents Task Very well Somewhat Not at all No answer Walk without assistance. . . . 35 26 35 5 Eat without assistance . . . . 30 32 34 5 Dress without assistance . . . 14 28 52 5 Perform simple household tasks, such as setting the table or simple home repairs. . . . . 6 19 69 5 Cope with small sums of money. . . 5 15 73 6 NOTE: This table is percentage horizontally. Also totals may not add because of rounding. SOURCE: Yankelovlch, Skelly, & White, Inc., Caregivers of Patients With Dementia, contract report prepared for the Office of Technology Assessment, 19S6 Table 2.5.Assessment of Dementia Patients Eating Skills Percentage of total Eating skills respondents Eats cleanly, with proper utensils . . 36 Eats messily . . . . . . 23 Only eats simple solids, like crackers, by self. ... . . . . . . 6 Has to be fed by others . . . . 28 Is tube fed . . . . . . . 4 No answer . . . . . . . 4 SOURCE: Yankelovich, Skelly, & White, Inc., Caregivers of Patients With Dementia, contract report prepared for the Office of Technology Assessment, 19s6. Table 2-6.Assessment of Dementia Patients Toilet Skills Percentage of total Toilet skills respondents Independent/fully functional. . . . 23 Has occasional accidents/needs some help or reminder . . . . . 25 Has frequent wet beds or accidents. . 12 Is doubly incontinent (has bowel and urine accidents) . . . . . 36 No answer ... . . . . . . 4 SOURCE: Yankelovich, Skelly, & White, Inc., Caregivers of Patients With Dementia, contract report prepared for the Office of Technology Assessment, 19s6. had impairments in ADLs and IADLs. l That survey encompassed caregivers of persons with dementia in all phases of their illness. Table 2-4 shows IThe Yankelovich, Skelly, & White data in this chapter and in ch. 4 differ by a few percentage points from the figures cited elsewhere in this assessment. This is because the Yankelovich report calculated the percents of people answering each question exclusive of the nonresponders. In these two chapters, where the bulk of this assessment is reported, those who completed a questionnaire but did not answer a specific question are shown as a separate column. There are no significant differences between the two sets of data. that persons with dementia are not uniformly impairedskills are lost at different times throughout the illness. More can walk independently than can eat or dress without help; few can do household tasks or cope with money. The ability to handle money or do household tasks unassisted is usually lost early in the course of the disease: the ability to walk is lost late. It is also clear that the majority of these people are severely impaired in vital skills. Other studies report comparable levels of impairments (6,11). The ability to perform various tasks of daily living depends on the severity of cognitive impairments. The ability to brush teeth, for example, is based on the interaction of the ability to remember, to recognize the toothbrush, to perform the motor action, and so forth. An individuals loss of a skill may be partial, and he or she may be able to get dressed but not to select the clothing, or be able to eat independently only if served finger foods. Persons suffering from nondementing illnesses may also lose these same abilities, although for different reasons. Therefore, the degree or type of impairment does not indicate a specific disease, and the treatment intervention varies with the cause of the condition. Scores on measures of IADLs and ADLs have been found to be more reliable than diagnoses for predicting the amount of care a person will need in a nursing home (8). In the absence of a diagnosis, however, the use of ADLs to measure disability can obscure an individuals potential for rehabilitation. The type of assistance an individual will need depends on the cause of the impairment: a blind person may need to be told where PAGE 77 72 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias food is; a paraplegic may need a prosthesis; a person with dementia may need to have his or her food cut up, be given reminders, or be given fewer foods at one time to reduce confusion. Although the ability of most persons with dementia to function independently will inevitably decline until the person becomes totally dependent on others, the extent of an individuals ADL handicap sometimes can be reduced, and total dependency postponed. Disability can be reduced in supportive situations and worsened in unsupportive settings (see ch. 7). Continence illustrates the interlocking issues of decline in ADLs and the potential for improvement. Incontinence may be embarrassing for the individual and upsetting to the caregiver. Some authorities report that it is one of the precipitant for nursing home placement (40). But some report that uncontrolled incontinence is unnecessary in most cases. Problems of incontinence vary from complete loss of bladder or bowel control to occasional leaking. Incontinence has multiple causes, some of which are reversible. The need for diapers or catheters can sometimes be avoided or postponed with proper treatment of the underlying problem (42). The true incidence of failure to treat incontinence is unknown. Clinicians report cases in which reversible causes of incontinence have been incorrectly ascribed to the dementing disorder, and their susceptibility to treatment overlooked (21). In addition, individualized schedules, reminders, and assistance can maintain continence even in severely demented persons (42). Thus an individuals ADL score for incontinence may depend on the aggressiveness of treatment and the willingness of caregivers to assist. Since an individual may be continent in one setting and incontinent in another, the measure of his or her independence in ADLs may reflect both the setting and the individuals intellectual ability. Behavioral or (psychiatric) Symptoms Behavioral or psychiatric symptoms include angry outbursts, depression, violence, apathy, stubbornness, resistance to care, suspicion and accusations, wandering, incessant repeating of the same question, being awake and active at night, use of obscene or abusive language, talking to deceased relatives, hallucinations, delusions, rummaging through other persons rooms, stealing, getting lost, urinating in unsuitable places, hiding things, refusing to give up activities that can no longer be performed safely, wearing clothing inside out or in the wrong order, refusing to change clothing or to bathethe list can go on and on. The presence or absence of these symptoms by themselves is not necessarily evidence of dementia or any specific dementing illness. Similar behaviors can be seen in persons suffering from a variety of organic and psychiatric disorders, as well as in persons not suffering from any mental illness. It is important, however, to note that the treatment of choice varies with the cause of the problem. Techniques appropriate for treating depression or schizophrenia may or may not help persons with dementia. Also, a person suffering from a dementia may have none of these behavioral disturbances, or the disturbances may be present for only part of the illness (e.g., accusations decline as language is lost; wandering declines as ambulation is lost). Table 2-7 shows the percentage of caregivers in the OTA study who reported patient behavior problems. Other surveys report even higher rates of disturbed behavior (6,11,31). Variations between the studies can be accounted for in part by differences in the number of persons who were too ill to engage in the behaviors. In a resurvey of one of these populations 2 years later, researchers found a significant decline in disturbed behaviors, which they reported as due at least in part to the subjects continued decline (23). The experience of ADRDA also provides compelling evidence of the prevalence of these behaviors these problems are frequently discussed in the associations (how-to books and newsletters. From this evidence it can probably be concluded that disturbed behaviors occur for part of the illness in a majority of victims. Aberrant behaviors can be extremely distressing both for the sufferer and for caregivers. Families and service providers alike report that it is often these behavior problems, rather than the cognitive symptoms or the need for nursing or PAGE 78 Ch. 2Characteristics of Persons With Dementia 73 Table 2-7.Frequency of Dementia Patients Engagement in Certain Behaviors Percentage of total respondents Dont know/ Very frequently Occasionally Rarely/never no answer How frequent/y does patient: Have periods of restlessness and agitation? . 39 33 10 18 Become listless and apathetic? . . . 32 29 14 26 Get in a depressed mood? . . . . 27 32 12 29 Wander away from home unless watched? . 29 24 36 Have inappropriate angry outbursts?. . . 19 32 30 19 Engage in crying episodes? . . . . 13 26 38 23 Engage in actions (hit, pinch, throw things) that physically hurt people? . . . . 9 17 53 22 aRe~POnd~ntS who are not the primary caregiver may not know the frequency of behavior problems. NOTE: This table is percentage horizontally. Also totals may not add because of rounding. SOURCE: Yankelovich, Skelly, & White, Inc., Caregivers of Patients With Dementia, contract report prepared for the Office of Technology Assessment, 19S6. personal care, that prove most distressing (40). Recent findings, however, indicate that these behaviors may be more responsive to treatment than previously assumed, and that they can be reduced even in the absence of significant change in cognitive impairment (see chs, 4 and 7). The division between behavioral and cognitive symptoms is arbitrary. A person suffering from damage to nerve cells or changes in brain chemistry can be expected to exhibit behavior that results from the neurological illness. It can also be reasoned that persons who cannot communicate their needs or thoughts, who cannot get dressed, or who do not know where they are or who is caring for them might experience depression, fear, anxiety, or anger. Thus these symptoms are not so much psychiatric as they are the clear result of the neurological illness. They maybe due both to brain damage and to an understandable reaction to the loss of mental abilities caused by that damage. Little is known about the relation of many behavorial symptoms to specific locations in the brain. Researchers disagree over whether a given behavior is primarily neurological, is a pyschological response to the neurological symptoms, or was a characteristic of an individuals personality before the onset of the dementing illness. As scientists understanding grows about the relationship of these symptoms to the underlying neurological disorder, so will the understanding of the broader relationship of brain to behavior, Fortunately, many behavioral symptoms of dementia are more responsive to currently available methods of treatment and intervention than the cognitive symptoms are (30). When the symptoms are not treated, the individual can be more impaired in functional ability than necessary. Medications are often the treatment of choice; however, they are easily overused or misused. The pharmacotherapy of aggressive or agitated behaviors in persons with dementia has not been extensively studied despite the prevalence of the problem (34). This section addresses a few of the many behavioral and mood problems that people with dementia may face. problems of Mood and Experience of Distress Persons with dementia often experience changes in mood or personality. Families may report that a formerly gentle person has become hostile and angry, or that a trusting person has become suspicious. Some persons with dementing illnesses shift quickly from laughter to tears or anger with little or no apparent cause. Catastrophic Reactions.Persons suffering from a dementia often become angry, irritable, or upset over seemingly minor situations. Families report that such outbursts are a major problem. Clinicians refer to such behavior as a catastrophic reaction (12) to distinguish it from behavior in a person with no brain injury. The episode maybe minor (shouting or stubbornness) or major (hitting, or swinging a weapon). Catastrophic reactions may precipitate placing the individual in a nursing home or other long-term care institution (40). PAGE 79 74 l Losing a Million Minds: Confronting the Tragedy of A/zheimers Disease and Other Dementias There is also evidence that when such behavior recurs frequently, however, it may cause the person to be denied admission to nursing homes, day care, home care, or other services, or may cause the person to be transferred to another setting (see ch. 7). The behavior often leads to heavily medicating or physically restraining the patient (28). Medications and restraints can lead to medical complications and severely limit the individuals freedom and quality of life. Unlike similar behavior in a cognitively well person, catastrophic reaction behavior is thought to be the result of brain damage and largely beyond the control of the person with dementia (19). It may result from failure to understand a request, failure to comprehend a situation, fatigue, or pressure to perform beyond the individuals limited capabilities (19). Persons whose thinking is impaired understandably can become frightened or anxious in situations they cannot understand, and that anxiety may translate into outbursts. These individuals may also have lost the ability to inhibit their behavior. Caregivers often view such outbursts in the same way they would view it in a well person deliberate and under the persons willful control. Their response may be restrictions, punishment, arguments, or explanationsresponses that further distress the individual and increase anxiety and agitation (22). When catastrophic reactions are properly recognized, however, they respond to a variety of interventions; one of the most successful is making the persons environment more supportive of his or her disability. Training family and professional caregivers in appropriate responses is often a key to controlling these behaviors (30). Confused, disoriented persons with compromised intellectual function may occasionally become combative or threatening. That is usually an extreme catastrophic reaction. Since these persons may also be strong and mobile, combative behavior can present serious problems to caregivers. A man suffering from dementia may repeatedly push, shove, or knock down his frail, elderly wife who is trying to care for him. The confused person may not know whom he is fighting; he may be frightened or misunderstand the situation. For example, he may believe that his son is a robber or that the nurse trying to bathe him is attempting to rape him (30). Respite programs or nursing homes may refuse to care for violent patients, whom they fear pose a threat to staff or other residents, Such behavior is not intentional on the part of the person with dementia and therefore must be treated differently from similar behaviors in persons with normal cognitive functions (22). Catastrophic reactions and violent behavior are often amenable to nonpharmacological interventions when steps are taken to reduce the stress the individual is experiencing. Judicious use of medication can effectively augment the supportive environment to control frequent or extreme reactions (22,43). Experienced professional caregivers report far less of this behavior than do untrained staff. Depression-Some persons suffering from dementia are also clinically depressed (43). The likelihood of depression secondary to the dementing process may vary with the disease entity (18). The literature presents contradictory data on the frequency with which depression arises in persons with Alzheimers disease or multi-infarct dementia. Clearly, not everyone with a dementing illness experiences such periods. Depression responds to a variety of treatments and it should be treated when possible both because it can further impair a persons thinking and because it causes suffering (18,41; also ch. 3). Persons whose primary problem is a clinical depression may also show cognitive impairment. Treatment of the depression may alleviate the cognitive problems. For that reason, persons showing symptoms of both depression and confusion or memory loss should be carefully evaluated. Apathy.Persons with some types of dementing illnesses may become apathetic, listless, unmotivated to participate in activities, or unwilling to maintain adequate personal hygiene. Such behavior may be misinterpreted by untrained caregivers as laziness or stubbornness (13,22). Victims of Alzheimers disease often lack the ability to plan or initiate meaningful activities. In an environment that offers little activity or sensory PAGE 80 Ch. 2Characteristics of Persons With Dementia 75 stimulation, these persons may lapse into apathy, wandering, or repetitious, meaningless motions. Dramatic changes can occur when such persons are transferred to a special care setting that offers suitable structured activity and sensory stimulation, and that encourages individuals to use remaining abilities (see ch. 7). Restlessness.Persons with dementia often become restlesspacing, wringing their hands, talking, etc. Pacing in front of the nurses station or asking the same question over and over for several hours is often reported as a source of distress to caregivers, who may ask that the individual be given tranquilizers, even though the restlessness presents no harm to the person with dementia. Motor restlessness is also a common side effect of medications and is responsive to reduction in dose. Some clinicians do not treat it because they assume it is part of the dementia. Subjective Feelings. Loss of cognition does not necessarily change a persons ability to experience a range of emotions. Until late in the course of the illness, people probably are experiencing the emotions that are reflected in their behavior (30). Thus, although they may not change how well a person remembers things, interventions can reduce a persons unpleasant feelings (21). Persons with Alzheimers disease may lose extensive cognitive skills and functions, but their ability to express and give affection remain for most of their illness. They can experience joy and enjoy humor. Caregivers report that these attributes can be elicited through provision of good, supportive care. Also that positive aspect helps to sustain family caregivers. Problems of Behavior Disruptions of the Sleep/wake Cycle.Recent work suggests that nocturnal sleep is disrupted in Alzheimers disease. Persons suffering from dementia are often awake at night and may dress, pack their clothing, attempt to use the stove, or leave the house and wander the streets. Such behaviors require constant night-time supervision or a secure setting to ensure safety (22). That requirement may lead to nursing home placement when the family caregiver becomes exhausted. However, clinicians report that sleep problems can be reduced both through careful use of medications (41) and with improved care techniques (5). Loss of the Internal Clock.Because these individuals have lost their internal sense of times passage, they may insist that it is time to go home immediately after arriving for a visitor they may accuse others of never visiting or never feeding them. An individuals impaired memory may make it impossible for him or her to understand explanations (22). Wandering. -Cognitively impaired people may pace the floor, or they may wander out of their residence. They may not realize that they are in traffic, or in a high crime area. They may say that they are in a different place or that they are returning to a home or job that existed in the past. They may be inappropriately dressed or they may fall, increasing the risk of injury. Those who realize that they are lost may panic, Unlocked care facilities may refuse to accept individuals with dementia who are known to wander, because they cannot provide adequate supervision. Wandering and the risks associated with it can be controlled through the use of nonrestraining environmental supports. Simple, unfamiliar latches can keep people with dementia on the premises because they are unable to learn how to operate the new latches (22). Several companies now market electronic monitoring systems for nursing homes. Research Triangle Institute has completed a feasibility study of devices to monitor wandering (36). Suspicion and Paranoia.Some persons with dementing illnesses may become suspicious; they may believe that they are being robbed, that others are attempting to poison them, or that their families have taken all their possessions and money (35). These individuals may be able to remember unfounded suspicions and fears in detail even when they cannot recall other simple information. Such suspicion can be understood in part as an aspect of the memory impairment (the individual has forgotten where things are), but for some persons with dementia it goes beyond that. It may be an expression of his or her experience of numerous losses (of memory, friends, freedom, health) or may be a direct result of the disease PAGE 81 76 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dernentias process. Family members who devote their lives to the care of such persons are often hurt by this accusatory behavior. In a group setting, the individuals adamant reports of mistreatment or theft may complicate efforts to ensure quality care and patient rights. Perseveration-persons with dementia may repeat a motion or activity over and over, a behavior known as perseveration. They seem to have gotten stuck in that activity. They may wash only their left arm, or may repeat the same meaningless phrase all day (22). Social Inappropriateness -As noted, persons with dementing illnesses may act inappropriately because they do not know where they are, who they are, or who is with them. They may mistake children for parents, a nurse for a wife, or another nursing home resident for a spouse. They may think they are in a childhood home. They may be unable to express their need to use the toilet. Such confusion leads to a range of socially inappropriate behaviors that can place an individual with dementia at risk. Some of these behaviors may be interpreted by caregivers as sexually abnormal: a man may take down his trousers because he is searching for a toilet, for example, or may climb into the wrong bed (22). Although lost, confused, or frightened individuals who have dementia may act inappropriately, persons with certain dementing illnesses may retain for a long time a semblance of social skills that helps conceal the extent of their intellectual difficulty; this can obscure their need for help and assistance. Trained caregivers can take advantage of these retained social skills to improve the quality of life for the individual; in supportive settings, these persons are able to enjoy social groups and make new friends (2 I). Sexual Behaviors-Most studies of patient behavior have shown that individuals who have never had a history of abnormal sexual behavior rarely develop such behaviors with the onset of a dementia (2). Occasionally, institutionalized persons will engage in self-stimulation in the presence of others. They may not realize they are not in private. That behavior seems to occur in persons who are severely demented and also are severely deprived of stimuli, activity, and pleasure, There is no evidence that persons with dementia pose any sexual threat to children or others (22). Impairment of Reason and Judgment.Persons with impaired intellectual function often show a loss of reason and judgment (35). That may be due to disorientation, to forgetting information before all the facts of a situation can be thought through, or to the disease process itself, which in Alzheimers disease and some other dementias afflicts these portions of intellect selectively. Persons with dementia who can no longer live alone safely because, for example, they continually leave the stove on, may be able to argue effectively they are fine and that their families are trying to take away their independence. Such skill in arguing can lead the caregiver to the false premise that an impaired individual is aware of the endangering behavior (22). A particularly difficult problem is knowing when someone can no longer drive safely. A car is the only available form of transportation for many people. Loss of driving privilege can be demoralizing for the individual with dementia and stressful for the caregiver and physician. However, persons with dementia are at significant risk of accidents. They often have poor judgment and a slow response time. They depend on habit to drive and may be unable to think quickly in an emergency. Most State laws do not require a test of intellectual function for renewal of a drivers license. Uniform guidelines for repeat testing of drivers, particularly over the age of 55, might be beneficial. Determining the extent of a persons ability to make responsible decisions regarding property may also be difficult (see ch. 5). Because of the selective nature of impairments, the usual tests of legal competency may not reveal the absence of good skills in reasoning and judgment or the ability to remember a decision long enough to think about it. Individuals with dementia may not realize they are being exploited or abused and maybe unable to remember or report abuse. In addition to being exceptionally vulnerable to poor care, such individuals may fall victim to unscrupulous sales people and to fraudulent business schemes. Other PAGE 82 Ch. 2Characteristics of Persons With Dementia l 7 7 individuals may erroneously charge that they are being raped or assaulted. These difficulties may be more complicated in special care programs where all the residents have dementia and no one is capable of giving evidence of abuse (see ch. 7). Hallucinations.Hallucinations are sensory experiences unique to the individual: he or she either hears, sees, smells, tastes, or feels something not experienced by others. When they occur, hallucinations are alarming to the family because of their association with insanity. They create risks for the patient who acts on them. Hallucinations usually respond to medication (37). People with dementia also have illusions: they misunderstand sensory information so that they have an incorrect perception of reality. A man may believe a nurse is his wife. One man believed that his adolescent son was a boarder renting a room. DelusionsDelusions are false, fixed ideas. As with suspicion, persons with dementia may be able to maintain a delusion for long periods, but at the same time be unable to remember factual information for more than a few minutes. The fixed nature of a delusion may seem to contradict an individuals memory impairment. The caregiver often feels that if the individual can remember a delusion, he or she should also be able to remember facts (22), paradoxical Behaviors. -Persons suffering from dementing illnesses often exhibit seemingly paradoxical behaviors, some of which have been mentioned. A person may be able to play cards but unable to remember a family members name. A person may be able to remember emotionally loaded material (e.g., being angry with someone) but unable to remember facts (e.g., that the matter that caused the anger has been explained). Someone may be able to do a task one day but not the next. Someone may still be able to work but suddenly get lost driving home from the office. An individual may behave in ways that seem to be deliberate actions to get attention or to control the responses of others, even when cognitive testing shows that the person is too impaired to carry out such manipulative behavior. Such seemingly paradoxical behaviors are probably due to which specific areas of function have been spared or impaired in the persons intellect and to the fluctuating and incomplete disruption of necrologic function. Whatever the cause, paradoxical behavior can affect the quality of the relationship between the individual with dementia and caregiver. This relationship can be positive: when much of a persons former personality is intact, a good deal remains that the family loves and enjoys. That retained personality can support the family in continuing to care for the individual (2 I). Yet when it appears that an individual can function well in one way, caregivers may expect an equivalent level of function in others, and, in so doing, may overstress the individual with dementia. When paradoxical behaviors appear to be intentional efforts to hurt or control a caregiver, caregivers sometimes respond as they would to such behavior in a well person. Such paradoxes can also cause confusion in the assessment of an individuals legal competence or ability to remain employed (22). Excess Disability Brought About by Outside Factors The level at which a person with a dementing illness is able to function is affected by other factors than the dementia. The first of these, treatment of secondary psychiatric symptoms, has been discussed. Others include the presence of other illnesses or reactions to medications, delirium, sensory impairments, or external stressors. Modifying or alleviating any of these factors can raise the level of function of the individual with dementia, even when the baseline impairment due to the dementia cannot be modified. The presence of symptoms that can be modified in this way has been labeled excess disability (16)a term used by clinicians because it effectively contradicts the therapeutic nihilism often assumed in the care of persons with dementia (21,37). Unfortunately a worsening of a persons behavior or thinking is often assumed to be evidence of worsening of the dementia, and such persons are not examined for other, potentially treatable conditions which compound their disability (2 I). Presence of Other Illnesses Elderly persons are at risk of many other illnesses: heart disease, arthritis, diabetes, osteoporosis, and so on. The presence of any other con- PAGE 83 78 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias dition in addition to the dementia complicates the management of both. Persons with dementia may not be able to learn self-care or compensatory skills (e.g., insulin administration, use of a walker, or diet management) (24). Further, the presence of another illness may further impair the individuals cognitive function. Thus, treatment of the condition may somewhat improve the intellectual function as well (41). Persons with a dementing illness may also suffer from preexisting psychiatric disorders, that can compound their behavioral problems. Presence of Delirium Delirium (also called acute brain syndrome) is a decline in intellectual functioning with clouded consciousness. As discussed earlier in this chapter, persons with dementia frequently develop a delirium from other illnesses or drug reactions. That can further impair their thinking. For these persons, the careful monitoring of health status and the adjustment of treatment regimen can improve the level of function (20). Presence of Sensory Impairment Persons suffering from a dementia may also suffer from sensory impairments (loss or reduction of hearing, vision, taste, or smell) common in the elderly. Such impairment may be overlooked in individuals who are unable to complain of disability or whose behavior is misinterpreted. Sensory loss doubly impairs a person who does not realize the impairment or who lacks the ability to compensate for it (41), A person who suffers from a hearing loss may hear only whispers. If the person is also intellectually unable to realize this impairment, the person may conclude that others are talking about him or her, and become suspicious or hostile (22). Individuals with dementia who need corrective eyeglasses or hearing aids should be assisted in using them. Caregivers must remind them to use these devices, and must assume responsibility for their maintenance. New eyeglasses, contact lenses, and hearing aids require that the person learn to use them; because they do not exactly reproduce the lost sense, they require that the user adapt to them. (Eyeglasses distort vision; in someone without dementia, the brain quickly learns to ignore the distortion. Similarly, hearing aids magnify all sounds including those that the brain must learn to filter out.) Some persons suffering from dementia may never learn to adjust to new devices. Research is needed to develop supportive devices that are easier to learn to use. Sensory deficits can be eased to some extent without the use of eyeglasses and hearing aids. Reducing background noise and glare, improving levels of lighting, and speaking clearly are important aids for confused persons (see ch. 7). Presence of External Stressors When a person suffers from a dementia, seemingly low levels of stress (e.g., the presence of several people in the room, a medical examination, or getting lost) can significantly reduce his or her ability to function (30). Indeed, whereas stress in the intact individual may enhance the ego, stress in the demented patient may lead to ego disintegration (41). The stressors that can precipitate such a drop in cognitive function maybe physical (mild illness, discomfort, or fatigue), exogenous (travel, or a change of environment), or psychological (fear, or discouragement over the inability to do a simple task). Keeping persons with dementia as healthy as possible, supporting sensory impairments, and adjusting demands on them can therefore improve function and reduce behavior problems. Terminal Stages of the Illness As the disease progresses, more function is lost and these individuals gradually become totally dependent on others for care. Damage to the brain is profound and more generalized than in earlier phases. As the apraxia and aphasia progress, disruptive behaviors such as wandering and suspiciousness are lost. Individuals may lose the ability to swallow without choking. Clinicians report that at some point persons with dementia are no longer able to participate in group social activities. Caregivers are often uncertain of the extent to which the individual is aware of their presence. Physical therapy and nursing care can reduce problems secondary to the dementia, such as contractures (abnormal shortening of muscle tissue), PAGE 84 Ch. 2Characteristics of Persons With Dementia l 7 9 bedsores, impactions, and dehydration. Sensory be kept alive for some time through aggressive stimulation (such as music) and touch can supmedical care and life-sustaining systems, raising port what function remains. Some individuals can difficult ethical questions for caregivers (see ch. 5). CONCEPTUAL ISSUES RAISED BY THE CHARACTERISTICS OF PERSONS WITH DEMENTIA Is Dementia a Disease or Normal Aging? In the past, the set of symptoms identified as dementia was termed senility and assumed to be a part of normal aging. The shift from that belief to anotherthat dementia is a pathological syndrome caused by a group of diseaseshas implications of public responsibility for the care of its victims: physicians have a responsibility to diagnose and treat the condition; caregivers and others must accept abnormal behavior as illness-produced rather than crazy or deliberate; research can be expected to improve treatment. Government can be expected to provide the same services for these individuals as for victims of other chronic illnesses such as heart disease or cancer. In fact, although most authorities agree that dementia is a disease syndrome, the case for its being a concomitant of normal aging has not been disproved. The distinction between mental deterioration that occurs with age and that caused by disease rests on several premises. First, a process that affects all individuals would be considered a part of aging, while one that affects only a fraction of people would be called disease. Second, a condition that is due to aging should not be confused with a factor that is caused by longterm exposures or repeated insults; it should be considered an intrinsic part of the aging process itself. Mental symptoms severe enough to be called dementia do not affect all people, even if they live to a very old age. Third, finding a cause not intrinsic to aging would confirm that dementia is not a part of (normal aging. A few dementing disorders have been traced to specific causes (viruses, head trauma, or small strokes that are not due to aging), but the cause of Alzheimers disease remains unknown. The impact of a shift in public attitude toward dementia has already been translated into increased funding for research, proposed legislation, media attention, consumer demand for services, and contributions to the medical literature. Yet existing State and Federal laws and the attitudes of some physicians and nursing home personnel reflect the confusion and ambivalence that result in uneven treatment and access to resources. Are Persons Eligible for Services on the Basis of Age or Disability? The Federal Government offers many services to people not because they are ill but simply because they are over age 64. Persons with dementia often fall between the cracks sometimes eligible for services to the elderly, sometimes eligible for services for the ill, and sometimes eligible for neither (see ch. 11). For example, Federal medical assistance does not provide for service in institutions for the mentally disabled to persons between ages 22 and 65. If institutional care is needed, persons with dementia who are under age 65 must be cared for in a nursing home if they are to receive medical assistance. Nursing homes are often reluctant to accept younger persons with dementia because they fear the potential behavior disorders in a physically able person. Some persons with dementia may have nowhere to go. Is Dementia a Mental Disorder; an Organic Disease t or Something In-Between? Disorders causing dementia lie on the border between traditional conceptions of mental disorders and organic diseases, Concepts of mental disorders are based on observed behavior; explanations of the cause can include madness incited by emotional stress, alcoholor drug-in- PAGE 85 80 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Oementias duced delirium, or cell surface receptor changes associated with depression, Concepts of organic diseases tend to focus on cancer, heart disease, or some other condition in which a concrete physical disability results from a structural or chemical disruption of normal body function. There has always been a broad and ill-defined gray zone between organic disease and mental disorder; progress in brain research over the last two decades has made the distinction even less defensible for many disorders. The disorders covered in this assessment are organic diseases caused by changes in the brain, an organ whose cells can suffer damage in much the same way other organs do. The resultant symptoms of such physical damage, however, are behavioral, those most often ascribed to mental illnesses: intellectual decline, cognitive impairment, and emotional instability. The diagnosis and treatment of persons with dementing disorders reflect that duality. Alzheimers disease, for example, falls precisely between neurology and psychiatry, and it is treated by both disciplines. Recent recognition of the prevalence of Alzheimers disease has attracted increased interest from physicians engaged in primary care, such as internists, geriatricians, and family practitioners. The diagnostic and therapeutic care that an individual receives may hinge on which type of practitioner the person sees. That may be advantageous in that different specialty groups may try different approaches, but it can also cause problems because care may be inconsistent or insufficient, depending on the training and competence of the physician in charge. The distinction between mental and physical illnesses is prominent in public policies. Federal programs for drug abuse and alcoholism, for example, are administratively grouped with programs for diseases such as schizophrenia and manicdepressive illness, and kept separate from programs for heart disease, cancer, or arthritis. Because disorders causing dementia include features of both organic disease and mental debility, they often fall into an administrative limbo: they are sometimes covered by a mental health program, sometimes by a medical program, and often by neither. An individual maybe excluded from one set of programs (e.g., under rules for determining eligibility for disability benefits), included in another (e.g., in Federal policies on biomedical research), or lost amidst a complex and sometimes contradictory combination of inclusive and exclusionary rules (as in many programs for long-term care). Each of these issues leads to local variations in the amount and type of care available to individuals or their families, based on local interpretations of normal aging, age-related eligibility, and mental or physical illness. Some community mental health centers offer excellent services for persons with dementia; others do not. Supportive services available to the elderly, such as transportation and meals, may not be available to younger persons with dementia. What Share of Funds Should Be Allocated to Research Into Patient Care? In a setting of limited resources, allocation decisions must be made between funds for research into the cure or prevention of dementing illnesses and funds for research into improved care techniques. The sheer numbers of persons expected to develop dementia and the enormous potential cost of their care argues strongly for additional funding to prevent or cure the condition. However, there are also excellent arguments for research into ways to alleviate the suffering of the victim and the devastation of the family caregiver; more efficient ways to provide care may well affect the long-term costs of care. Ample precedent exists for treating symptoms and alleviating suffering in persons with chronic irreversible diseases. But several unique problems arise with dementia. First, there is a widely held assumption that nothing can be done for persons with dementing disorders. If this were true, then failure to spend funds on unnecessary interventions would be justified. By the same token, a physicians failure to spend time with a patient presenting with dementia would be justified as a responsible conservation of valuable time. If interventions are beneficial, however, persons with dementia and their families are justified in PAGE 86 Ch. 2Characteristics of Persons With Dementia 81 asking for as much treatment as victims of other chronic illnesses receive. The second problem is the type of treatment persons with dementia seem to require. Persons with progressive dementing illnesses will experience continual declines in intellect and in their capability for self-care and independent living, and will eventually reach a state of total dependency, But decline in some abilities can sometimes be postponed, and some disturbing symptoms can be treated. The recommended intervention is often not medication or a medical procedure, but modifying the environment. Doing so appears to improve the quality of life for such individuals, and clearly benefits the caregivers. Clinical experience has demonstrated that good medical care and family support can reduce distressing behaviors in the home (30). And pilot projects have shown that persons with dementia function better in specifically designed settings than in traditional nursing homes (see ch. 7). The needs of a person with dementia can be compared with those of the mobility-handicapped person: providing access routes treats the mobility-handicapped so that his or her life can be more normal. Yet spending funds on a caregivers home is more difficult to justify than spending them on medications for the person with dementia. Critical questions remain unanswered. Research into improving care is in its infancy, and the effectiveness of specific interventions is not fully understood. Little is known about which individuals would benefit from improved care. Scant research has been done on medications to control certain symptoms or on technologies that would support self-care. The number of persons with dementia who would actually benefit from new methods of care or who are now overmedicated, undertreated for concurrent illness, restrained, or deprived of needed sensory stimulation is unknown; estimates range from a few to most, Nor are the costs of supporting optimal function well understood. The rate of disease progression when function is maximally supported has not been completely documented. Thus the cost-effectiveness of optimal care cannot be established. Investment in research in patient care and health care delivery is needed to answer these questions. Some estimate that it may be many years before a cure is found. If so, research is urgently needed to tell us how to provide humane care at an acceptable cost. CHAPTER 2 REFERENCES 1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 3d ed. (Washington, DC: 1980.) 2. Berlin, F., Associate Professor, School of Medicine, Johns Hopkins University and Director, Sexual Disorders Clinic, Johns Hopkins University, School of Medicine, personal communication, February 1986. 3. Blessed, G., Tomlinson, B. E., and Roth, M., The Associations Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects, British Journal of Psychiatry 114:797-811, 1968. 4. Cohen, D., Kennedy, G., and Eisdorfer, C., Phases of Change in the Patient With Alzheimers Dementia: A Conceptual Dimension for Defining Health Care Management, Journal of the American Geriatrics Society 32(1):11-15, 1984. 5. Coons, D., A Residential Care Unit for Persons With Dementia, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. 6. Coons, D,, Chenoweth, B., Hollenshead, C., et al., Final Report of Projection Alzheimer's Disease: Subjective Experience of Families (Ann Arbor, MI: Institute of Gerontology, University of Michigan, 1983). 7. Cross, P. S., and Gurland, B.J., The Epidemiology of Dementing Disorder s, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. 8 Foley, W. J,, Dementia Among Nursing Home Patients: Defining the Condition, Characteristics of the Demented, and Dementia on the RUG-II Classification System, contract report prepared for the PAGE 87 82 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias 9. 10. 11. 12. 13. Office of Technology Assessment, U.S. Congress, 1986. Folstein, M.F., and Rabins, P. V,, Psychiatric Evaluation of the Elderly Patient, Primary Care 6:609620, 1979. Folstein, M. F,, Folstein, S. E., and McHugh, P. R., Mini-Mental State: A Practical Method for Grading the Cognitive State of Patients for the Clinician, Journal of Psychiatric Research 12:189-198, 1975, George, L. K., The Dynamics of Caregiver Burden, final report submitted to the Association of Retired Persons-Andrus Foundation, 1984, Goldstein, K., The Effect of Brain Damage on the Personality, Psychiatry 15:245-260, 1952. Gwyther, L. P., Care of the Alzheimers Patients: A Manual for Nursing Home Staff (Washington, DC: Alzheimers Disease and Related Disorders Association and American Health Care Association, 1985). 14. Hachinski, V., Different Diagnosis of Alzheimers Dementia: Multi-Infarct Dementia, Alzheimers 15. 16. 17. 18. 19. 20. 21 22 Disease, B. Reisberg (cd.) (New York: Free Press, 1983), Hughes, C. P., Berg, L., Danziger, W. L., et al., A New Clinical Scale for the Staging of Dementia, British Journal of Psychiatry 140:556-572, 1982. Kahn, R. L., The Mental Health System and the Future Aged, The Gerontologist 15:24-31, 1975, Katzman, R., Clinical Presentation of the Course of Alzheimers Disease: The Atypical Patient, Modern Approaches to the Dementias, Part II, C ,F. Rose (cd.) (Basel, Switzerland: Krager, 1985). Katzman, R., Lasker, B., and Bernstein, N., Accuracy of Diagnosis and Consequences of Misdiagnosis of Disorders Causing Dementia, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. Mace, N. L., Assessment and Intervention for Behavioral Issues in Dementia, paper presented at the Annual Conference, Alzheimers Disease and Related Disorders Association, Minneapolis, 1984, Mace, N. L., Self-Help for the Family, Alzheimers Disease and Related Disorders, W.E. Kelly (cd.) (Springfield, IL: Charles Thomas Publishing, 1984). Mace, N. L., Home and Community Services for Alzheimers Disease: A National Conference for Families, U.S. Department of Health and Human Services and Alzheimers Disease and Related Disorders Association, May 2, 1985. Mace, N. L., and Rabins, P.V,, The 36-Hour Day: A Family Guide To Caring for Persons With Alzhei mers Disease, Related Dementing Illnesses, and Memory Loss in Later Life (Baltimore, MD: Johns Hopkins University Press, 1981). 23. 24. 25. 26. Mace, N. L., and Rabins, P. V., The Impact of Dementia on the Family: Two-Year Followup, paper presented at the Gerontological Society of America, 1982. Mace, N. L., Hardy, S. R., and Rabins, P. V., Alzheimers Disease and the Confused Patient, Physical Therapy of the Geriatric Patient, O. Jackson (cd.) (New York: Churchill Livingston, 1983). Markesberry, W., Professor of Pathology and Neurology, University of Kentucky College of Medicine, personal communication, 1986. McHugh, P. R., and Folstein, M. F., Psychopathology of Dementia: Implications for Neuropathology, Congenital and Acquired Cognitive Disorders, R. Katzman (cd.) (New York: Raven Press, 1979). 27. McKhann, G., Drachman, D., Folstein, M,, et al., 28 29 30. 31. 32. Clinical Diagnosis of Alzheimers Disease, Neurology 34:939-944, 1984. Orr, N., Director, Hillhaven Corporation Special Care Units, personal communication, 1986. Price, D, L., Basic Neuroscience and Disorders Causing Dementia, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. Rabins, P. V., Management of Irreversible Dementia, Psychosomatic 22(7):591-597, 1981. Rabins, P. V., Mace, N. L., and Lucas, M.J., The Impact of Dementia on the Family, Journal of the American Medical Association 48:333-335, 1982. Reisberg, B., Ferris, S., and de Leon, M.J, Senile Dementia of the Alzheimers Type: Diagnostic and Differential Diagnostic Features With Special Reference to Functional Assessment Staging, Proceedings, Second International Tropon-Bayer Symposium, 1984. 33. Reisberg, B,, Ferris, S.T., de Leon, M.J., et al., Age34. 35 36 Associated Cognitive Decline and Alzheimers Disease: Implications for Assessment and Treatment Thresholds in Aging (London: Academic Press, 1985), Risse, S. C., and Barnes, R., Pharmacologic Treatment of Agitation Associated With Dementia, Journal of the American Geriatrics Society 34:368-376, 1986. Roth, M., Senile Dementia and Its Borderlands, Psychopathology in the Aged, V.J.O. Cole and J.E. Barrett (eds.) (New York: Raven Press, 1980). Rouse, P.J,, Griffith, J.D., Trachtman, L. H., et al., Aid for Memory Impaired Older Persons: Wandering Notification Report of a Needs Assessment and Feasibility Study, Research Triangle Institute NASA: NASW, 3841, 1986. Royal College of Physicians, Organic Mental Impairment in the Elderlv, 15(3), 1981. PAGE 88 38. Sjogren, H., Clinical Analysis of Morbus Alzheimer and Morbus Pick, Acta Psychiatric and Neurological Scandinavia 82:69-113, 1952. 39. Swash, M., Smith, C. M., and Hart, S., The Dementia of Alzheimers Disease, Modern Approaches to the Dementias, Part II, C.F. Rose (cd.) (Basel, Switzerland: Krager, 1985). 40. U.S. Department of Health and Human Services, Alzheimers Disease: Report of the Secretarys Task Force on Alzheimers Disease, DHHS Pub. No. ADM 84-1323 (Washington, DC: U.S. Government Printing Office, 1984). Ch. 2Characteristics of Persons With Dementia 83 41. Wells, C. E., Diagnostic Evaluation and Treatment in Dementia) Dementia, 2d ed., C.E. Wells (cd.) (Philadelphia, PA: F.A. Davis, 1977). 42. Wells, T., Urinary Incontinence in Alzheimers Disease, contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. 43. Whitehouse, P.J., Alzheimers Disease) Current Therapy in Necrologic Disease 1985-1986, R.T. Johnston (cd.) (Philadelphia, PA: B.C. Decker, 1985). PAGE 89 Chapter 3 The Diseases: Diagnosis, Treatment, and Scientific Background While it is important to keep the perspective that the vast majority of elderly people do not demerit, from the neurologists perspective these numbers of patients [with dementia] are staggering. Stuart A. Schneck, M.D. American Academy of Neurology Annual Meeting, 1986 The question Why study dementia? is coming to be answered very clearly. There are few issues receiving public attention today whose ramifications touch upon so many areas of human well-being. The large number of lives involved; the severity of the physical, psychological, and economic influences of the disease upon the victims and related persons; and the long duration of the illness and [their] poor prognosis establish [the] dementia(s) as a fundamental problem in our society. Mary L.M. Gilhooly and James E. Birren, in The Dementias: Policy and Management, M.L.M. Gilhooly, S.H. Zarit, and .J.E. Birren (eds.] (Englewood Cliffs, NJ: Prentice-Hall, 1986) The attitude of (nothing can be done results in nothing being done, and the functional ability of the patients is adversely affected. James A. Greene, Jan Asp, and Nancy Crane, Journal of the Tennessee Medical Association, September 1985, vol. 559, p. 5.59 PAGE 90 CONTENTS Page Diagnosis . . . . . . . . . . . . . . . 87 Problems in Diagnosis . . . . . . . . . . . 87 The Diagnostic Process . . . . . . . . . . . 89 Characteristics of Specific Diseases . . . . . . . . . 97 Alzheimers Disease. . . . . . . . . . . . . 97 Dementia Caused by Blood Vessel Disease. . . . . . ........112 Other Dementias . . . . . . . .....................113 Chapter 3 References . . . . . . . . . . . ....115 Tables Table No. Page 3-1. Examples of Diseased Brain States Caused by Failure of Organ Systems. 90 $2. Selected Laboratory Tests To Diagnose Specific Diseases and Search for Reversible Causes of Dementia . . . . . . . . . 92 3-3.Diagnostic Criteria for Dementia. . . . . . . . . . 96 PAGE 91 Chapter 3 The Diseases: Diagnosis, Treatment, and Scientific Background Dementing disorders exact a staggering toll on patients and their families. Many of the worst problems are caused by the behavioral and intellectual effects of the diseases, which rob patients of their autonomy and exert emotionally wrenching pressures on family and friends. The larger issues related to caring for patients are covered elsewhere in this assessment; this chapter provides clinical and scientific background on the diseases themselves. The clinical and scientific information is intended to introduce other sections of the report, and is not followed by policy issues and options because these are found in other, more policy-oriented chapters. Over 70 disorders can cause dementia. This chapter describes the clinical and scientific background on some of these disorders. Medical management of the various disorders causing dementia depends on the characteristics of individual patients. Treatment is quite effective for a few disorders, and several behavioral symptoms common to many of the most prevalent diseases frequently respond to medication. Symptoms of dementia are often made worse by acute medical illnesses and drugs, and prompt medical attention can reduce excess disability caused by poor health and medications. No cure is available, however, for the vast majority of dementing conditions, and the symptoms of intellectual decline frequently continue to worsen despite the best medical efforts. DIAGNOSIS Once the symptoms of dementia have been identified, the search for a specific cause commences. In the hands of experienced and capable physicians, the diagnostic process is highly efficient and conveys relevant information about the putative causes, possible treatments, and probable course of the disease in a given patient. The accuracy of detecting dementia has improved to over 90 percent at specialized centers in recent years (163). Yet diagnostic error is higher for identifying the specific diseases causing dementia and detection of the symptoms remains poor among some physicians. Many physicians are now apt to make the diagnosis of Alzheimers disease, for example, any time a patient has notable intellectual or memory impairment. This contrasts markedly with medical practices common until recent years, when Alzheimers disease was underdiagnosed because of ageism, different medical terminology, and errant theories of the causes of the disease (228). Many patients now in nursing homes were evaluated during the periods of underdiagnosis, and their records retain outdated diagnostic labels such as (cerebral atherosclerosis or chronic brain syndrome. The diagnosis of a disease that causes dementia usually begins with identification of mental decline, either from querying patients or others who know them. Detecting early dementia can be dif ficult, but: ., dementia should be suspected whenever mental changes of insidious onset emerge without sufficient situational stress and gradually interfere with the daily living activities. Dementia can be reversible or irreversible, precipitously progressive or indolent, bristling with multiple cognitive deficits, or characterized almost exclusively by disturbances of affect, motivation, and personality (218). Problems in Diagnosis Inaccurate diagnosis can arise from several sources. The errors may stem from atypical presentation of the disease, denial or misunderstanding by the patient or family, or physician error. 87 PAGE 92 . 88 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Symptoms may be mild and ill defined, or the disease may have progressed so far that any number of diseases could have caused the patient to lose most mental functions (84). The patient may not experience memory loss, or may exhibit bizarre behavior that is ascribed to depression or schizophrenia (163,289). The history may be inaccurate, due to inadvertent or deliberate reporting errors by the patient or the family. The patient or family may wish to deny the presence of any problems, or they may have identified the wrong ones. No family members maybe available to give a medical history. The onset of most dementing illnesses is not sudden, but patients and families may not notice a problem until a cataclysmic event or new source of stress dramatically highlights a loss of mental function. Finally, tests may be misinterpreted, the proper tests may not be ordered, or the symptoms of dementia may be missed by the health professionals who care for the patient. Several factors predisposing to diagnostic error l l l l l l have been identified: ageism (neglect caused by expectations that a patient is just senile); failure to use strict diagnostic criteria; insufficient time devoted to obtaining a history or examining patients; absence of a policy of searching for remediable causes of confusion; inadequate recourse to special tests; and incompatibility between the diagnostician and the patient (due to cultural, educational, or ethnic background (125)), Some error is due to lack of knowledge, and this can be addressed by improved education. Other errors are due to failure to apply what is known. This can be due to the pressure of time, the clinical complexities of a particular case, lack of access to diagnostic technologies, or physician disinterest. Discovery of effective medical treatments for the common dementing conditions, especially Alzheimers disease and multi-infarct dementia, would give physicians a major reason to find the correct diagnosis, likely reducing the diagnostic error rate in routine practice. The problems of misdiagnosis that arise from patients and their families can be addressed by public education and family support groups, but this type of problem will never be eliminated completely. Self-help groups, media attention, and accurate dissemination of scientific and medical information from laboratories into the general society are the major policy initiatives that could reduce this form of diagnostic error. Misdiagnosis by physicians can be reduced through improved education during professional training, continuing medical education, and rapid dissemination of scientific data in medical journals and books. The Federal Government has taken the lead in sponsoring basic and clinical biomedical research, and also supports many extremely useful information dissemination mechanisms through the National Library of Medicine and the National Institutes of Health (NIH). The Federal Government generally has not had a role in assuring the incorporation of new information in the curricula of health professional programs (see ch. 9). Clinical diagnosis is only as reliable as the process used to make it. Beginning with a patients history of mental change, a diagnostic algorithm is then followed to identify possible specific causes. The breadth and adequacy of these procedures depends on the knowledge of the supervising physician, the availability of diagnostic tests, and the quality of the tests. The diagnosticians knowledge is related to the availability of current medical information, active continued reading of the medical literature about diagnostic options, and the persons educational background. The availability of diagnostic tests depends on a groundwork of basic and clinical science, marketing, and local access to people trained to perform the tests, whereas quality is linked to the limitations of the test itself (how well it works at best), the competence of those who perform it, and the accuracy with which results can be interpreted. Many factors that influence the diagnosis of dementing conditions have been changing in recent years as a result of the greatly heightened interest in studying dementia. A consensus development conference of diagnosis of dementia will be held at NIH July 6-8, 1987. Diagnostic practices among specialized groups at major medical centers are often quite differ- PAGE 93 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 89 ent from those in other services at the same institutions, as well as from practices that prevail in community hospitals and private clinics. Most of the published data come from centers of expertise and reflect high standards for evaluation; the actual care of patients inmost communities is generally less thorough. The degree of diagnostic error is difficult to determine, however, because most studies are conducted at academic medical centers specialized in the care of dementia. Yet many persons with dementia reside in nursing homes, where they receive less thorough diagnostic evaluation. The most serious problem of diagnosis in nursing homes is widely believed to be underdiagnosis or failure to even recognize symptoms of dementia (274). Failure to detect dementia among patients ranges from 4 to 60 percent in recent studies (125). These errors are, by and large, most frequent among patients known to have confusion or behavioral change. Even more troubling is the failure to notice that a patient is confused; examining physicians missed 79 percent of the cognitive deficits at a university hospital in a recent preliminary study (207). Another report found that errors in initial diagnosis affected therapy in 41 percent of the patients referred to a specialized hospital service for dementia (145). Great improvements are thus possible in the sensitivity of detecting mental impairment and identifying its specific cause even without technological advances. Diagnostic uncertainty complicates clinical research by mixing patients with different diagnoses. A drug or diagnostic procedure maybe tested on patients with disparate diseases. Those with different illnesses or in different stages may respond but be undetected because they are lost among a large group of patients who show no effect. This can mask a benefit or danger. For a response to be detected, therefore, a drug or test must either be highly effective in a small group of patients or effective in most patients. Patient heterogeneity is thus the bane of efficient clinical testing. It does not preclude it, but it makes tests significantly less sensitive to small or moderate effects. There is no clear way around this problem in clinical research on dementia. The standard for approving clinical protocols for mentally incompe tent patients requires that the experimental procedure either pose minimal risk or promise direct patient benefit (45 CFR 1983 ed. 46). Neither condition clearly holds for most investigational work, but it is unlikely that the regulations for research on human subjects will be altered. Such changes would require, at a minimum, extensive public review before being implemented. (Consent of dementia patients to participate in clinical research is dealt with more fully in ch. 5.) The Diagnostic Process The possibility of treating some reversible syndromes that masquerade as irreversible dementia provides a strong incentive for accurate diagnosis. Families wanting to know about possible genetic risks, furthermore, cannot be advised until a specific disease has been identified. The process followed in obtaining a clinical diagnosis centers on cultivating several different sources of potentially useful information: in the patients medical and behavioral history, physical signs, laboratory tests, psychological tests, and brain imaging technologies. The process of diagnosis also includes investigating other illnesses. One recent study of persons with dementia in the community found that 30 percent had medical conditions that contributed to the patients mental deterioration, and that removal of some medications and correction of metabolic abnormalities actually improved the function of most (181). Thus broad inspection of a patients possible medical problems is important. Diagnosis is the function that both physicians and families regard as the doctors strength. Families regard diagnosis as the doctors function, above patient education, emotional support, or assistance in obtaining health and social services. Physicians concur in finding diagnosis less difficult to provide than counseling, coordination of care, or other services (113), The diagnostic process is thus generally directed by a physician with the assistance of family members or others familiar with the patients history. Patient History The specific mental and physical changes reported by patients or those who know them well PAGE 94 90 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias are extremely important in determining the possible causes of dementia. The age at which intellectual changes began, the exact functions lost, and the rate of change are all quite helpful in sorting among the various disorders. The type, frequency, and severity of mood swings, personality changes, and catastrophic emotional reactions are also useful. A history of mental decline at specific times with some recovery after each episode strongly suggests multi-infarct dementia, for example. Medication frequently causes symptoms of dementia in older patients, and examiners should find out what medication a patient is taking. Dementia pugilistic (brain damage induced by repeated head trauma) is immediately suspected in former boxers, and a history of alcoholism may suggest a detailed search for alcoholrelated damage to the brain. The patient history is taken, if possible, from the patient. This cannot be done for many individuals with moderate or severe dementia. In such cases, a history must be taken from family or friends, and corroboration by several sources is often helpful in deciding fine points about the course of the illness. The resort to secondary sources is common for pediatricians, pathologists, and veterinarians, but is unusual for many physicians who specialize in other areas. The added complexities of surrogate informants often necessitate finding corroboration for important points, especially if there is a conflict of interest between the patient and the informant (see ch. 5). The history will include the main reason medical help is sought, information volunteered by the patient or informant, and answers to questions posed by the interviewer. Specific questions are asked to elicit certain points helpful in distinguishing among the different disorders that might explain the symptoms. Abnormal involuntary movements combined with a history of a similar illness in other family members, for example, can be quite informative for Huntingtons disease. An insidious onset with early deterioration of memory for recent events is typical of Alzheimers disease, while early disturbance of a patients gait with a only a mild memory deficit inclines a physician toward a diagnosis of normal pressure hydrocephalus. The history of the illness becomes the first, and in many cases the most important, step in determining the diagnosis. It often indicates which tests will be performed to rule out or suggest specific diseases, and also alerts the diagnostician to look for specific physical symptoms in the subsequent examination of the patient. Physical Examination The physical examination consists of a battery of tests of body functions to detect signs of dysfunction or other findings associated with particular diseases. For a patient with dementia, the exam has two main emphases: signs of damage to the nervous system, and evidence of diseases of other organs that could affect mental function. Testing of several organ systems, such as the cardiovascular system, the lungs, and digestive organs, is done by an algorithm that physicians, nurses, and physician assistants learn during their professional education and progressively refine during their practice. Diseases of many organs other than the brain can induce confusion, loss of memory, and strange behavior, especially in older individuals (68) (see table 3-1), and such causes must be eliminated before a firm diagnosis of brain disease can be made. The general physical examination can, for example, identify signs of heart failure or thyroid dysfunction, which in elderly individuals can involve symptoms that resemble dementia. Table 3=1.-Examples of Diseased Brain States Caused By Failure of Organ Systems Organ system Symptoms and signs Heart failure Headache, confusion, stupor Liver failure Confusion, stupor, or coma; focal or generalized seizures, tremor Kidney failure Apathy, fatigue, confusion, stupor, generalized seizures, dialysis dementia, disequilibrium syndrome Endrocine Hypoglycemia Episodic headaches, seizures, confuHyperglycemia sion, coma Hypothyroidism Apathy, psychosis, coma Hyperthyroidism (apathetic) Cushings syndrome (CS) Apathy, psychosis, severe dementia, Addisons disease (AD) depression SOURCE Adapted from B.M, Coull, Necrologic Aspects of Dementia, Geriatric Medicine, VOI 1 C K. Cassel and J E. Walsh (eds. ) (New York Sprmger-Verlag, 1964) PAGE 95 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 91 Testing functions controlled by the brain and nerves-the neurological examination-is another important component. The examiner typically asks the patient to perform maneuvers or answer questions that are designed to elicit information about the health of specific parts of the brain or peripheral nerves. The examiner tests smell, vision, eye movement, muscle tone and power, touch, hearing, taste, and reflexes (both muscle reflexes and those that involve involuntary functions such as constriction of the pupils). The neurological examination distinguishes signs of brain disease. Symptoms caused by damage to a particular anatomic location in the brain or spinal cord, for example, suggest stroke, tumor, or some other physically localized phenomenon. Multi-infarct dementia is suspected in a patient with dementia who also shows other localized brain damage and has high blood pressure or diabetes, while a patient without these findings is more likely to have Alzheimers disease (48). Involuntary movements, rigidity of the limbs, and general slowness of speech and gait may induce a high suspicion of Parkinsons disease. Recent preliminary studies suggest that Alzheimers disease may be correlated with specific tests of brain functions (217). The characteristics of cognitive loss may also be useful in differentiating among possible explanations of mental change. A skillful examiner may be able to distinguish the patient with depression from one with a degenerative dementing condition, based on errors on the mental status examination due to lack of motivation or to inattention (favoring depression) versus those due to inability (thus implying brain disease). Taken together, the history and physical examination permit an 80-percent diagnostic accuracy of dementing conditions (163), lower than the accuracy of detecting the symptoms of dementia, but well within the range of many other types of disease. Laboratory Tests The diagnostician selects specific laboratory tests based on the clinical history and physical examination, which typically leave the physician with a list of possible explanations of the symptoms and signs that range from the highly probable to the improbable. Tests that might reinforce suspicion of some diseases or eliminate others from consideration are then performed. These include measurements of the concentration of cells and chemicals in the blood that might yield clues of infection or disordered metabolism, measurements of electrical activity in the brain (electroencephalograms or other more sophisticated tests), and measurements of chemicals and cells in the fluid that surrounds the brain (the cerebrospinal fluid [CSF]). A large number of white blood cells in the blood combined with fever, for example, can indicate an ongoing infection. Abnormal blood concentrations of hormones, vitamins, electrolytes, or chemicals normally filtered by the kidneys can uncover diseases of the liver, kidney, or endocrine glands or exposure to heavy metals. Abnormal concentrations of chemicals in the urine may disclose poor kidney function or exposure to toxins or drugs. Several lists have been developed of tests to distinguish among different conditions causing symptoms of dementia (see table 3-2); most include several blood tests and at least one brain imaging technique (discussed later in this section). No single standard protocol exists, however, because of both the variation among patients and disagreement about the usefulness of some tests. The utility of any one type of test may be uncertain, and its use may then vary from place to place. Tests also vary in expense, risk, and discomfort for the patient. obtaining a sample of cerebrospinal fluid, for example, requires entering the sac that encloses the spinal column in a procedure called lumbar puncture. Tests of CSF can reveal syphilis of the nervous system, evidence of bleeding, or ongoing infection (323). The test is relatively expensive ($381 in one study), carries a small risk for the patient, often causes discomfort, and picks up relatively a few diseases compared with the number of patients tested (17, 130). Several authors have concluded that lumbar puncture should not be done unless a brain infection is suspected or the patient is under age 55 (17,130,201); other authors include the procedure in their recommendations (84,314,323). The debate about performing the lumbar puncture on all pa63-218 0 87 4 QL : 3 PAGE 96 92 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Table 3=2-Selected Laboratory Tests To Diagnose Specific Diseases and Search for Reversible Cause of Dementia Test Diseases suggested by test results Blood count Pernicious anemia, infection Sedimentation rate Immune disorders Electrolytes, glucose, calcium, liver, Clue to metabolic etiologies, liver disease, kidney disease and renal function tests Urinalysis Kidney disease Syphilis serology (VDRL, etc.) Syphilis Vitamin B, Bo, vitamin B12~, folate Vitamin deficiencies, pernicious anemia Thyroid and adrenal function tests Hypeor hyparthyroidism; Cushings disease, Addisons disease (TSH, T4, T3, resin uptake, cortisol) CT or MRI Normal pressure hydrocephalus, stroke, vascular disease, tumor Lumbar puncture Syphilis, cryptococcus, brain hemorrhage, other infection of the brain EEG Seizure disorder, transmissible dementia Special Studies (When Appropriate): RISA study Hydrochephalus, when other studies or history suggest possibility of that disease Toxic screen including heavy metals Environmental or occupational exposure; poisoning SOURCES: Adapted from P.V. Rabins, Reversible Dementia and the Misdiagnosis of Damentia, Hosp/ts/ and Corrrrnun/ty Psych/Wy 34: S30-S35, 19S3; and K.L. Tyier and H.R. Tyier, Differentiating Organic Dementia GerWr/cs 39:-52, March 19S4. tients with dementia thus continues, and different articles about diagnostic procedures include the test, exclude it, or list it as optional (5,30)84,165) 171,253,314). Lumbar puncture could rapidly become routine if a specific CSF test for Alzheimers disease became available. Several of the promising new tests do require CSF samples at present. Physicians may thus be unsure of the proper course of testing, and their uncertainty will not diminish until more studies indicate the appropriateness or lack of utility of lumbar puncture. Similar uncertainties are associated with many other diagnostic tests. A consensus on essential versus nonessential tests can only result from clinical trials that demonstrate a particular tests utility. The need for practicing physicians to know what tests to perform is one of the important drives behind clinical research. The rate at which diagnostic and treatment controversies are resolved depends, therefore, on continued funding of clinical research. Investigators hold great hope for significant advances in the laboratory diagnosis of disorders causing dementia. Many researchers are now attempting to identify biological markers of Alzheimers disease, for example, that would vastly simplify its diagnosis (308). Alzheimers disease can now only be confirmed if tissue from the patients brain can be directly inspected under the microscope, so clinical diagnosis proceeds by elimination of other possible explanations of dementia in a patient with a history of symptoms applicable to several disorders. Specific tests of blood, CSF, and other more accessible tissues that could reliably identify patients with Alzheimers disease or its subtypes would be highly desirable. The search for specific laboratory markers is promising, but there is no evidence yet that it will be successful. One group recently found a soluble protein that is found at much higher levels in brains of patients with Alzheimers disease than in brains of controls (336). Another group reports loss of an enzyme in patients with Alzheimers disease (77). Some scientists have found biochemical aberrations in the blood cells of patients with Alzheimers disease, but the diagnostic usefulness of the findings has not been established (32). Cells grown in culture after removal from patients with Alzheimers disease have demonstrated abnormalities of glucose metabolism (292). Irregularities that might be detected in the chemistry of CSF have also been found (111,313); but their presence has either not been confirmed by later investigators or cannot be detected by routine methods early enough in the illness to be diagnostically useful. Recent studies have demonstrated chemical imbalances that might be detected relatively early in the disease (99), but diagnostic tests based on these findings have not yet been devised. If a protein can be found in spinal fluid or blood that is not associated with other diseases, its detection would permit a specific diagnostic test for PAGE 97 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 93 Alzheimers disease. That would revolutionize the diagnosis of dementias in general. For those cases of Alzheimers disease that clearly run in families, it may be possible to develop a direct test of DNA analogous to that under development for Huntingtons disease (126,325, 326). An association of Alzheimers disease with an unusual gene for an immunological blood protein (C4) has been shown in one study (234), but its specificity to Alzheimers disease and its diagnostic importance have not been established. Other genetic tests either are nonspecific or have not yielded consistent results to different investigators (308). Several scientific groups are developing antibodies against abnormal brain proteins found in those with Alzheimers disease (83,123,321)336,342), but, again, the antibodies have yet not been used as diagnostic tools, either alone or in combination with brain imaging techniques. psychological Tests Psychological tests are used to screen for the presence of dementia (e.g., to distinguish depression from dementia), to follow up on initial findings, and to differentiate among the disorders causing dementia (e.g., to distinguish Huntingtons from Alzheimers disease). Short screening tests, called mental status tests, can be used by physicians, nurses, or other health professionals to estimate changes in global intellectual performance (33,74,90,97,124,128,158, 162,169,170,204,243, 24-4,260) 261,269)270,302,3 19); they are discussed at some length in chapter 8, and only their role in diagnosis will be covered here. Different tests either measure specific mental functions or briefly survey those functions deemed most likely to be diagnostically decisive. Most of the tests developed over the past two decades have focused on questions and tasks that can be performed at the bedside in a relatively short time. The two tests most commonly used correlate well with each other among patients with Alzheimers disease, and a formula to convert scores has been developed (307). Screening tests are judged most likely to be useful in routine practice, but generally are not sensitive to detection of mild dementia, and cannot differentiate among patients with severe dementia. They are thus useful mainly for preliminary identification of symptoms, and can be followed up by more elaborate and specific tests. More extensive tests of mental functions can be used to refine analysis of the clinical features. Extensive psychological testing can take several days and involve batteries of specific tests. Their use varies from place to place, but a panel of experts recently listed a number of specific tests found useful in the clinical diagnosis of Alzheimers disease and dementia (212, table 2 and pp. 941-942). Psychological tests are used primarily to confirm diagnoses that are already suspected, but they sometimes serve to distinguish among different diseases (224). The tests are intended to assess the functions performed by different parts of the brain (e.g., memory, calculation, knowledge of place and time, attention, understanding, and language use). These must be used carefully, because they can be influenced by a patients educational background or socioeconomic status, but they are often successful in separating impairments of memory, for example, from those influencing perception or language. In addition, they are important in distinguishing disease from the effects of aging. Psychological tests are essential to track the effects of experimental treatments, to trace the rate of deterioration of mental function, and to study subtypes of heterogeneous disorders like Alzheimers disease. They are also useful for following the stages of illness in a group of patients and in the care of an individual over time. Variations on psychological tests may help identify need for service or measure fair payment to caregivers, but their use for these purposes introduces complexities such as examiners vulnerability to deliberately being fooled. The tribulations of using psychological tests for assessment of the type and amount of care a patient needs are dealt with in chapter 8. Finally, psychological tests are important for indicating not only what is wrong, but also what functions are preserved. Knowledge of spared functions can assist family members or other caregivers in dealing with a patient. PAGE 98 94 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Brain Imaging All commentators agree that brain imaging is an essential component in the diagnosis of dementia, but the technique used depends on local availability and rapidly changing medical standards. Several methods for directly assessing the anatomy of the brain have been developed in the last two decades. The most powerful new technologies use computer analysis to create images of the brain. The differences among the techniques stem from the type of measurement used to generate data for the computer. CT Scanning-Computerized axial tomographic (CT) scanning is an extension of traditional X-ray diagnostic testing. CT scanning uses the same type of energy, X-radiation, as used for chest or skeletal x-rays, but the computer processes the information in a way that permits analysis of the internal anatomy of the head, including the brain. CT scanning machines are available in most major hospitals and many other clinical centers now, and the procedure is routinely used in most investigations of dementia. It can be useful by specifically detecting some causes of dementia, such as tumors or enlarged ventricles suggesting hydrocephalus or strokes in some locations of the brain. CT has also been used to study Alzheimers disease and assess patient prognosis (1)61,80,85). Applied to Alzheimers disease, CT scanning has been more helpful to date in establishing averages for Alzheimer patients compared with normal individuals than in differentiating Alzheimers disease from other dementias. PET Scanning. -Positron emission tomography (PET) relies on computer analysis similar to that used in CT scanning, but the machine detects positrons (electrons that have a positive rather than a negative electric charge) rather than X-rays. PET scanning works by injecting chemicals that radiate positrons. By using carefully chosen positron-emitting chemicals, the technique allows investigation of the brain in actionanalysis of the physiology of the brain displayed in threedimensional splendor. Injection of chemicals that closely resemble glucose, for example, reveals how fast the cellular fuel is taken into cells. That technique provides a rough measure of how actively nerve cells are firing in particular anatomic regions, which in turn gives clues about the functions of large groups of nerve cells in the brain. Several different causes of dementia reveal distinctive features in the PET scanner. Patients with Huntingtons disease, for example, show lower glucose intake in the caudate nucleus, a group of cells known to be lost during the course of the disease (133,177). Several studies of Alzheimers disease have also shown characteristic abnormalities in specific regions of the cerebral temporal cortex (55 and others cited therein, 75,76,86,92,98,102, 208,227). The PET scanner is a fascinating and highly useful research tool, but it has several drawbacks that will prevent it from becoming a part of routine diagnosis soon. The major constraint is its dependence on availability of a nearby cyclotron (atom smasher). The chemicals that emit positrons must be made in such a machine, and they release positrons only for a relatively short time (minutes to hours). Cyclotrons are not available in most communities, and they are extremely expensive to construct. The combination of time and expense involved in setting up a PET scanning facility thus precludes its general applicability. Some of the advantages of functional imaging available using the PET scanner might be developed for other imaging techniques, however. The special chemicals used in PET scanning might well have functional analogs that could be detected using brain scanning machinery available in major hospitals or adapted for magnetic resonance scanners, which are becoming more widely available.. SPECT Scanning. -Single photon emission computed tomography (SPECT) is another method for indirectly measuring physiological activity. It has been called the poor mans PET scan because it may eventually be able to perform many of the functions now only available through PET although with diminished precision and resolution (163). The technique uses radiation detection machines available in hospitals with nuclear medicine departments, SPECT is likely to be useful in detecting strokes, hemorrhage, and areas of poor blood circulation to the brain (60). A few studies have shown diminished blood flow to the lateral regions of the cerebral hemispheres PAGE 99 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 95 in Alzheimers disease similar to the pattern found with PET (288). Patients with multi-infarct dementia and Picks disease have also been studied (59, 146,322). One study used SPECT to detect the binding of specific chemicals known to be lost in Alzheimers disease and was able to distinguish Alzheimer patients from controls (147). It is not yet clear whether SPECT will be widely useful in the diagnosis of dementia. Although less expensive than PET scanning, SPECT is nonetheless costly and may not prove more useful than other diagnostic procedures (163). MRI Scanning. Magnetic resonance imaging (MRI) is a new technology for making images of the brain and other parts of the body (315). The technique depends on detection of a phenomenon called nuclear magnetic resonance (NMR), and is also sometimes called NMR scanning. The nuclei of some atoms in the body are composed of odd numbers of nuclear particles. (Most atoms are stable only with an even number of nuclear particles.) Such nuclei can be detected by sending weak energy signals through very strong magnetic fields. The MRI machine consists of a set of powerful magnets and a source of energy in the same general range used for broadcasting radio. The radio signal is affected in predictable ways by the number of odd-numbered nuclei in its path, The most common element with an odd number of nuclei is hydrogen, and water is the molecule most frequently associated with hydrogen in the body. In its usual application, therefore, MRI produces a map of the water content of various tissues in the body. (It can also be used for other, more specialized purposes, but they are not relevant to this discussion.) MRI has several advantages and disadvantages. The biggest advantage is that it does not involve high-energy radiation such as X-rays, and its potential adverse effects are thus judged to be minimal. MRI also gives better images of the difference between the white and gray matter of the brain than CT scanning (differentiating cell-rich from cell-poor areas). The disadvantages include its current exclusion from use in patients who have artificial heart valves or limb prostheses that might be affected by the strong magnetic fields. MRI machines are also more expensive than CT scanners, are available only at a few large hospitals, and are being acquired at a slower rate than CT scanners (299)315). Magnetic resonance imaging can, in principle, be used for most of the same purposes as CT scanning, with the added benefit of higher resolution and ability to better differentiate subregions in the brain. For detecting strokes, and perhaps tumors, MRI maybe more sensitive (103). Preliminary studies report that MRI can distinguish dementia caused by Alzheimers disease from multiinfarct dementia (20). MRI could theoretically supplant CT scanning in assessing the fluid-filled cavities in the brain and in measuring brain tissue density. One study compared the cost-effectiveness of CT scanning to MRI scanning in evaluating dementia. It found that MRI was significantly more expensive, but not a great deal more sensitive at picking up surgically correctable lesions in the brain (normal pressure hydrocephalus, blood clots, and tumors) (291). The validity of the studys results depends crucially on two factors: the prevalence of such surgically correctable causes of dementia (for which there are widely divergent estimates) and whether applications of MRI not included in the study are important. Many MRI studies are being performed to detect vascular dementia, for example, but the benefits of such use were not assessed in the study. Omitting this analysis is justified in the absence of a widely accepted treatment for vascular dementias. Consensus on optimally effective treatment of vascular dementia would likely enhance the importance of MRI as a diagnostic tool. Finally, MRI might be useful in the future for functional imaging of a type possible now only with the PET scanner. This would presuppose the development of chemicals containing nuclei that could both be detected by the MRI machine and be used in cellular metabolism. Such developments would permit the great benefits of PET scanning without the prohibitive cost and constraints of proximity to a cyclotron. Examination of Brain Tissue A final diagnosis of Alzheimers disease, Picks disease, and many other disorders causing dementia can be made only if tissue from a patients brain PAGE 100 96 l Losing a Mi//ion Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias is directly examined under the microscope. Tissue can be obtained either at autopsy or by taking a sample of the brain of a living patient (a biopsy). (The characteristics that define th e microscopic appearance of brain tissue for each disease are described in the next section.) Brain biopsy is not a routine clinical practice because of its invasiveness and high cost. It can be performed specifically for diagnostic purposes when entering the skull for some other reason. Although recent studies suggest that the risk of biopsy is relatively lowwith complications of less than 5 percent (231) and mortality under 1 percent (163)it requires a major operation, and its findings do not usually influence therapy. A major breakthrough in treatment, however, might well provide incentive for more frequent biopsy diagnosis (163). For now, biopsy is restricted to research centers and hospitals engaged in implanting drug delivery devices. The low frequency of biopsy means that the specific disease causing dementia in a particular patient is often uncertain until death. Indeed, uncertainty often prevails even after death because many patients are not autopsied. (The autopsy rate in the United States is now 14 percent, down from 50 percent at the turn of the century (211,215)). Determining Which Tests To Use The serious problem of misdiagnosis of irreversible dementia has led to several multidisciplinary conferences on the diagnostic approach to be followed. The National Institute on Aging (NIA) held a conference in December 1983 (166), and the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimers Disease and Related Disorders Association (ADRDA) cosponsored a widely reported conference (212). The American Medical Association (AMA) also recently reviewed the diagnosis of dementia, although the AMA document does not prescribe a diagnostic protocol (5). All of these are in addition to a large number of diagnostic strategies promulgated in textbooks of neurology and psychiatry. Different physicians and other health professionals use the terms Alzheimers disease, dementia, and multi-infarct dementia in different ways. The greatest confusion arises in defining Alzheimers disease, because the diagnosis can be made only by excluding other illnesses (26). These conferences have not yet yielded a uniform diagnostic approach, and any such algorithm would be expected to change rapidly as more is discovered about the different diseases. For now, the criteria promulgated at the NIA and NINCDSADRDA conferences appear to be the best available for Alzheimers disease, combined with the American Psychiatric Associations Diagnostic and Statistical Manual criteria for the presence of dementia and specific diagnosis of multi-infarct dementia (7) (see table 3-3). Lists of criteria, however, do not specify the tests to be performed, so the performance and interpretation of tests will probably remain varied among physicians. In one study of laboratory tests used in the diagnosis of dementia, the cost per patient depended primarily on the strategy used Table 3-3.Diagnostic Criteria for Dementia Criterion DSM-III ADRDA/NINCDS NIA/AMA Memory deficit . . . . . . . . . . . . . . . + + + Loss of intellectual function confirmed by mental status test. . . . . . + + + Impaired social or work functions . . . . . . . . . . . + Impairment of additional cognitive functions (language, construction, personality, etc.) . . . . . . . . . . . . . . . . . + +/ + State of consciousness not impaired (alert and awake). . . . . . . + + + Evidence of brain damage (organic cause). . . . . . . . . . + KEY: + Required for diagnosis. +/ Suggestive of but not required for diagnosis. DSM-111 = DiWnostlc and Statistical Manual of Mental Disorders, 3d ed. ADRDA/NINCDS = Alzheimers Disesee and Related Disorders Association, Inc./National Institute of Neurological and Communicative Disorders and Stroke. NIA/AMA National Institute on Aging/American Medical Association. SOURCES: American Paychiatrtc Association, fllagnostlc and Stat/st/ca/ &farrua/ of Mental Dkorr/ers, 3d ad. (Washington, DC: 1980); G. McKhann, D. Drschman, M. Folatein, et at., Clinical Diagnosis of Alzheimers Disease, Neurology 34:939-944, 19S4; National Institute on Aging, Task Force Report, Senility Reconsidered. Treatment Possibilities for Mental Impairment in the Eiderly, Journal of the American Medcal Assodatlon 244:259-263, 19S0. PAGE 101 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 97 to order tests. There were tradeoffs-some minor slowly through large numbers of clinical investiproblems would be missed by the less costly stratgations, medical textbooks, journal articles, and egies. The range of costs per patient was large, health professional conferences. Rigorous studies from $153.92 to $1,109.50 [182). The optimal diagof comparative costs and benefits of different diagnostic algorithm for dementia is likely to be as nostic approaches will, however, permit both elusive as for other syndromes. Diagnostic procgreater certainty of diagnosis and more efficient esses will defy unanimity and become established delivery of care. CHARACTERISTICS OF SPECIFIC DISEASES This section describes briefly some of the major disorders that cause dementia, emphasizing those that are most common or have yielded most to scientific inquiry. Alzheimers disease, which accounts for the majority of cases of dementia among the U.S. population, is the focus of most discussion because so little is known about its cause, prevention, or treatment. This discussion is followed by descriptions of multi-infarct dementia (the second most common cause of dementia) and other disorders that are scientifically or clinically instructive. The final part of this section considers disorders that may provide important scientific insights, present prospects for future research, or threaten to grow in magnitude and thus act as new sources of demand for long-term care. Alzheimers Disease Alzheimers disease refers to the disease process occurring in a patient who shows both the clinical symptoms of dementia and the characteristic microscopic changes in the brain. The clinical diagnosis is made on the basis of finding typical symptoms that progress over time and by eliminating other possible diagnoses that could explain those symptoms. (The symptoms have been described in the preceding section, and also in chs. 2 and 8.) Symptoms are only part of the picture, however; the definitive diagnosis of Alzheimers disease requires biopsy or autopsy examination of brain tissue. Microscopic Changes Alois Alzheimer first noted microscopic changes that occurred in the brain of a woman patient with clinical dementia in 1906, and the following year he reported this first case of the disease that bears his name (2). The findings he described are still those used to make the diagnosis of Alzheimers disease, although the microscopic features that define the disease continue to be refined (193). The significance of the abnormal findings in Alzheimers disease can best be understood by describing some aspects of the organization of the human brain. The brain is organized differently from other organs in several ways. It consists of at least IO billion nerve cells, with 10 times as many supporting cells. The nerve cells are connected to each other, each connecting with hundreds or thousands of other nerve cells. Scientists have made significant progress in understanding the complex organization of the brain over the past decade, although what they do not know still overwhelms what they do. The relationship between disrupted brain cell organization and certain disorders is becoming clearer, and Alzheimers disease is one such disorder. Anatomy of Abnormal Changes.Death of nerve cells occurs in several locations in brains of patients with Alzheimers disease. Pathologists have long noted a loss of cells from parts of the brain called the cerebral cortex (constituting the outer layers of nerve cells covering the brain) and the hippocampus (a large, curved aggregation of nerve cells near the underside of the brain). The abnormal microscopic findings are found both within nerve cells and between cells (near specialized junctions with other cells). The locations of the microscopic abnormalities appear to correspond roughly to the distribution of cells that use the chemical acetylcholine for cell-to-cell communication (see following discussion). PAGE 102 98 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias More recently, investigators have found that nerve cells are lost from a number of brain regions in Alzheimers disease. Loss of nerve cells from one group, called the nucleus basalis of Mey nert (10,279,329), is thought to be especially relevant. These cells are believed to be part of a circuit of nerve cells that communicate with one another and are involved in the physiological processes that perform memory and other complex brain functions (7o). The loss of the nerve cells in the nucleus basalis is increasingly believed to be an important feature of Alzheimers disease. The nerve cells of the nucleus basalis connect to the two areas where the microscopic changes, Alois Alzheimer originally noted, take place: the cerebral cortex and the hippocampus. The parts of the hippocampus that are destroyed in Alzheimers disease are those generally thought to be involved in memory (149). Some researchers have even suggested that symptoms of the disease could be explained by the lesions in the hippocampus alone (13), although there is disagreement on this point (62). Recent advances in identifying specific hippocampal cells lost in Alz heimers disease may further elucidate their role in causing symptoms (199). Types of Microscopic Changes.Two patterns of microscopic change are generally used to make the diagnosis of Alzheimers disease. The first consists of an aggregation of abnormal filamentous proteins in nerve cells called neurofibrillary tangles (22o), which do not dissolve in solvents that dissolve most other proteins (65,285), although they have recently been dissolved in special solvents (151,284,285). Neurofibrillary tangles are not the same as normal fiberlike proteins found in nerve cells (150), although they share some features with proteins involved in maintaining the cells shape (174). Neurofibrillary tangles are not found exclusively in Alzheimers disease, but are also found in several other diseases, and the relationship of tangles to other microscopic abnormalities typical of some other diseases is not yet clear (114). The second type of change is found in the area between cells, near the points of contact at which a nerve cell receives signals from other cells. These abnormal clusters of proteins and associated components are called senile plaques or neuritic plaques. Neurofibrillary tangles and senile plaques look quite different under the microscope, and their relation to one another is uncertain. Some studies suggest that they may be aggregates of similar types of protein (168), but preliminary characterizations of the protein components suggest significant biochemical differences (285). It also appears that the disease processes that have been known for years to affect the cortex and hippocampus are quite similar to those that affect cells in the nucleus basalis (279), suggesting that analogous processes may be taking place in many different parts of the brain. Several other changes in the brain are often found in Alzheimers disease, called granulovacuolar bodies, Lewy bodies, and Hirano bodies (248), but these are not generally used to identify patients with Alzheimers disease, and may even suggest involvement of another disease (e.g., Parkinsons). Neurofibrillary tangles and senile plaques are not found exclusively in the brains of patients with Alzheimers disease. Both are found in most people as they age (33). One investigator found plaques or tangles in almost three-fourths of patients age 55 to 64 who did not have dementia (318). That may confuse those trying to understand the difference between normal aging and Alzheimers disease, but the confusion is warranted only in a minority of cases. In most patients with this type of dementia, the plaques and tangles are found in dramatically increased numbers and their profusion is concentrated in the regions of the hippocampus and certain parts of the cerebral cortex (247,248). In aging patients who do not have dementia, the plaques and tangles are much less frequent and are dispersed, Physicians do occasionally encounter patients in whom there are mild symptoms of dementia combined with autopsy findings showing an intermediate number and distribution of plaques and tangles. It is difficult to be certain whether these individuals had Alzheimers disease, but such patients are exceptions, rather than the norm. PAGE 103 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background 99 Photo credit: Office of Technology Assessment Microscopic appearance of senile plaques, taken of brain tissue from the cerebral cortex of a 60-year-old woman with Alzheimers disease of over 10 years duration. The photo is taken at 100x magnification of tissue stained with a silvercontaining dye that binds to the abnormal material associated with senile plaques. The plaques are dark areas dispersed throughout the photograph. PAGE 104 100 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Heterogeneity of Aizheimers Disease Alzheimers disease is primarily defined by its clinical symptoms and microscopic changes. It is quite likely, however, that this combination of clinical and microscopic findings actually refers to a group of disorders, each with possibly different causes. Researchers in recent years have increasingly focused on identifying subtypes of patients with clinically diagnosed Alzheimers disease. A consensus is beginning to form that there are several types (35,118,205,286). Several different findings have been suggested as defining important subtypes: familial aggregation (presence of many cases in one family); disturbance of reading, writing, and speaking ability; age at onset of symptoms; presence of uncontrollable abnormal movements; and severe personality disorders and psychoses. Patients showing the brain changes typical of Alzheimers disease can have a wide variety of symptoms (232). Investigators have found younger patients to have more severe cognitive deterioration (205), more severe behavioral disruption (14), and more severe disturbance of language use (56). Several other features differentiate early from lateonset cases. Younger patients have poorer results on psychological tests (190). They also show degeneration of additional groups of brain cells (36) and more circuits of nerve cells (272). PET scanning devices have been reported to detect differences between patients who develop the disease at younger ages and those who first show symptoms when older (175). These differences may be due to the illness lasting longer for patients with younger age of onset (investigators could be measuring duration rather than finding real biological differences). The most recent studies have attempted to assess that issue and have concluded that there are differences in the disease process itself, rather than merely in stage of illness when patients are studied. Other variants may be due to atypical presentations whose cause and relationship to more typical cases are unclear (289). Despite all the suggestions that there may be distinct subtypes of Alzheimers disease, no single way of defining such groups has emerged, and conflicts between the different studies of subgroups must be resolved before the categories are widely accepted (156). The diagnosis of Alzheimers disease may thus be refined over the next several decades, as subtypes are better defined and their characteristics are codified into diagnostic practice. In the meantime, it is likely that work being done on patients with Alzheimers disease is focused on a diverse group of disorders with different causes. The treatment and prevention of the illness will likely depend on identifying specific causes and characteristics that differ for the various subgroups. This dependence of new treatments and preventive strategies on understanding the etiology and biological processes of the disease reinforces the importance of finding the cause or causes of Alz heimers disease. Possible Causes of Alzheimer's Disease Scientists have not identified a cause of Alzheimers disease. But various hypotheses have been supported by different amounts and quality of supporting data. There is substantial evidence for some ideas (e.g., the loss of some chemicals used in nerve cell communication and the existence of familial clustering), while others are primarily working hypotheses. (For an overview about the possible causes, see ref. 338, or one of the books on the topic written for the lay audience: see refs. 57a,141,191). A recent scientific review is also available in Neuroscience (246). The possible causes of Alzheimers disease can be roughly divided into several groups. The groups overlap extensively, and one cause does not preclude others. They may even be directly linked. The disruption of nerve cell circuits often cited as a potential cause does not explain why the nerve cells die. Complete understanding of the etiology will thus need to elucidate the sequence of events that lead to the expression of disease, and is likely to involve many steps. The loss of specific nerve cells is not, for example, incompatible with the PAGE 105 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 101 role of genetic factors, infectious agents, or environmental exposures that might explain why the cells die. One way of grouping possible causes is: l l l l l l genetic factors (e.g., familial aggregation, association with Downs syndrome, and altered DNA-binding proteins); exaggerated aging (i.e., the severe form of a normal process-discussed in ch. 2); environmental factors (e.g., metal exposures, head trauma, viruses, and other infectious agents); immunologic factors (e.g., special susceptibility to infectious agents or proclivity for reacting against ones own brain cells); disrupted nerve cell circuits (including loss of specific populations of nerve cells and disruption of communication between certain groups of brain cells), which is a causal hypothesis that would require a further explanation for cell death; and intrinsic metabolic factors (e.g., disruption of biochemical pathways in brain cells or in different types of cells throughout the body, disturbance of protein transport in nerve cells, and changes in cell membranes), which would also require a further explanation of why certain factors were lost. Genetic Factors.-One of the questions about Alzheimers disease most often asked of physicians and other health professionals is: Is it genetic? This is a common fear among relatives of affected patients. Unfortunately, the answer is not simple. Clearly in some families Alzheimers disease appears in a way that looks very much like a genetic trait. When a pattern suggests an inherited trait, the disease is called familial Alzheimers disease. The largest such family discovered so far, spanning seven generations, was reported in 1983 (233), and more than 100 smaller families had been reported in various medical journals (63,64,296). In familial Alzheimers disease, the children of an affected parent have been found to have a 5050 chance of having the putative gene that leads to the disease (although a person carrying the disease gene may die before showing symptoms). The chances of eventually developing the disease are high if a person carries the gene and lives past age 85. This pattern of inheritance is called autosomal dominant transmission by medical geneticists, and it suggests that the presence of a single gene confers predisposition to Alzheimers disease in such families. Although there is no longer any doubt that some families are affected by Alzheimers disease in a way that suggests a single gene trait, substantial disagreement exists on how many cases of Alzheimers disease can be traced to genetic factors and whether there is only one genetic form. Some researchers have found that early onset cases (beginning before age 65) are more likely to be familial than late-onset (337), but this has not been confirmed by all investigators (56). If genetic and nonfamilial forms exist, what can families be told about their genetic risks? One physician who has studied families with Alzheimers disease extensively has developed a way to calculate risks (141, app. C) and suggests that a case is most likely to be genetic if it begins before age 65 and if there are two or more immediate relatives also affected (139). If the case is of the genetic form, then the risk to the patients children depends on the age at which the disease began later onset means lower risk to children. Some investigators have suggested that disturbance of language function might predict familial occurrence (38,40)96), but others have reported just the opposite (171). One group has constructed a mathematical model based on preliminary clinical studies. The model suggests that a single gene may predispose to Alzheimers disease among patients with a specific set of clinical symptoms (41,42). The model also suggests that all such cases may be genetic, and account for 78 percent of all cases of Alzheimers disease. Many if not most people who develop Alzheimers disease do not have relatives who are also affected. This evidence has been offered to suggest that fewer than a third of cases are genetic, but the data cannot be so simply interpreted. Most studies exclude investigation of cases over a certain age (often 69 or 79) because of the unreliable nature of medical information available about very old individuals. Yet such exclusion can unduly diminish the reported number of cases in relatives, particularly since Alzheimers disease becomes increasingly common with age and is highly PAGE 106 102 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias prevalent only among those over 80. Any age cutoff thus precludes investigation of the group most likely to be informative. A definitive answer about the prevalence of familial versus nonfamilial Alz heimers disease thus awaits rigorous study of large families with longitudinal investigation of all patients into advanced old age. Because of these uncertainties, the relative number of genetic and nonfamilial cases of Alzheimers disease is difficult to estimate. Recent studies have shown familial rates as low as 25 percent (142), but most show higher familial prevalence (40,96, 140)312). One statistical analysis of patients with Alzheimers disease estimated that over half of all cases may be of the genetic form (40,96), but this has not been uniformly accepted (258). Some confusion over the conflicting studies is due to the unusual genetic characteristics of Alzheimers disease in affected families: Because of its late manifestation this trait should appear in only about one-third of predisposed individuals (39). when life expectancy is age 70 to 75, two-thirds of the people carrying the postulated Alzheimers gene will die before they show symptoms, and only one-third would develop the disease. The child of an affected patient would thus stand a one in six chance of developing Alzheimers disease. Yet life expectancy is rapidly increasing, especially among older age groups in the United States, and so the relative prevalence of the familial form of Alzheimers disease may well increase. In addition to the confusion caused by the delayed onset of Alzheimers disease in affected families, many other uncertainties surround the prevalence and special characteristics of the genetic form of Alzheimers disease. Some of these uncertainties are due to different scientists studying relatively small groups of patients that differ from one medical center to another. Other differences arise from varying measurement techniques for assessing the type, severity, and clinical characteristics of dementia in the studies. There may even be more than one genetic form of Alzheimers disease (308). The presence or absence of a single gene that predisposes people to developing Alzheimers disease does not imply that other factors do not also play a role. The delay in onset of the disease caused by the postulated gene is difficult to explain, although this is also true of another genetic disease, Huntingtons disease (discussed later). Other factors, including all other possible causes discussed in this section, could also play a role in the genetic form of Alzheimers disease. Uncertainty about the familial form of Alzheimers disease should be resolved as soon as possible because of the importance of such information in counseling families. Some families are clearly affected by a familial form of the disease, and others are clearly affected by a form that is not primarily genetic. Many families, however, do not have enough information about their relatives to be sure whether the disease is genetic or not, and it is these people who most need guidance. Environmental Factors.Several scientists have attempted to identify personal or dietary habits, drug use, environmental toxins, or infectious agents that might cause Alzheimers disease. Epidemiologic surveys of large numbers of patients have looked at many factors. One factor found by many studies is association with previous trauma to the head (100,143,223,340 citing 3)4). The age of the mother at birth of the affected patient, higher prevalence of thyroid disease, and risk of Downs syndrome in relatives have been reported by a few studies but not most; even the association with head trauma is not found in all studies (4,266). The association of Alzheimers disease with prior head trauma may simply be due to the family members being more likely to remember a head injury for a patient with Alzheimers disease than if the patient did not later develop the disease. Careful analysis of the data suggests this is unlikely, however (101,264). There are other reasons to suspect that the association of Alzheimers disease with head trauma may be more than mere coincidence, First, the association has been uncovered in three independent studies that did not have other findings in common. Second, there have been several reports of individuals with severe head trauma who have subsequently (after years) developed Alzheimers disease (reviewed in ref. 277). Third, the pathological changes that take place in Alzheimers disease resemble those that have long been known to take place in boxers PAGE 107 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background 103 who live to old age. Most boxers sustain repeated and severe head trauma as part of their sport; the knockout is, after all, a form of concussion in which the brain temporarily fails to function normally because of acute trauma. Many boxers who live to old age develop a clinical syndrome called dementia pugilistic (boxers dementia) that includes tangles in the cerebral cortex and elsewhere (66,72). Dementia pugilistic has traditionally been classified separately from Alzheimers disease because its cause is known, additional anatomical changes characteristic of previous trauma are usually absent in Alzheimers disease, and the distribution of neurofibrillary tangles is not identical to that found in Alzheimers disease. The evidence is equivocal at present, and the concept of head trauma causing Alzheimers disease is controversial (277), but investigators are now reexamining the association to see if head trauma might not be a cause of Alzheimers disease. Viruses or other transmissible dementia agents have also been suggested as causes of Alzheimers disease. Several disorders that cause dementia are known to be caused by viruses or unusual agents. The hypothesis that Alzheimers disease might be caused by infection is based on such clinical associations, combined with additional scientific evidence. Plaques from patients with Alzheimers disease are sometimes similar to those found in the animal disease scrapie, which is known to be infectious (268). Some patients also develop microscopic plaques in a part of the brain often affected in kuru, a transmissible human dementia (106,250). The relationship between Alzheimers disease and transmissible dementia is puzzling. Kuru is just one of several dementing conditions caused by an unusual group of slow-acting infectious agents unlike conventional viruses, bacteria, or other known microbes. Kuru was discovered on the island of New Guinea, where it was propagated by ritual cannibalism of those who died (106). Creutzfeldt-Jakob disease and GerstmannStrassler syndrome are two other dementing conditions caused by similar agents. The scientific work that elucidated the infectious cause and unusual characteristics of the agents causing kuru and Creutzfeldt-Jakob disease earned the 1976 Nobel Prize for Physiology and Medicine for D. Carleton Gajdusek. Subsequent work has noted several associations between the microscopic plaques and protein constituents thought to be part of the infectious agents that cause these diseasesscrapie, CreutzfeldtJakob disease, Gerstmann-Strassler syndrome, and kuru (107,251,252,294). A gene whose expression is increased in mice infected with scrapie also binds to senile plaques of patients with Alzheimers disease, providing another tantalizing association of unknown significance (332). Familial Alzheimers disease was initially reported to be infectiously transmitted to primates, but these reports have not been replicated despite numerous attempts (44,120). Finally, some have questioned the evidence for the chemical similarity of Alzheimers disease changes and the plaques associated with the unusual infectious disease scrapie (268). The hypothesis that unusual infectious agents cause Alzheimers disease thus remains an intriguing but unconfirmed speculation. It is also possible that a virus that acts in an unconventional way in some patients, causing a slow and insidious disease, may also cause Alzheimers disease. The evidence for this is based primarily on knowledge that several other diseases believed to be caused by viruses can also cause dementia (e.g., progressive multifocal leukoencephalopathy and subacute sclerosing panencephalitis). On the other hand, no viruses have ever been consistently associated with Alzheimers disease, despite extensive searches, and no immune reaction is found in the brains of patients with Alzheimers disease comparable to that found in other viral dementias. In summary, the possibility of a viral cause of Alzheimers disease cannot be either ruled out or definitely confirmed by existing studies. Several groups of scientists have found that the abnormal protein aggregations that make up plaques and tangles are also associated with high concentrations of aluminum and silicon. The elevation of silicon concentrations was first described in 1972 (11,235), and several groups found high aluminum content beginning in 1976 (71,241). The findings are not disputed, but their interpretation is not yet clear. Both aluminum and silicon are PAGE 108 104 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias very common elements in the Earths crust, and high exposure levels to dust containing both silicon and aluminum is normal. Recent studies have noted the association of aluminosilicates in damaged areas of the brain, and researchers postulate that these deposits are causing the alterations (50,51). Other studies show an association of several neurological diseases with aluminum deposition and trace mineral content in water supplies (234). Many Alzheimers disease researchers interpret the presence of aluminum and silicon as a result of cell death, rather than its cause. Their explanation is that the nerve cells die, or for some other reason insoluble abnormal protein aggregates begin to form in nerve cells and near nerve terminals. Aluminum and silicon, highly prone to forming insoluble complexes, then deposit on the protein moieties and are thereby concentrated. This explanation relegates the role of aluminum and silicon to a secondary and relatively unimportant function rather than serving as primary toxins. More work must be done, however, to determine whether silicon and aluminum deposition is a cause or a consequence of Alzheimers disease. Other metals may also play a role, particularly if absent from the diet. A disease process that resembles Alzheimers disease in some respects is found in Guam, some islands in Japan, and a few other Pacific islands. This disease has clinical and microscopic overlap with Parkinsons disease, amyotrophic lateral sclerosis (Lou Gehrigs disease), and Alzheimers disease. The factor common to each of these regions is a deficiency of calcium and magnesium in the water supply (107, 239). Immunologic Factors. -Defects in the immune system have also been proposed as working hypotheses in explaining Alzheimers disease. The involvement of the immune system theoretically could be independent of other factors, or could also involve infectious agents, genetic predisposition, or environmental toxins. Nerve cells share many surface features with cells of the immune system, and so might be affected by similar mechanisms (104,105). One study showed that the immune function of one type of cell-so-ailed T8+ suppressor lymphocytes-is lower in patients with Alzheimers disease than in control patients (293). Another showed diminished production of interleukin-1, a substance that stimulates immune cells, associated with Alzheimers disease (167). Antibodies of a particular type, called IgG, are specifically increased in some patients with Alzheimers disease (57,58,88,136). And a gene that controls a blood protein involved in immune function, factor C4B, has been associated with Alzheimers disease (234). However, the significance of these findings is not clear. Several investigators have failed to find any significant decline in immune function or specific lymphocyte function that is predictive of Alzheimers disease (136,155, 185)304). Disrupted Nerve Cell Circuits. -Researchers in the last decade have correlated Alzheimers disease with loss of specific groups of nerve cells and disrupted communication between nerve cells. Studies of the loss of cells in the nucleus basalis and hippocampus, noted earlier, are good examples of this work, but the story does not stop with the loss of nerve cells. Discovery of effects in the nucleus basalis and hippocampus was preceded by the work of several investigators who were studying cell -to-cell communication in the brains of patients who had died with Alzheimers disease or other disorders. Investigators in the United Kingdom noted that there was a dearth of protein that makes the chemical acetylcholine in some parts of the brains of patients with Alzheimers disease (reviewed in 16). The relative absence of acetylcholine suggested that the cells using it to communicate with other cells might be dying off. Other evidence suggested that such a defect might explain the loss of memory in Alzheimers disease (16)69), and researchers found that the cells lost from the nucleus basalis were a major source of acetylcholine for the cerebral cortex (69,329,330). Others were able to confirm that the nucleus basalis cells did indeed make acetylcholine (226), and transport it to the cortex (209). Taken together, the different studies began to present a coherent picture: Nerve cells that use acetylcholine were lost from the nucleus basalis and other areas, reducing the amount of acetylcholine released to cells in the cortex and hippocampus, and disrupting memory processes. The story is not so simple, however, because nerve cells that use acetylcholine are not the only PAGE 109 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background 105 ones lost in Alzheimers disease (245)295)) and cell loss is not strictly correlated with the use of acetylcholine as a chemical transmitter (219). Several other regions of the brain suffer loss of nerve cells (193). Nerve cells that use the chemicals serotonin (73), somatostatin (78,116,178,272,287) and corticotropin-releasing factor (22,81,93,303) are also lost. These discoveries represent a major advance in the understanding of Alzheimers disease, but there are lingering complexities, and much is left unexplained (246). Some cell groups lost in Alzheimers disease also die off in other disorders. Groups of cells that die off in some patients remain healthy in others (36,272), and different patients show contrasting patterns of cell loss and chemical defects (70,78). Some of the abnormal changes of Alzheimers disease can also be induced in nerve cells grown in tissue culture by adding two chemicalsaspartate and glutamatethat are believed to be naturally used to communicate between cells (79), and these chemicals are found diminished in brain regions of patients dying with Alzheimers disease (238,281). That finding suggests that cell communication involving these two chemicals may cause cell death in the brain, in addition to cells that use acetylcholine to communicate. Despite such evidence that other factors may be involved, the loss of acetylcholine does appear to be a consistent finding, affecting all subgroups (99). Some subgroups may have other defects in addition to the loss of cells that use acetylcholine. Scientists do not appear near a complete explanation of why Alzheimers disease occurs in some people and not others, or why only some cells die. Even if nerve cell circuits are involved, this provides only an intermediate explanation, and does not suggest an ultimate cause. Many questions remain unanswered. Are certain nerve cells genetically programmed to die in some people? Are they killed by viruses or toxins? Do they have specific biochemical or metabolic aberrations? Or are they mistakenly killed by the bodys own immune defenses? Intrinsic Metabolic Factors. -Several investigators have reported disrupted biochemical pathways and other metabolic abnormalities inpatients with Alzheimers disease. Enzymes are proteins that facilitate chemical reactions. Some researchers have found abnormal function of specific enzymes involved in sugar metabolism in brain cells (28,32,280), in patients cells grown in tissue culture (293), and in red blood cells (29). Others have found abnormalities of proteins that affect DNA or RNA, the genetic material of all cells. One group found that patients with Alzheimers disease had less RNA in their brains at autopsy, and they traced the defect to more rapid degradation of RNA. The amount of a protein that slows RNA degradation was abnormally low, and so release from normal inhibition led to accelerated decay of RNA (278). That defect would make it difficult for cells to produce normal amounts of protein, and it might explain other biochemical abnormalities or cause cells to be vulnerable to insults. The specific metabolic features of RNA metabolism in Alzheimers disease are still under study, and the results are not completely consistent from report to report (306). Other investigators have found slowed repair of DNA (189), increased sensitivity to damage of DNA (283), or changes in the proteins that stick to DNA (that might regulate which genes are turned on and off) (213)324). Another focus of study has been the cell membranethe thin layer of material that separates cells from one another and from body fluids. The cell membrane includes elements that determine its electrical properties (and the ability to transmit nerve cell impulses) and that allow other cells and proteins to recognize the cell from its exterior. Abnormalities of cell membranes could, therefore, have profound disrupting effects in nerve cell communication and recognition. Several researchers have produced preliminary evidence of such membrane changes (339,345). Nerve cells need contact with other nerve cells or muscle cells in order to survive. The exact requirements for nerve cell survival are not known, but likely include trophic factors carried back to the nerve cell. One hypothesis suggests that trophic factors specific to particular nerve cell populations are lost in Alzheimers disease, leading to loss of the nerve cells (8,9). Replacing the trophic factors might lead to partial clinical recovery or growth of new cells to replace those that are lost. This possibility of nerve cell regrowth has been PAGE 110 106 l Losing a Million Minds: Confronting the Tragedy of Alzheimer's Disease and Other Dementias supported by finding that some cells in certain regions of the brain do proliferate in Alzheimers disease, but do not find their normal attachments (109). Recent studies of a protein called nerve growth factor (NGF) suggest that it may promote growth and sustenance of nerve cells that use acetylcholine in the nucleus basalis, and preliminary studies show improvement of learningimpaired rats in response to administration of NGF (reviewed in 198). Some investigators have suggested that the nerve cells that die off in Alzheimers disease do so because they cannot adequately move important structural proteins over long distances through the thin threadlike projections of the cell that conduct electrical impulses (107,121). These theories are based, in part, on the nature and location of abnormal protein aggregates (plaques and tangles) in the brain. Others interpret the location and composition of abnormal protein condensation as suggesting that proteins related to plaques and tangles accumulate around small blood vessels and impede the flow of oxygen and nutrients to nerve cells (112). That interpretation is supported by many reports of reduced metabolism in certain parts of the cortex of patients with Alzheimers disease, but this condition could also be found if cells died from other causes. Finally, the abnormal protein aggregates in tangles share some features with proteins that are involved in maintaining the cells shape (174). Summary .Many different causes of Alzheimers disease have been postulated, and others may be suggested. It appears likely that genetic factors are important in some cases. Infectious agents, head trauma, immune dysfunction, toxins, and metabolic aberrations may also be involved and are being investigated vigorously. Research on Alzheimers disease has become a priority only in the last decade, and the effort to track down a cause can succeed only with further work. That additional work will require substantial and sustained research support from Congress (see ch. 13). Issues in Treatment of Alzheimers Disease No fully effective treatments or means of preventing Alzheimers disease has been found. Although a few drugs can marginally alleviate some of the symptoms, the most effective way to manage patients is by adapting the environment to patient needs rather than prescribing a specific medical treatment. Medical options are limited, but much can be done to reduce the adverse impact of Alzheimers disease on patients, families, and others (328). A physician who makes a diagnosis of Alzheimers disease must also make several related determinations. The health and safety of patients, their families, and those who come in contact with patients can be influenced by these considerations. Several issues commonly confronted are whether the l l l l patient: should continue to drive, can retain his or her job (especially difficult for those in highly skilled positions that involve substantial responsibility for others or affect public safety), can make decisions about financial and legal matters, and is eligible for special disability or health programs. These determinations are not purely medical, but they involve a medical evaluation and assessment of the severity of illness. Physicians who care for a patient with dementia are therefore involved in these complex and difficult considerations (282). Correct determinations require understanding of the particular patient, the patients environment, the family structure, the availability of outside supports, and eligibility criteria for government programs. These nonmedical considerations become a part of patient management, although they are not commonly considered medical treatment. Other issues raised by the treatment of those with Alzheimers disease are more directly linked to medical care. Quackery .Diseases that are common, devastating, and incurable attract crank remedies. Hope and desperation conspire to create a market that is open ground for opportunism. Many diseases are subject to this phenomenon: cancer, acquired immune deficiency syndrome (AIDS), and arthritis, among others. Alzheimers disease, and many other dementing disorders, are among the targets PAGE 111 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background 107 for quackery. Bizarre treatments such as chelation therapy and blue-green algae manna have been promoted for those with Alzheimers disease in the absence of evidence of efficacy (52), and there will doubtless be more such remedies proposed in the future. Distinguishing legitimate treatment from quackery can be difficult. Quackery implies a cynical intent to profit from what is known to be useless, or failure to gather evidence that questions the legitimacy of a practice. The way that numerous accepted medical treatments work is only poorly understood, and many start out as accidents; few important treatments were expected, and many are irrational in their origins. A few characteristics of quack remedies, however, distinguish them from standard medical practice. Potential patients and families should ask several questions before embarking on a treatment regimen: l How is it advertised? Quack remedies are often purveyed through popular magazines and are notably absent from medical journals. l How accessible is it? Quack remedies are generally costly, and available only through special outlets. In contrast to experimental clinical trials, the promoters are not associated with universities, major medical centers, or reputable practitioners. l What is in the treatment? Elixirs and miracle potions will not specify what they contain, while clinical trials involve clearly defined components. l Are the practitioners qualified? Those involved in clinical trials will be licensed to practice medicine, and are likely to have specialty certification as well. Those with legitimate qualifications are not threatened by prospective patients asking about them. Those who lack qualifications cannot provide patients with the information and are more likely to take offense. l What is the rationale behind the treatment? This may be difficult for someone not expert in the field to judge, but those explaining clinical experiments will be able to cite support in the medical literature, while quacks may refer only to a popular journal or offer no rationale. What evidence supports the effectiveness of the treatment? For early clinical trials, there will be evidence from animal testing; quack remedies will refer only to anecdotes of successful use. Another difference between them is the elaborate data-gathering methods and analysis for clinical trials. Remedies that have been used for years on many patients and yet lack rigorous scientific data on effectiveness are highly suspect. False Hope and Preliminary Data.The same factors that encourage charlatans can also generate problems for the most careful, well-meaning investigator. Preliminary reports of small increments of medical progress can be greeted by the release of pent-up emotions, leading to unjustifiably high hopes that are dashed in bitter disappointment. That phenomenon has happened at least twice for preliminary reports of Alzheimers disease treatments. One was a study on the use of nalox one, a drug that blocks the effect of heroin-like drugs, and the second a report on implantable drug pumps. Both were both picked up by the national press. The story on naloxone resulted from a small clinical trial in a few patients that was published in a letter to the New England .Journal of Medicine (259). The trial was carefully planned, but involved only seven patients. Such a small sample is common for treatments on the frontier of inquiry. The report was singled out by Margaret Heckler, then Secretary of Health and Human Services, at a press conference on the efforts of the Federal Government to address the problems of Alzheimers disease. It then was widely publicized, The Secretary had merely cited it as an example of promising research, but the preliminary nature of the data could not support the onslaught of public attention. Subsequent trials of the agent belied the initial optimism (298). The other episode attracted even wider publicity. A group at Dartmouth Medical School implanted drug pumps in four patients with Alzheimers disease (diagnoses that were confirmed by biopsy at the time of insertion). The pumps were used to deliver a drug that simulates the ac- PAGE 112 I @ l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias tion of acetylcholine, based on the theory that the reduction in acetylcholine might be corrected by direct replacement of the drug. The primary interest in doing the study was to test the feasibility of using such pumps to deliver drugs for patients with Alzheimers disease, not to cure the disease in the four initial patients. The investigators did, however, distribute questionnaires to the patients families to find out if they could detect any changes in the patients. The families did not know which drugs were infused into the pumps, and the investigators alternated between using the drug and a harmless fluid. The preliminary drug pump study is being followed up by studies at 10 centers across the United States. A few members of the national press heard about the initial experiment and asked permission to cover the story. The investigators wrote a short description in the medical journal Neurosurgery (131). They also held a press conference because of the interest the story had generated. Although one reason for the press conference was to note the preliminary nature of the data (the title of the paper started with the words preliminary report), it had the opposite effect, making reporters believe there was a big story to cover (242). Reports on the pump therapy eventually reached the public through 160 newspapers, many national magazines (including Newsweek, McCalls, Forbes, and Family Circle), and most of the national television news services (PBS, NBC, CBS, and Cable News Network) (242). One result was that the ,600 personsmany desperately trying to stop the dementia consuming their loved ones who contacted Dartmouth Hitchcock officials in the weeks following the news all had to be told the same thing: there is no new treatment at Dartmouth for Alzheimers disease, only a research program; it is unproven, however good-looking in principle (242). The article in Neurosurgery contained only passing reference to the beneficial effects reported by families, but the television and news services talked mainly to enthusiastic family members and doctors. The press release distributed at the news conference referred to patient benefits in the opening sentences, and added qualifications only in the third paragraph (242). Neither the medical article nor the press release noted that the psy chological tests that had been given to the patients throughout the trial had failed to show significant improvements. Although it is standard practice to spice up stories in public relations work and the Dartmouth press release is not atypical the result in terms of the effects on the hospital, the investigators, and the families who heard about the work and yearned for good news was far from the benign, good publicity intended. The bloating of preliminary research data, whether by reporters, investigators, or research subjects, has several untoward effects. The ensuing publicity can impede the conduct of the very research being reported, endangering the validity of results and making life difficult for investigators who must split their time between doing their work and fielding questions from the media. Other investigators doing similar work are often irritated by such episodes. Some of that irritation might be due to jealousy, but it can also stem from adverse effects on their work and suddenly having to temper the unrealistic hopes of their own patients. Finally, the hopes of those desperately looking for progress are dramatically lifted, then suddenly dropped and shattered. Recently, the problem of constraining public expectations has taken a new twist. Stories about scientific advances in finding biological markers for diagnostic purposes have appeared in Time, Newsweek, business publications, and many newspapers, resulting in many physicians being asked to do the diagnostic tests, yet the tests are clearly stated in the articles to be in experimental stages of development. Even more instructive is the intense publicity surrounding the publication of the lead article in the November 13, 1986, issue of the New England Journal of Medicine (302a). The article reports encouraging results from testing of the drug tetra hydroaminoacridine (THA, first discovered in 1909, but newly applied to treatment of Alzheimers disease) on 17 subjects with the diagnosis of Alzheimers disease. The Associated Press report about the article reads Researcher Fears Hysteria Over Alzheimers Drug Discovery (130a). The researchers in this case have clearly anticipated that their drug trial would be widely reported, and that the public would demand quick action to PAGE 113 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background 109 make the drug available. (THA is nonpatentable, raising yet another issue, because private firms state they are reluctant to manufacture it and push it through the expensive FDA approval procedure without any way to guarantee a profit.) Press hunger for new results is clear in this instance, where all the rules of careful reporting were followed. The study was carefully controlled, the results dispassionately displayed, and the steps leading to the trial were called a triumph for the scientific method in an accompanying editorial (78a). Yet many physicians learned of the story from their patients (the AP story was released on a Wednesday about the Thursday issue of the Journal, and most subscribers do not receive their copies until Friday or early the following week). People do in fact want to know the results of reliable studies as soon as they can, and the early news accounts of the THA article contain the important qualifiers, yet the scientists clearly anticipate widespread misunderstanding. There is no simple way to prevent public relations disasters. Any institutional or regulatory solutions are likely to be worse than the problem. Reporters can work to be more objective, and investigators can be open but not unrealistic. The line between enthusiasm for work in progress and the creation of unjustified optimism is thin. Most researchers are working in this field, after all, just so they can contribute to the eradication of the blight of Alzheimers disease. Progress is welcomed and feeds the emotional drives of investigators as well as patients and their families. Further, it is important that such events not inhibit the reporting of preliminary results. Preliminary reports are efficient ways to test new approaches to treatment, and reporting them when preliminary results are known whether successful or not-can save other investigators time and wasted effort. But physicians and other scientists can be careful in how the results are reported. Many family members are grasping for straws. In research on dementia, many such straws are reported each month, but most are buried in medical journals. Both the reports cited here were covered not only in the medical literature (where their significance was likely to be understood), but also heralded at press conferences (where it was likely to be misunderstood). It is safe to report failures, but success must be handled carefully. Perhaps the most important preventive measure is for clinical investigators to anticipate the publicity, think through how to handle it, and at times eschew it. A delicate balance must be struck between informing the public and the risk of misinforming it. Medical Management.Health professionals can manage Alzheimers disease in several ways. Some of their functions are: diagnosis of the disease causing dementia; the search for diseases of other organ systems that can be treated, which might improve the patients mental function; assessment of the type and severity of the disease or diseases; management of those aspects of the disorder that can be treated (e.g., behavioral problems amenable to treatment by medication or to family education on avoidance or management); referral to medical supports (e.g., participation in clinical trials can be therapeutic not only for medical benefits but also in providing a feeling of contributing to the ultimate conquest of Alzheimers disease); education of the patient and family about the disease (e.g., what to expect, genetic risks, drugs and foods to avoid); and referral to social and legal supports (e.g., family support groups, legal services, government programs). The importance of family education, legal referral, and recommendation of family support groups is elaborated in several other chapters. The focus here is on management of the medical aspects of this dementing disease. Some pharmaceutical agents have been reported to diminish the cognitive impairment of patients with Alzheimers disease. Only one, however, has been approved for clinical use by the U.S. Food and Drug Administration (FDA) (based on several clinical trials). Although patient improvement is consistent, it is minimal. The agent in question, a mix of different drugs, has been in clinical use for three decades; it is marketed under the trade name Hydergine. Hydergine has been used in Europe for treating dementia for over a decade, and is increasingly being used in the United States. PAGE 114 110 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Its mechanism of action is unknown. Hydergine was once thought to improve blood flow, but it is now called a metabolic enhancer. It alters the biochemistry of nerve cells in several ways, but the reason for mild mental improvement is not known (47,180,328). Medical management of behavioral symptoms can improve mental function of the patient, simplify the patients care, or both (135,265). Many patients develop depression, which can be treated by both education and antidepressant medications. Care must be taken to avoid those antidepressant agents that inhibit the action of acetylcholine, which can worsen the patients dementia, and to use agents less likely to exacerbate dementia (83, 154,239). Management of hallucinations, anxiety, sleep disorders, agitation, aggression, and wandering often includes changing the patients habits, adapting the environment, educating the family, and administering drugs targeted specifically at the behavior in question. One physician has suggested that the guidelines for treatment should be to treat disability not abnormality, to reverse associated curable illnesses, to limit troublesome symptoms, and to maintain continued support (27). Most physicians with extensive practice in treating dementia occasionally use medications to control patients behavior, but the drugs are carefully monitored, and a different selection of agents is usually tried than for other kinds of patients. The drugs used to manage behavioral symptoms, for example, are chosen to minimize their untoward effects on intellectual functions (333). Older individuals in general, and patients with dementia in particular, are more likely to develop adverse side effects from drugs affecting behavior. Thus special care must be taken to prescribe those medications least likely to worsen the dementia and to induce unwanted side effects (328). This careful approach to medications contrasts with the situation found in some nursing homes. One study reported a more than 300-fold variation among different long-term care facilities in the dose and frequency of medications used to control patients behavior (256). Such large differences cannot be explained by variations in accepted medical practice, and the pattern of use suggested that drugs were relied on in some facilities as substitutes for staff. Difficulty in eating can be a major problem among dementia patients. It is not clear why patients with dementia have difficulty eating. They may forget how to eat, refuse to eat-expressing a wish to die-or lose their desire for food. One preliminary report of eating in a nursing home suggests that the cause may be difficulty in swallowing. That study found that of those who depended on caregivers to eat there was a strong correlation with poor mental function, but only a minority of those with very poor mental function had eating difficulties (290). This suggests that there may be a common factor linking eating difficulty to severity of dementia for a fraction of residents. If true, that common factor might also indicate that difficulty in swallowing is an organic symptom, and refusal to eat more involuntary than conscious. For those experiencing eating difficulty, it is important to evaluate the cause of the difficulty. Is it confusion about how to eat, or tendency to gag or cough when swallowing? Training both family and institutional caregivers how to differentiate organic from voluntary refusal to eat, and how to deal with eating difficulty is the main avenue to treatment. Referral to a speech therapist may help to determine the nature of the eating difficulty, if ability to swallow is in question. Incontinence of bowel and bladder is a significant problem for many of those with dementia. Half of all patients in nursing homes have urinary incontinence, and this group overlaps extensively with those suffering with dementia, The majority of those in nursing homes with urinary incontinence also have bowel incontinence (64 percent), and most showed severe mental impairment (57 percent). Despite the magnitude of the problem, fewer than 5 percent had a specific cause for the incontinence noted in their medical record (237). Many cases of incontinence can be either eliminated or compensated for using existing technologies, but require a careful evaluation of the cause of incontinence, use of appropriate drugs or devices, and staff training (237). Many of the problems faced by those with dementia are probably susceptible to improvement PAGE 115 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background 111 by using current technologies with more rigorous application of existing knowledge. One hope for improved care of dementia patientsnot only in nursing homes, but also in hospitals, clinics, homes, and day care centersis knowledge that will be developed in special teaching nursing homes. The National Institute on Aging, the Robert Wood Johnson Foundation, and the Veterans Administration are supporting a new movement to affiliate nursing homes with centers of medical excellence such as nursing and medical schools. These facilities will be much more involved in testing new methods of treatment and management, and will in the long run likely set new standards for care of the chronically ill. Prospects for Research on Drugs and Devices.Although only one minimally effective agent has been approved by FDA to be marketed for use in dementia, many other drugs and devices are under investigation. These are too numerous to describe here, and the list changes rapidly as new ideas or agents emerge. One promising route to discovering new drugs has been the study of chemical imbalances in Alz heimers disease. The acetylcholine hypothesis suggests numerous possible treatments, and many have been tried or are under investigation. The rationale behind these trials has been extensively reviewed (see 25,54,119,132 )200,255,271)341). Many agents are also being tested in relation to other theories of causation, such as the siliconaluminum hypothesis, the viral hypothesis, the improvement of membrane characteristics, and the correction of immune deficiency. Other agents being tested in the United States have been used in other countries with some reported success (216). Some experimental therapies are directed at chemical imbalances in the brain that involve chemicals other than acetylcholine. These include very short proteins (called neuropeptides), nicotine, and drugs that oppose the action of opiate drugs (117). Advances in therapy may arise from these numerous clinical trials, but existing reports of successful treatment are either preliminary, have not been replicated by other investigators, are inconsistent, or result in only minimal clinical improvement. Novel ways to deliver drugs to the brain are also important in treatment research. Many chemicals that are active in the brain are digested before they reach the bloodstream or cannot get into the brain even if they enter the blood. Many investigators are developing drug pumps or altering drug structure in attempts to circumvent these problems. Use of nerve cells themselves for treatment of Alzheimers disease or other brain diseases is an especially intriguing possibility. The technique involves directly placing nerve cells in the brain, where they grow and can release chemicals that communicate with other brain cells. The method has been used successfully in several animal model diseasesmost recently in primates (257) and cell growth can be confirmed and behavioral deficits corrected by the new cells (23,68,95,199). Nerve cells from one species can also grow in another; they appear to be protected from the immune system of the recipient, but they do not function as well (23). Investigators hope that nerve cell implantation (sometimes called brain transplants in the popular press) can eventually benefit patients with Alzheimers disease (as well as those with Parkinsons disease) (23), but such therapies will hinge on extensive animal testing and preliminary human trials and are unlikely to be available within the next decade. Many technical problems must be overcome, and the appropriate source of nerve cells is not at all clear. Use of human fetal cells would be ethically objectionable to many, and cells from other species do not work as well and might also be rejected by some recipients on moral grounds (95). A neutral source of tissue (e.g., from a source in the patient) may yet be found. Implantation of patients own cells has already been tried in Swedish patients suffering from Parkinsons disease (described later in this chapter), but it yielded no clinical benefit (23). The cells were taken from the core of the adrenal gland, which contains nerve-like cells. None of the barriers to development of this technique now appears insurmountable, although it will likely take many years of research before practical treatments are found. PAGE 116 112 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Dementia Caused by Blood Vessel Disease Diseases of the blood vessels cause more deaths in the United States than any other group of disorders. Coronary heart disease and stroke are the most prominent examples. In addition to causing death, blood vessel disease can cause many other clinical syndromes, including dementia. Vascular disease is believed to be the second most common cause of dementia. In one large study, it accounted for 17 percent of cases, and was found in combination with Alzheimers disease in an additional 18 percent (310). The prevalence of pure vascular dementia is, however, now a topic of clinical debate (221). Current methods of classifying patients are being questioned, and some clinicians are uncertain about the relationship between symptoms of dementia and brain cell loss due to vascular disease. Some investigators beginning clinical trials specifically for patients with multi-infarct dementia are noting difficulty in identifying sufficient numbers of patients (31a). The prevalence of vascular dementia can be resolved only with further rigorous longitudinal studies. Some answers may be found in the ongoing Systemic Hypertension in the Elderly Project, whose primary sponsor is the National Heart, Lung, and Blood Institute. The National Institute on Aging is sponsoring an analysis of the data that will track the incidence of multi-infarct dementia in response to treatment of high blood pressure. Detection of vascular dementia is important for several reasons. If dementia is caused by large strokes, further deterioration may be prevented using standard treatments for stroke. Finding vascular disease in the brain can also alert the physician to look for damage to the heart, kidneys, or other organs. Evaluation of patients with vascular dementia may also disclose preventable or treatable underlying risk factors such as hypertension or diabetes. And risk to other family members is different if the dementia is caused by blood vessel disease rather than by Alzheimers disease. (The genetic aspects of vascular disease are more indirect, generally related to underlying causes such as blood lipids, diabetes, or hypertension. Relatives may benefit from detection of such risk factors if they take action to reduce the chances of developing vascular disease themselves.) The incidence of and mortality from stroke and heart disease have declined dramatically over the past two decades. Mortality from stroke decreased almost 50 percent from 1968 to 1982, for example (91), The decline is likely due to a combination of changing dietary patterns, other changes in personal habits, and improved medical care of the elderlythe major factors behind the parallel decline in mortality from heart disease (188). Most of the statistics on this decline are for large strokes, however, and do not yield direct information about vascular dementia. It is likely that this encouraging trend also pertains to vascular dementia, but that relationship has not been studied directly. Dementia caused by blood vessel disease results from death of nerve cells in regions nourished by diseased vessels. The death of brain tissue due to poor delivery of blood is called cerebral infarction. Dementia may ensue after a certain total mass of brain tissue has been destroyed (273). Such damage can be caused by one or a few large strokes, several smaller ones, or many microscopic ones. Dementia may also result from death of brain cells due to lack of oxygen reaching the brain (following a heart attack or heart failure, or for other reasons) (46)320). Large strokes are not usually difficult to differentiate from other dementing conditions because they affect many brain functions in addition to mental activity. When cerebral infarcts are smaller, however, dementia may be the main symptommaking it difficult to distinguish from Alzheimers disease or other dementias. The precise symptoms and physical findings depend on which parts of the brain die, and attempts are being made to define more specifically the characteristics of vascular dementia (89,152)221)225,344). When there are multiple infarcts, the diagnosis is called multi-infarct dementia (MID). The number can range from a few to over a dozen. On average, individual infarcts are about a half inch in diameter (1 centimeter), and symptoms are commonly absent until 100 to 200 cubic centimeters of brain tissue have been destroyed (160)273), unless the patient has another dementing condition. PAGE 117 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background 113 Multi-infarct dementia can be distinguished from Alzheimers disease and most other disorders by its association with: l l l l l a relatively abrupt onset; progression of dementia in (steps rather than gradual deterioration; history of previous strokes; symptoms or physical findings that can be anatomically traced to loss of specific nerve cells; and presence of diabetes, high blood pressure, or cardiovascular disease affecting other organs. Poor blood flow in the major arteries feeding the brain can be directly detected and correlated with dementia (317). Such poor blood flow typically precedes symptoms in patients with MID, but is found only after symptoms arise in Alzheimers disease (267). Rigidity of blood vessels in the brain can be indirectly measured, and corroborates the association with MID compared with controls or those with Alzheimers disease (157). The special features of MID are measured in standardized questionnaires developed to differentiate it from other dementias (108,128)270), and these are used in research studies to classify patients with dementia. Life expectancy is somewhat shorter for patients with MID than for those with Alzheimers disease (15). Patients with MID also tend to be older and more frequently have abnormal electrocardiograms (indicating higher likelihood of heart disease) (48), although one recent study found a 5 to 6 percent prevalence of dementia among young stroke victims (under 65) (176). If MID is associated with high blood pressure, diabetes, or disease in other organs, the associated conditions can be treated. Some believe MID should be treated like stroke, but the treatment of stroke is itself controversial and variable when the stroke is not caused by identifiable factors. As with Alzheimers disease, treatment of MID awaits new discoveries. In addition to multi-infarct dementia, dementia can arise from occlusion of blood vessels by debris in the blood stream (emboli) (reviewed in 159). These emboli can arise from diseased heart valves, damage to cells lining the heart, dislodging of clots in large vessels, the release of fat from large bones, or large sudden infusions of air or other gases. Death of cells due to loss of blood supply can also affect the white matter of the brain, rather than the cerebral cortex. The white matter contains relatively few nerve cell bodies; death of nonneural cells and nerve cell processes in these regions results in disconnection of different nerve cell groups rather than loss of nerve cells. This can nonetheless cause dementia. One name for this type of disease is Binswangers disease, or subacute arteriosclerotic encephalopathy (236). Its prevalence may be higher than previously estimatedsomething newly discovered because MRI scanning makes its detection possible. One recent study described a number of patients with a disorder that is clinically difficult to distinguish from Binswangers disease, but that appears to have a cause other than hypertension or arteriosclerosis (46). That new finding further demonstrates the uncertainty of classification and cause even among clinical subtypes of vascular dementia. Further studies employing MRI scanning may confirm that brain infarction is more common than previously believed, and should clarify the relationship between infarction and clinical symptoms of dementia (160). Dementia can follow bleeding into the brain caused by diseased or malformed blood vessels. Blood vessels in the brain may also form balloon like sacs, called aneurysms, that can disturb adjacent structures or rupture to cause bleeding. Both bleeding and aneurysm formation are relatively common, but patients presenting with just dementia only rarely have them. Finally, some very rare diseases of the brains blood vessels, such as MoyaMoya disease or Takayasus disease, can cause dementia. Other Dementias Parkinson% Disease Parkinsons disease is a relatively common disorder, and some Parkinsons patients develop dementia. The prevalence of symptomatic dementia among Parkinsons patients is somewhat controversial (19). Some investigators have found a disproportionate fraction of patients with Parkinsons PAGE 118 114 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias disease exhibit symptoms of dementia (87,184, 206), while others find that the rate of cognitive impairment has been inflated, and is actually no higher than the risk for the general population (45,183,305). Most neurologists now consider Parkinsons disease to be associated with dementia in a minority of patients even in those who do not have Alzheimers disease or another dementia (148)245,300). There is also a clear subset of patients whose brains show the changes of both Parkinsons and Alzheimers diseases (34,186,276,331). That group of patients underscores the confusing relationship between the various disorders causing dementia. The dementia occurring in Guam and other Pacific islands combines features of Alzheimers disease, Parkinsons disease, and other disorders, and is now thought to be historically (and probably causally) related to decreased calcium and increased levels of other minerals in local water supplies (107)240). The primary symptoms of Parkinsons disease are involuntary movements, slowness, and rigidity. Speech is often slow, and movement is difficult to initiate. Most patients have a characteristic tremor (rapid shaking) of the fingers that is traditionally likened to pill-rolling. Parkinsons disease is associated with loss of nerve cells located in the substantial nigra (black substance, so called because the cells contain dark pigment). whereas the cells lost in Alzheimers disease are believed to use acetylcholine or other chemicals to communicate with other cells, those lost in Parkinsons disease use primarily dopamine. The work on the biochemistry of Parkinsons disease in fact predates that on Alzheimers disease by over a decade, and Parkinsons disease serves as the model for researchers studying Alzheimers disease (245). Drugs that partially replace the function of dopamine have been discovered, and these substantially reduce the abnormal movements in most patients with Parkinsons disease. The advent of such drugs was welcomed as a therapeutic revolution in neurology in the 1970s. There are several different varieties of Parkinsons disease. The cause of classic Parkinsons disease is not known. Another type, postencephalitic Parkinsonism, has been linked to previous brain infection with a virus. It is most often found among those who contracted brain infections during the influenza epidemic of 1918, but it can occur in others as well. One interesting feature of postencephalitic Parkinsons disease that distinguishes it from classic Parkinsons disease is the finding of neurofibrillary tangles in nerve cells of the substantial nigra. The tangles are similar to those found in other groups of cells in Alzheimers disease. Another interesting aspect of Parkinsons disease and its relation to dementia has emerged from an unfortunate experiment that began a few years ago in Stanford, CA. A former chemistry student began manufacturing a drug resembling heroin in his home. The process he used also yielded a side product that was ingested with the drug. This side product, called l-methyl-4 -phenyl-1,2,3,6tetrahydropyridine (MPTP), caused him and others who took the drug to develop symptoms of Parkinsons disease. Administration of the drug to primates also induces a disease resembling Parkinsons disease, and the animals lose cells in the substantial nigra just as would a human patient with Parkinsons disease, The cells that die do not look like those found in classic Parkinsons disease, however, and the degree to which MPTPinduced Parkinson symptoms suggests the primary cause of classic Parkinsons disease remains unknown. MPTP-induced symptoms bear on the debate about whether Parkinsons disease can cause dementia in the absence of other diseases, because MPTP patients showed intellectual decline (301). Progressive Supranuclear Palsy (PSP) PSP is a disorder with several clinical similarities to Parkinsons disease. It was first described in 1904 (153). Half to two-thirds of the patients with PSP deteriorate intellectually (192). PSP was not clinically distinguished from Parkinsons disease until 1964 (297), and accounts for roughly 4 percent of patients with Parkinsons disease (343). It differs from Parkinsons disease in that patients lose the ability to gaze up or down, and it is usually not associated with a tremor. Recent reports have shown that the chemical imbalances in PSP, like Parkinsons disease, involve dopamine, but these same studies disagree on the extent to PAGE 119 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 115 which there are also Alzheimer-like changes in acetylcholine (169,276). An interesting group of recent findings bears on the relationship among these disorders. The pathological changes of PSP are anatomically located in places characteristic of Parkinsons disease, but microscopically they more closely resemble the neurofibrillary tangles of Alzheimers disease (although they can be distinguished on careful inspection). Further, investigators have found some suggestive, but not conclusive, chemical similarities in the tangles found in Alzheimers disease, PSP, postencephalitic Parkinsons disease, and several other rare disorders (82). These similarities represent one more of the mysterious and poorly understood relationships among the various disorders causing dementia. Huntingtons Disease Huntingtons disease is a genetic disorder that causes uncontrollable twisting and writhing movements and also leads to dementia. Most patients with Huntingtons disease do not develop symptoms until late middle age, and the symptoms may vary from person to person even in the same family. The movement disorder is thought to be caused by a loss of nerve cells in brain regions called the caudate nucleus and putamen. Children of an affected parent have a 50-percent risk of developing the disease. The social and longterm care needs of these patients are similar to those for Alzheimers patients (325,326). A group of investigators recently tracked the gene from parents to children in large families, including one extended family living near Lake Maracaibo in Venezuela. Molecular genetic techniques were used to map human chromosomes (37) and were applied to families with Huntingtons disease (126). The disease-causing gene is located on chromosome number 4, and the test can be used in some families to predict whether particular individuals will develop Huntingtons disease (326). The test is not available for clinical use and is not useful in many families (e.g., because tracking the gene usually requires that DNA from an affected parent be available). Even in the best studied families, the test is not always accurate (because it does not detect the Huntingtons gene itself, but rather one close to it), and so interpretation must be cautious. Such care is important in Huntingtons disease because test results are fraught with serious social, emotional, economic, and financial problems (21,173,197,325,326). Current experience with the Huntingtons disease test will be relevant to genetic risks of familial Alzheimers disease if an analogous test can be developed for Alzheimers and other dementing disorders, Problems in techniques, information dissemination, and privacy protection encountered by Huntingtons families will likely prove true for those concerned with familial Alzheimers disease as well. The work on Huntingtons disease is thus an important pioneering effort. Dementias Caused by Infection Infection by bacteria, viruses, fungi, or unconventional agents can all cause dementia, but do so only rarely. Two infectious dementias transmissible dementia and AIDS dementiaare of special note because of their prevalence and scientific interest. Other infections can cause dementia, but only rarely. Longstanding syphilis, for example, was once among the most common causes of dementia, but it is now quite rare in the United States. Transmissible Dementia.The transmissible dementias caused by unusual infectious agents Creutzfeldt-Jakob disease, Gerstmann-Strassler syndrome, and kuru-have already been discussed in describing possible infections caused by Alzheimers disease above. Several interesting features were not mentioned there, however. Transmissible dementias characteristically kill patients much more rapidly than Alzheimers disease does, although the transmissible dementias are also clinically heterogeneous. Creutzfeldt-Jakob disease has become a concern among those receiving hormone therapy for congenital short stature because several young patients who were treated with human growth hormone recently died with Creutzfeldt-Jakob disease; an additional four patients are being investigated to see if they too have transmissible dementia (43,304). The dementing disease in these young patients is thought to be linked to con- PAGE 120 116 Losing a Million Minds: Confronting the Tragedy of Alzheimer's Disease and Other Dementias lamination of growth hormone by patients with Creutzfeldt-Jakob disease (110,172,309), Until mid1985, growth hormone was only available from preparations purified from pooled human pituitary glands, but that supply has been terminated and a new source derived from genetically engineered bacteria has been approved. Current and future stocks of growth hormone should thus not be contaminated. A related concern has emerged in connection with blood donations. Creutzfeldt-Jakob disease can be transmitted to animals from the blood of affected human patients (195). That finding has led one group to urge that patients with dementia refrain from donating blood, and that blood banks reject blood from dementia patients (202). The handling of tissues and fluids of patients with Creutzfeldt-Jakob disease and other transmissible dementias also requires special precautions (6). The relationship between Alzheimers disease and transmissible dementia has long been a topic of speculation. As with Alzheimers disease, there is clustering of cases in some families (12,203). Familial cases of transmissible dementia can clearly infect primates (12,44,203). The microscopic changes of the transmissible dementias are quite different from those of Alzheimers disease loss of nerve cells, proliferation of nonnerve supporting cells, and a peculiar spongy appearance of defined brain regions under the microscope. In some patients, however, there is overlap of microscopic findings (64,203). Attention has recently shifted from atypical transmissible dementias to infections caused by more conventional viruses as causes of Alzheimers disease (195). Dementia caused by lingering brain infections with conventional viruses is also well known, but it was rare until recently except in patients whose immune systems were debilitated. AIDS Dementia,A most alarming cause of dementia has been recently identified in patients with acquired immune deficiency syndrome. AIDS is caused by a small virus that attacks and kills specific cells of the immune system, rendering the patient defenseless against microorganisms. The AIDS virus causes infectious dementia through two mechanisms: the immune dysfunction of AIDS leads to brain infections by other organisms, and the AIDS virus also appears to cause dementia directly (24,144,229,230,246,262). Brains of patients who die with AIDS dementiathat directly caused by the AIDS virusshow clusters of immune cells in some areas, affecting primarily cells deep in the brain rather than in the cerebral cortex. AIDS dementia is now the most common cause of dementia caused by infection (161). A large fraction, probably most, of patients with AIDS develop dementia (245). The majority of such cases appear to be due to the AIDS virus itself, while a minority are caused by a variety of other organisms in addition to AIDS virus infection (230). Researchers do not yet know whether the dementia also afflicts those who are infected by the virus and do not get full-blown AIDS (249). Dementia in such patients can precede other symptoms of AIDS, and at least some patients with this type of dementia do not fulfill all the criteria of AIDS (187,214). That is of concern for several reasons. Patients infected with AIDS virus who do not develop clinical AIDS far outnumber those who do. Those who succumb to AIDS invariably die under current therapies, but mortality rates among those who do not develop AIDS though infected with the virus are unknown. Children and infants infected with AIDS can also develop dementia and malformations of the brain (18). Investigations in this area are just beginning, and the magnitude of the problem of AIDS dementia will not be known until many more investigators are involved and more data accumulated. Dementias caused by Toxins Alcohol.Alcohol is associated with over a dozen forms of brain disease. The diseases may be due to direct effects of alcohol, to nutritional factors, or to indirect effects of damage to the liver or other organs. The most common alcohol-related dementia is Wernicke-Korsakoff syndrome. Korsakoffs syndrome is not found only among chronic alcoholics, but alcoholism is by far its most common cause. Wernickes encephalopathythe early, shortterm part of the Wernicke-Korsakoff syndrome is characterized by disorders of eye movement, abnormal gait, and global confusion. If left un- PAGE 121 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 117 treated, it can progress to coma or permanent neurological damage, and severe cases can be fatal even if treated. Eighty percent of those who develop Wernickes encephalopathy go on to develop Korsakoffs syndrome (263) although some patients develop Korsakoff syndrome without ever showing Wernickes encephalopathy. Korsakoff syndrome is characterized by loss of recent memory, often attended by disorientation to time and place and other mental symptoms. Some cases of Korsakoff syndrome have only memory loss, and represent a pure amnesia rather than dementia. Wernicke-Korsakoff syndrome is related to deficiency of vitamin B-1 (thiamine), and the standard initial treatment is thiamine administration (122). The disease appears to be caused by poor nutritional intake in patients with a genetic predisposition to the disease (31). The chain of events leading to the syndrome is not fully understood, however, in part because animal models of thiamine deficiency are not exact duplicates of the human disease (122,263). There is currently a debate in neurology and psychiatry about whether there is a dementia directly caused by long-term alcoholism, in the absence of nutritional problems or diseases of other organs (such as heart, liver, and endocrine glands) (49,115). Circumstantial evidence indicates that those who have a history of heavy drinking for 15 to 20 years develop a dementia that is distinct from either Alzheimers disease or WernickeKorsakoff syndrome, Such patients typically show listlessness, poor judgment, carelessness, diminished attention, and slowing of thought processes. They do not usually have the language problems or difficulty drawing figures typical of Alzheimers disease (115). The debate is about whether these changes are due to direct chronic toxicity of alcohol on the brain or to other factors. Other Toxic Dementias.Liver damage due to alcohol or severe liver disease can also cause dementia. The liver is responsible for clearing many toxins out of the body, and liver failure due to cirrhosis can cause accumulation of byproducts followed by dementia and even coma. Chronic exposure to heavy metals (especially mercury and lead) at home or in the workplace can cause dementia, Many alcohol-related diseases in addition to Korsakoff's syndrome and liver disease can induce dementia. Dementia can result from excess blood lipids, exposure to toxic chemicals, and severe nutritional deficiencies. Normal Pressure Hydrocephalus Normal pressure hydrocephalus (NPH) is a relatively uncommon cause of dementia. Its importance lies not in its frequency, but in its potential for correction. The classic description of the findings is a combination of dementia with urinary incontinence, a slow and hesitant gait, and dilation of the fluid-filled spaces in the brain. Another symptom that suggests NPH is a history of bleeding in the brain or head trauma, In practice, NPH may lack some of these features or have characteristics of other dementing conditions (47). Normal pressure hydrocephalus was first described in 1964 (210), and the condition began to be more widely noticed the following year (129). The treatment for NPH is to provide a surgically implanted conduit (shunting) for fluid to drain from the brain into another body cavity, usually the abdominal cavity (164). The efficacy of shunting varies widely, depending on severity, diagnostic accuracy, and duration of illness (success hinges on accurate detection and prompt treatment). Many studies find successful relief of symptoms in 40 percent of cases (127)164)291). When shunting works, it brings rapid clinical improvement. One consideration in shunting for NPH is whether a sample of brain tissue should be taken for microscopic examination while inserting the shunt inside the skull. That procedure may permit a diagnosis of another dementia if the shunting procedure fails, but it does entail a slight added risk to the patient. A problem with current treatment for NPH is the high rate of major complications, estimated at 40 percent, and this emphasizes the need for careful selection of patients (164). Downs syndrome There are several interesting relationships between Alzheimers disease and Downs syndrome. First, the number of individuals affected with Downs syndrome among relatives of patients with Alzheimers disease is greater than expected (137, PAGE 122 118 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias 138,140,141). But even more curious is the similarity in brain changes that occur with age in Downs syndrome. Young individuals with Downs syndrome have a reduced number of cells in the nucleus basalis, and these cells may die off with age (53). Patients with Downs syndrome who survive into middle age frequently develop a dementia, and the microscopic and anatomic features of the findings in the brain are visually indistinguishable from those that occur in Alzheimers disease (194)247,327,334, 335). There may be some differences, however, in the detailed chemical composition of tangles and plaques between Alzheimers disease and Downs syndrome (179). The similarities between Alzheimers disease and premature aging in Downs syndrome have led to speculations about causal links between the two diseases (94). Downs syndrome is usually caused by the presence of an extra chromosome 21 in the patients cells. More rarely, it is caused by chromosomal rearrangements or malformations that lead to excess of only part of chromosome 21. These findings have led to investigation of whether there is a chromosome defect in Alzheimers disease as well, but results are mixed, and no aberration is consistent (reviewed in 327). Many investigators are studying Downs syndrome as a model of Alz heimers disease in a relatively homogeneous population, assuming that the brain changes that occur are part of the syndrome and might provide clues to the origin of Alzheimers disease. Picks Disease Picks disease is a rare dementing disorder clinically similar to Alzheimers disease. The diagno sis of Picks disease is, in fact, most often made on autopsy of a patient with clinically diagnosed Alzheimers disease. The cause of Picks disease is mysterious and uncertain, and it also can occur in families. The distinction between Picks and Alzheimers diseases rests on the microscopic appearance of the brain. While someone with Alzheimers disease has plaques and tangles, a patient with Picks disease has pale and swollen nerve cells that contain globules of protein that are designated Pick bodies. Recent evidence suggests biochemical similarities between Alzheimer tangles and plaques and Pick bodies (254). The intriguing relationship between these two dementing disorders is underscored by a newly described genetic disease that combines features of both (222). Dementia without Detectable Brain changes One final category of dementia is defined by the absence of any abnormal findings in the brain despite clear clinical symptoms. Such cases constituted a small fraction (2 of 50 patients) of those in a classic autopsy study of dementia (311), and cases continue to be reported of 99 patients in a recent study (134). One 91-year-old man whose brain revealed no plaques at all (despite extensive search) but who suffered from dementia is of particular interest (13) since most persons his age without dementia would have a few plaques. This mysterious group of patients has been called the percent problem (163). The condition has also been called simple atrophy or idiopathic dementia because its cause and mechanism are unknown. CHAPTER 3 REFERENCES 1. Albert, M., Naeser, M. A., Levine, H. L., et al,, CT Density Numbers in Patients With Senile Demen~ia of the Alzheimers Type, Archives of Neurology 41:1264-1269, 1984. 2. Alzheimer, A., Uber Eine Eigenartige Erkrankung der Hirnrinde, Gesamte Psychiatric 64:146-148, 1907. 3. Amaducci, L. A,, Fratiglioni, L,, Rocca, W. A., et al., Risk Factors for Alzheimers Disease (AD): A Case-Control Study on an Italian Population, (abstract) Neurology 35 (Supplement 1):277, 1985. 4. Amaducci, L. A., Fratiglioni, L., Rocca, W. A., et al., Risk Factors for Clinically Diagnosed Alzheimers Disease: A CaseControl Study of an Italian Population, Neurology 36:922-931, 1986. 5. American Medical Association, Council on Scientific Affairs, Dementia, pending. PAGE 123 Ch, 3The Diseases: Diagnosis, Treatment, and Scientific Background 119 6. American Neurological Association, Committee on Health Care Issues, Precautions in Handling Tissues, Fluids, and Other Contaminated Materials From Patients With Documented or Suspected Creutzfeldt-Jakob Disease, Annals of Neurology 19:75-77, 1986. 7. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 3d ed. (Washington, DC: 1980). 8. Anderson, B., Is Alpha-MSH Deficiency the Cause of Alzheimers Disease? MedicaZ Hypotheses 19:379-385, 1986. 9. Appel, S. H., A Unifying Hypothesis for the Cause of Amyotrophic Lateral Sclerosis, Parkinsonism, and Alzheimer Disease, Annals of Neurolo&v 10:499-505, 1981. 10. Arendt, T., Bigl, V., Tennstedt, A., et al., ( Neuronal Loss in Different Parts of the Nucleus Basalis is Related to Neuritic Plaque Formation in Cortical Target Areas in Alzheimers Disease, Neuroscience 14:1-14, 1985. 11, Austin, J. H., Rinehart, R., Williamson, T., et al., Studies in Aging of the Brain, III. Silicon Levels in Postmortem Tissues and Body Fluids, Progress in Brain Research 40:485-495, 1973. 12. Baker, H. F., Ridley, R. M., and Crow, T.J., ( Experimental Transmission of an Autosomal Dominant Spongiform Encephalopathy: Does the Infectious Agent Originate in the Human Genome? British Medical Journal 291 :299-302, 1985, 13. Ball, M.J., Hachinski, V., Fox, A., et al., A New Definition of Alzheimers Disease: A Hippocampa] Dementia, Limcet, Jan. 5, 1985, pp. 14-16. 14. Barclay, L. L., Zemcov, A., B]ass, J. P., et al., Factors Associated With Duration of Survival in Alz heimers Disease, Bio]o@cal Psychiatry 20:8693, 1985. 15. Barclay, L. L., Zemcov, A., Blass, J. P,, et al., Survival in Alzheimers Disease and Vascular Dementia, Neurology 35:834-840, 1985. 16. Bartus, T. R., Dean, R. L., Beer, B., et al., The Cholinergic Hypothesis of Geriatric Memory Dysfunction, Science 217:408-417, 1982. 17. Becker, P. M., Feussner, J. R., Mulrow, C.D., et al., The Role of Lumbar Puncture in the Evaluation of Dementia) Journal of the American Geriatrics Society 33:392-396, 1985. 18. Belman, A. L., Ukmann, M. H., Horoupian, D., et al., Neurological Complications in Infants and Children With Acquired Immune Deficiency Syndrome, Annals of Neurology 18:560-566, 1985. 19. Benson, D. F., Subcortical Dementia: A Clinical Approach, Advances in Neurology 38 (The Dementias) (New York: Raven, 1983). 20. Besson, J. A. O., Corrigan, F. M., Foreman, I., et al., Nuclear Magnetic Resonance (NMR). II. Imaging in Dementia, British Journal of Psychiatry 146:31-35, 1985. 21. Bird, S.J., Presymptomatic Testing for Huntingtons Disease, Journal of the American Medical Association 253:3286-3291, 1985. 22. Bissette, G., Reynolds, G. P., Kits, C. D., et al., Corticotropin-Releasing Factor-Like Immunoreactivity in Senile Dementia of the Alzheimer Type) Journal of the American Medical Association 254:3067-3069, 1985. 23. Bjorklund, A., and Gage, F. H., Neuronal Replacement After Traumatic or Age-Dependent Brain Damage, International Journal of Technology Assessment in Health Care 1:93-107, 1985. 24. Black, P. H., HTLV-111, AIDS, and the Brain, New England Journal of Medicine 313:1538-1540, 1985. 25. Blackwood, D. H. R., and Christie, J. E., The Effects of Physostigmine on Memory and Auditory P300 in Alzheimer-Type Dementia, Biolo#cal Psychiatry 21:557-560, 1986. 26. Blass, J. P., Editorial: NIH Diagnostic Criteria for Alzheimers Disease, Journal of the American Geriatrics Society 33:1, 1985. 27. Blass, J. P., Pragmatic Pointers in Managing the Demented Patient, Journal of the American Geriatrics Society 34:548-549, 1986. 28. Blass, J. P., Gibson, G. E., Shamada, M., et al., Brain Carbohydrate Metabolism and Dementia, Biochemistry of Dementia, P.J. Roberts (cd.) (London: John Wiley, 1980). 29. Blass, J. P., Hanin, I., Barclay, L., et al., Red Blood Cell Abnormalities in Alzheimer Disease, Journal of the American Geriatrics Socie~V 33:401405, 1985. 30. Blass, J. P., and Barclay, L. L., New Developments in the Diagnosis of the Dementia, Drug Development Research 5:39-58, 1985. 31, Blass, J. P., and Gibson, G. E., Abnormality of a Thiamine-Requiring Enzyme in Patients With Wernicke-Korsakoff Syndrome, New England Journal of Medicine 297:1367-1370, 1977. 31a. Blass, J. P., Makesberg, W., and Whitehouse, P.J., comments at a meeting of the OTA advisory panel, June 1986. 32. Blass, J. P., and Zemcov, A., Alzheimer Disease: A Metabolic Systems Degeneration? Neurochemistry and Pathology 2:103-114, 1984. PAGE 124 IZO Losing a Mi//ion kfinds: Confronting the Tragedy of Alzheimers Disease and Other Dernentias 33. Blessed, G., Tomlinson, B.E., and Roth, M., The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects, British Jourmd of Psycfuatry 114:797-811, 1968. 34. Boiler, F., Mizutani, T., Roessmann, U., et al., Annals of Neurology 7:329-335, 1980. 35. Bondareff, W., Age and Alzheimer Disease, Lancet, June 25, 1983, p. 1447. 36. Bondareff, W., Mountjoy, C.Q., and Roth, M., Loss of Neurons of Origin of the Adrenergic Projection to the Cerebral Cortex (Nucleus Locus Coeruleus) in Senile Dementia, Neurology 32: 164-168, 1982. 37. Botstein, D., White, R. L., Skolnick, et al., Construction of a Genetic Linkage Map in Man Using Restriction Fragment Length Polymorphisms, American Journal of Human Genetics 32:314333, 1980. 38. Breitner, J.C.S., Aphasia/Apraxia and Familial Aggregation in Alzheimers Disease, Annals of Neurology 15:614-615, 1984. 39. Breitner, J.C.S., Familial Nature of Alzheimers Disease, New England Journal of Medicine 311:1318-1319, 1984. 40. Breitner, J.C.S., and Folstein, M.F., Familial Alzheimer Dementia: A Prevalent Disorder With Specific Clinical Features, Psychological Medicine 14:63-80, 1984. 41. Breitner, J.C.S., Folstein, M.F., and Murphy, E.A., Familial Aggregation in Alzheimer Dementia-I. A Model for the Age-Dependent Expression of an Autosomal Dominant Gene, Journal of Psychiatric Research 20:31-43, 1986. 42. Breitner, J.C.S., Murphy, E.A., and Folstein, M.F., Familia] Aggregation in Alzheimer Dementia H. Clinical Genetic Implications of Age-Dependent Onset, Journal of Psychiatric Research 20:45-55, 1986. 43. Brown, P,, Gajdusek, D.C., Gibbs, C.J., et al., Po44 45 tential Epidemic of Creutzfeldt-Jakob Disease From Human Growth Hormone Therapy, New England Journal of A4edicine 313:728-730, 1985. Brown, P., Salazar, A. M., Gibbs, C.J., et al., Alzheimers Disease and Transmissible Dementia (Creutzfeldt-Jakob Disease), Annals of the New York Academy of Sciences 396:131-144, 1982. Brown, R.G., and Marsden, C.D., How Common Is Dementia in Parkinsons Disease? l!xmcet, Dec. 1, 1984, pp. 1262-1265. 46. Brun, A., and Englund, E., A White Matter Disorder in Dementia of the Alzheimer Type: A Pathoanatomical Study, Annals of Neurolo~ 19:253-262, 1986. 47. Brust, J.C.M., Dementia and Cerebrovascular Disease) Advances in Neumlofl 38 (The Dementias) (New York: Raven, 1983). 48. Bucht, G., Adolfsson, R., and Winblad, B., Dementia of the Alzheimer Type and Multi-Infarct Dementia: A Clinical Description and Diagnostic Problems, Journal of the American Geriatrics Society 32:491-498, 1984. 49. Butters, N., and Brandt, J., The Continuity Hypothesis: The Relationship of Long-Term Alcoholism to the Wernicke-Korsakoff Syndrome, Recent Developments in Alcoholism 3:207-226, 1985. 50. Candy, J.M., Edwardson, J. A., Klinowski, J., et al., Co-Localization of Aluminum and Silicon in Senile Plaques: Implications for the Neurochemical Pathology of Alzheimers Disease) Senile Dementia of Alzheimer Type, J. Traber and W .H. Gispen (eds.) (Berlin: Springer-Verlag, 1985). 51. Candy, J.M., Klinowski, J., Perry, R. H., et al., Aluminosilicates and Senile Plaque Formation in Alzheimers Disease, Lancet, Feb. 15, 1986, pp. 354-356. 52. Cardelli, M.B., Russell, M., Bagne, C. A., et al., Chelation Therapy: Unproved Modality in the Treatment of Alzheimer-Type Dementia, Journal of the American Geriatrics Society 33:548551., 1985. 53. Casanova, M. F., Walker, L.C., Whitehouse, P.J., et al., Abnormalities of the Nucleus Basalis in Downs Syndrome, AnnaJs of Neurology 18:310313, 1985. 54. Caulfield, M., and Smith, C., British Pharmacological Society Symposium: Alzheimers Disease ---central Cholinergic Mechanisms, Neurobiology of Aging 6:61-63, 1985. 55. Chase, T.N., Brooks, R.A., DiChiro, G., et al., Focal Cortical Abnormalities in Alzheimers Disease, The Metabolism of the Human Brain Studied With Positron Exmssion Tomography, T. Greitz (cd.) (New York: Raven, 1985). 56. Chui, H.C., Teng, E. L., Henderson, V.W., et al., Clinical Subtypes of Dementia of the Alzheimer Type) Neurology 35:1544-1550, 1985. 57. Cohen, D., and Eisdorfer, C., Serum Immunoglobulins and Cognitive Status in the Elderly: 1. A Population Study, British Journafof Psycluatry 136:33-39, 1980. 57a. Cohen, D., and Eisdorfer, C., The Loss of Self (New York: Norton, 1986). 58. Cohen, D., Eisdorfer, C., Prinz, P., et al., Immunoglobulins, Cognitive Status and Duration of Illness in Alzheimers Disease, Neurobiolo# of A@ng 1:165-168, 1980. PAGE 125 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 121 59. 60. 61. 62. 63, Cohen, M.B., Graham, L. S., Lake, R., et al., Diagnosis of Alzheimers Disease and Multiple Infarct Dementia by Tomographic Imaging of Iodine-123 IMP) Journal of Nuclear Medicine 27:769-774, 1986. Coleman, R. E., Blinder, R. A., and Jaszczak, R.J., Single Photon Emission Computed Tomography (SPECT). Part II: C1inical Applications, investigations in Radiology 21:1-11, 1986. Colgan, J., Regional Density and Survival in Senile Dementia. An Interim Report on a Prospective Computed Tomographic Study, British Journal of Psychiatry 147:63-66, 1985. Collerton, D., and Fairbairn, A., Alzheimers Disease and the Hippocampus,Lancet, Feb. 2, 1985, pp. 278-279. Cook, R.H., Schneck, S.A., and Clark, D.B., Twins With Alzheimers Disease, Archives of Neurol0~ 38:300-301, 1981. 64. Cook, R.H., Ward, B.E., and Austin, J. H., Studies in Aging of the Brain. IV. Familial Alzheimer Disease: Relation to Transmissible Dementia, Aneu ploidy, and Microtubular Defects, Neurology 29:1402-1412, 1979. 65. Cork, L.C., Sternberger, N. H., Sternberger, L. A., et al., Phosphorylated Neurofilament Antigens in Neurofibrillary Tangles in Alzheimers Disease, Journal of Neuropatholo~ and Experimental Neurolo@ 45:56-64, 1986. 66. Corsellis, J. A. N., Posttraumatic Dementia, R. Katzman, R.D. Terry and K.L. Bick (eds.), Aging, Volume 7: Alzheimers Disease: Senile Dementia and Related Disorders (New York: Raven, 1978). 67. Coull, B. M., Necrologic Aspects of Dementia, Geriatric Medicine, vol. 1, C.K. Cassel and J.E. Walsh (eds.) (New York: Springer-Verlag, 1984). 68. Cowen, R., Brain Cell Implants and Studies of Disease Mechanism Performed on Animal Models of Parkinsonism, Research Resources Reporter 10:1-5, February 1986, vol. X, pp. 1-5. 69. Coyle, J.T., Price, D.L., and DeLong, M. R., Alzheimers Disease: A Disorder of Cortical Cholinergic Innervation, Science 59:277-289, 1983. 70. Coyle, J.T., Singer, H., McKinney, M., et al., Neurotransmitter Specific Ahernations in Dementing Disorders: Insights From Animal Models) Journal of Psychiatric Research 18:501-512, 1984. 71. Crapper, D, R., Krishnan, S. S., and Quittkat, S., Aluminum, Neurofibrillary Degeneration and Alzheimers Disease, Brain 99:67-80, 1976. 72. Critchley, M., Medical Aspects of Boxing, Particularly From a Neurological Standpoint, British Medical Journal 1:357-362, 1957. 73. Cross, A.J., Crow, T.J., Ferrier, I. N., et al., The Selectivity of the Reduction of Serotonin S2 Receptors in Alzheimer-Type Dementia, Neurobiology of Aging 7:3-7, 1986. 74. Cummings, J. L., and Benson, D. F., Dementia of the Alzheimer Type: An Inventory of Diagnostic Clinical Features, Journal of the American Geriatrics Society 34:12-19, 1986. 75. Cutler, N. R., Haxby, J. V., Duara, R., et al., Brain Metabolism as Measured With Positron Emission Tomography: serial Assessment in a Patient With Familial Alzheimers Disease, Neurology 35: 1556-1561, 1985. 76. Cutler, N. R., Haxby, J. V., Duara, R., et al., Clinical History, Brain Metabolism, and Neuropsychological Function in Alzheimers Disease, Annals of Neurolo@ 18:298-309, 1985. 77. Cutler, N. R., Kay, A.D., Marangos, P.J., et al., Cerebrospinal Fluid Neuron-Specific Enolase Is Reduced in Alzheimers Disease, Archives of Neurolo@ 43:153-154, 1986. 78. Davies, P., Katzman, R., and Terry, R.D., Reduced Somatostatin-Like Immunoreactivity in Cerebral Cortex From Cases of Alzheimer Disease and Alzheimer Senile Dementia, Nature 288:279-280, 1980. 78a. Davis, K.L., and Mohs, R.C., Cholinergic Drugs in Alzheimers Disease, New England Journal of Medicine 315:1286-1287, 1986. 79. DeBoni, U., and McLachlan, D. R.C., Controlled Induction of Paired Helical Filaments of the Alzheimer Type in Cultured Human Neurons, by Glutamate and Aspartame) Journal of the Neurological Sciences 68:105-118, 1985. 80. DeLeon, M.J., and George, A. E., Computed Tomography in Aging and Senile Dementia of the Alzheimer Type) Advances in Neurology 38 (The Dementias) (New York: Raven, 1983). 81. DeSouza, E.B., Whitehouse, P.J., Kuhar, M.J., et al., Reciprocal Changes in Corticotropin-Releasing Factor (CRF)-Like Immunoreactivity and CRF Receptors in Cerebral Cortex of Alzheimers Disease, Nature 319:593-595, 1981. 82. Dickson, D.W., Kress, Y., Crowe, A., et al. Mon83. 84. oclonal Antibodies to Alzheimer Neurofibrillary Tangles. 2. Demonstration of a Common Antigenic Determinant Between ANT and Neurofibrillary Degeneration in Progressive Supranuclear Palsy, American Journal of Patholo~ 120:292-303, 1985. DiGiacomo, J., and Prien, R., (Pharmacologic Treatment of Depression in the Elderly, Physicians Guide to the Diagnosis and Treatment of Depression in the Elderly, T. Crook and G.D. Cohen (eds.) (New Canaan, CT: Mark Powley and Associates, 1983). Drachman, D. A., Alzheimers Disease: Diagnos PAGE 126 122 l Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias tic Dilemmas, Proceedings of the National Conference on Alzheimerk Disease: A Challenge for Care, J.E. Hansan (cd.) (Memphis, TN: Hillhaven Foundation, 1985). 85. Drayer, B. P., Heyman, A., Wilkinson, W., et al., 86, 87. 88. 89. 90. Early-Onset Alzheimers Disease: An Analysis of CT Findings, Annals of Neurology 17:407-410, 1985. Duara, R., Grady, C., Haxby, J., et al., Positron Emission Tomography in Alzheimers Disease, Neurology 36:879-887, 1986. DuBois, B., Hauw, J.J., Ruberg, M., et al., Demence et Maladie de Parkinson: Correlations Biochimiques et Anatomo~liniques, Revue Neuro]ogique 141:184-193, 1985. Eisdorfer, C., and Cohen, D., Serum Immunoglobulins and Cognitive Status in the Elderly: 2, An Immunological-Behavioral Relationship? British Journal of Psychiatry 136:40-45, 1980. Erkinjuntti, T., Sulkava, R., and Tilvis, R., HDL Cholesterol in Dementia, Lance?, July 6, 1985, p. 43. Eslinger, P.J., Damasio, A. R., Benton, A. L., et al., Neuropsychologic Detection of Abnormal Mental Decline in older Persons, Journal of the American Medical Association 253:670-674, 1985, 91. Feinleib, M., The Magnitude and Nature of the Decrease in Coronary Heart Disease Mortality Rate, American Journal of Cardiolo@ 54:2C-6C, 1984. 92. Ferris, S. H., de Leon, M.J., Wolf, A. P., et al., Positron Emission Tomography in Dementia, Advances in Neurology 38 (T.he Dementias) (New York: Raven, 1983). 93. Fine, A., Peptides and Alzheimers Disease, Na ture 319:537-538, 1986. 94. Fishman, M, A., Will the Study of Down Syn95. 96, 97. 98. drome Solve the Riddle of Alzheimer Disease? Journal of Pediatrics 108:627-629, 1986. Fishman, P. S., Neural Transplantation: Scientific Gains and Clinical Perspectives, Neuro]o# 36:389-392, 1986. Folstein, M.F., and Breitne$, J.C.S., Language Disorder Predicts Familial Alzheimers Disease, Johns Hopkins Medical Journal 149:145-147, 1981. Folstein, M. F., Folstein, S. E., and McHugh, P. R., Mini-Mental State: A Practical Method of Grading the Cognitive State of Patients for the Clinician, Journal of Psychiatric Research 12:189198, 1975. Foster, N. L., Chase, T. N., Patronas, N.J., et al., Cerebral Mapping of Apraxia in Alzheimers Disease by Positron Emission Tomography, Annals of Neurology 19:139-143, 1986. 99. Francis, P. T., Palmer, A. M., Sims, N. R., et al., Neurochemical Studies of Early-Onset Alzheimers Disease, New England Journal of Medicine 313:7-11, 1985. 100. French, L. R., Schuman, L. M., Mortimer, J. A., et al., A CaseControl Study of Dementia of the Alzheimer Type, American Journal of EpidemiolO@f 121:414-421, 1985, 101. French, L. R., Schuman, L. M., Mortimer, J. A., et al., (reply to letter), The Authors Reply, American Journal of Epidemiolo@ 123:753-754, 1986. 102. Friedland, R. P., Brun, A., and Budinger, T. F., Pathological and Positron Emission Tomographic Correlations in Alzheimers Disease, Lancet, Jan. 26, 1985, p. 228. 103. Friedland, R. P., Budinger, T.F., Brant-Zawadzki, 104, 105 106. 107. 108 109 110 M., et al., The Diagnosis of Alzheimer-Type Dementia, Journal of the American Medical Association 252:2750-2752, 1984. Fudenberg, H. H., Whitten, H. D., Arnaud, P., et al., Is Alzheimers Disease an Immunological Disorder? Observations and Speculations, Clinical Immunology and Immunopathology 32:127-131, 1984. Fudenberg, H. H., Whitten, H. D., Arnaud, P., et al., Immune Diagnosis of a Subset of Alzheimers Disease With Preliminary Implications for Immunotherapy, Biomedicine and Pharmacotherapy 38:290-297, 1984. Gajdusek, D.C., Unconventional Viruses and the Origin and Disappearance of Kuru, Nobel Lecture, Dec. 13, 1976, reprinted in Science 197:943960, 1977. Gajdusek, D. C., Hypothesis: Interference With Axonal Transport of Neurofilament as a Common Pathogenetic Mechanism in Certain Diseases of the Central Nervous System, New England Journal of Medicine 312:714-719, 1985. Gauthier, S., Practical Guidelines for the Antemortem Diagnosis of Senile Dementia of the Alz heimer Type) fhw@ss in Neuro-Psychopharma colo@and Biolo@cal Psychiatry 9:491-495, 1985. Geddes, J. W., Monaghan, D.T., Cotman, C. W., et al., Plasticity of Hippocampal Circuitry in Alz heimers Disease) Science 230:1179-1181, 1985. Gibbs, C.J., Joy, A., Heffner, R., et al., Clinical and Pathological Features and Laboratory Confirmation of Creutzfeldt-Jakob Disease in a Recipient of Pituitary-Derived Human Growth Hormone, New England Journal of Medicine 313:734-738, 1985. 111. Gibson, C.J., Logue, M., and Growdon, J., CSF PAGE 127 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 123 112. 113, 114. 115, 116. 117, 118, Monoamine Metabolize Levels in Alzheirners and Parkinsons Disease, Archives of Neurolo&v 42:489-492, 1985. Glenner, G. G., (On Causative Theories in Alzheimers Disease, Human Pathologv 16:433-43.5, 1985. Glosser, G., Wexler, D., and Balmelli, M., Physicians and Families Perspectives on the Medical Management of Dementia, Journal of the American Geriatrics Societuy 33:383-391, 1985. Goldman, J. E., Yen, S. H., Cytoskeletal Protein Abnormalities in Neurodegenerative Diseases, Annals of Neurologv 19:209-223, 1986. Goldstein, G., Dementia Associated With Alcoholism, Alcohol and the Brain: Chronic Effects, R.E. Tarter and D.H. van Thiel (eds.) (New York: Plenum, 1985). Gomez, S., Davous, P., Rondot, P., et al., Somatostatin-Like Immunoreactivity and Acetylcholinesterase Activities in Cerebrospinal Fluid of Patients With Alzheimer Disease and Senile Dementia of the Alzheimer Type, PseYchoneuroendocrinologv 11:69-73, 1986. Goodnick, P., and Gershon, S., Chemotherapy of Cognitive Disorders in Geriatric Subjects, Journal of C]inica] Ps~Vchiatry 45:196-209, 1984. Gottfries, C. G., Alzheimers Disease and Senile Dementia: Biochemical Characteristics and Aspects of Treatment, Ps&Ychopharmacologv 86:245-252, 1985. 119. Gottfries, C. G., Critique: Transmitter Deficits in Alzheimers Disease, Neurochemistry International 7:565-566, 1985. 120. Goudsmit, J., Morrow, C. H., and Asher, D. M., Evidence for and Against the Transmissibility of Alzheimer Disease, Neuro]ogv 30:945-950, 1980. 121. Gray, E. G., Spongiform Encephalopathy: A Neu 122 123 rocytologists Viewpoint With a Note on Alzheimers Disease, Neuropathology and Applied Neurobiology 12:149-172, 1986. Greenberg, D. A., and Diamond, I., WernickeKorsakoff Syndrome, Alcohol and the Brain: Chronic Effects, R.E. Tarter and D.H. van Thiel (eds.) (New York: Plenum, 1985). Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., et al., Alzheimer Paired Helical Filaments: Immunochemical Identification of Polypeptides) Acta Neuropathologica (Berlin) 62:259-267, 1984. 124. Gurkmd, 13,, Golden, R. R., Teresi, J. A., et al., (The SHORT-CARE: An Efficient Instrument for the Assessment of Depression, Dementia, and Disability, Journa] of Gerontology 39:166-169, 1984. 125. Gurland, B., and Toner, J., Differentiating De126. 127, mentia From Nondementing Conditions, Advances in Neurologv 38: The Dementias, (New York: Raven, 1985). Gusella, J. F., Wexler, N .S. Conneally, P. M., et al., ( A Polymorphic DNA Marker Genetically Linked to Huntingtons Disease, Nature 306:234-238, 1983. Haase, G. R., Differential Diagnosis and Clinical Features of the Dementing Illnesses, Annual Course No. 215, Dementia and Aging (S.A. Schneck, course director), American Academy of Neurology, April 27-May 3, 1986. 128. Hachinski, V., Iliff, L., Shilkha, E., et al., ( Cerebral Blood Flow in Dementia, Archives of Aeurology 32:632-637, 1975. 129. Hakim, S., and Adams, R. D., Clinical Problem 130 130a of Symptomatic Hydrocephalus With Normal Cerebrospinal Fluid Pressure. Observations on CSF Hydrodynamics, Journal of Neurological Sciences 2:307-327, 1965. Hammerstrom, D. C., and Zimmer, B., The Role of Lumbar Puncture in the Evaluation of Dementia, Journal of the American Geriatrics Society 33: 397-400, 1985. Haney, D. Q., Researcher Fears Hysteria Over Alzheimers Drug Discovery, Associated Press Newswire, Nov. 12, 1986. 131. Harbaugh, R. E., Roberts, D. W., Coombs, D. W., et al., Neurosurger y 15:514-518, 1985. 132. Hardy, J., Adolfsson, R., Alafuzoff, I., et al., Review: Transmitter Deficits in Alzheimers Disease, Neurochemistr y International] 7:545-563, 1985. 133. Hayden, M. R., Martin, W. R. W., Stoessel, et al., Positron Emission Tomography in the Early Diagnosis of Huntingtons Disease, Neurologv 36:888-894, 1986. 134. Heilig, C. W., Knopman, D. S., Mastri, A. R., et al., Dementia Without Alzheimers Pathology, Neurology 35:762-765, 1985. 135, Helms, P. M., ( Efficacy of Antipsychotics in the Treatment of the Behavioral Complications of Dementia: A Review of the Literature, Journal of the American Geriatrics Society 33:206-209, 1985. 136. Henschke, P.J., Bell, D. A., and Cape, R. D. T., Immunologic Indices in Alzheimer Dementia, Journal of Clinical and Experimental Gerontology 1:23-37, 1979. 137, Heston, L. L., Alzheimers Disease, Trisomy 21, 138 and Myeloproliferative Disorders: Associations Suggesting and Genetic Diathesis, Science 196:322-323, 1977. Heston, L. L., Alzheimers Dementia and Downs 63-218 0 87 5 QL : 3 PAGE 128 . 124 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Syndrome: Genetic Evidence Suggesting an Association, Annals of the New York Academy of Sciences 396:29-38, 1982. 139. Heston, L. L., Ask the Doctor: Genetics and De140 141, 142, 143. 144. 145 146 147. 148. 149. 150. 151. mentia of the Alzheimer Type, ADRDA Newsletter 5:4, 1985. Heston, L. L., Mastri, A. R., Anderson, V. E., et al., Dementia of the Alzheimer Type: Clinical Genetics, Natural History and Associated Conditions, Archives of Genera] Psychiatry 38:10851090, 1981. Heston, L. L., and White, J .A., Dementia: A Practical Guide to A]zheimers Disease and Related Illnesses (New York: W. H. Freeman, 1983). Heyman, A., Wilkinson, W. E., Hurwitz, B.J., et al., Alzheimers Disease: Genetic Aspects and Associated Clinical Disorders, Annals of Neurology 14:507-515, 1983. Heyman, A., Wilkinson, W .E., and Stafford, J. A., et al., Alzheimers Disease: A Study of Epidemiologic] Aspects, Annals of Neurology 15:335-341, 1984. Ho, D. D., Rota, T. R., Schooley, R. T., et al., Isolation of HTLV-H1 From Cerebrospinal Fluid and Neural Tissues of Patients With Necrologic Syndromes Related to the Acquired Immunodeficiency Syndrome, New England Journal of Medicine 313:1493-1497, 1985. Hoffman, R. S., ( Diagnostic Errors in the Evaluation of Behavioral Disorders, Journal of the American Medical Association 248:964-967, 1982. Holman, B, L., Perfusion and Receptor SPECT in the Dementias-George Taplin Memorial Lecture, Journal of ~uc]ear Medicine 27:855-860, 1986. Holman, B. L., Gibson, R. E,, Hill, T. C., et al., Muscarinic Acetylcholine Receptors in Alzheimers Disease: In Vivo Imaging With Iodine 123-Labeled 3-C@inuclidinyl-4 -Iodobenzilate and Emission Tomography, Journal of the American Medical Association 254:3063-3066, 1985. Huber, S.J., Shuttleworth, E. C., Paulson, G. W., et al., Cortical Versus Subcortical Dementia, Archives of Neurology 43:392-394, 1986. Hyman, B.T., van Hoesen, G. W., Damasio, A. R., et al., Alzheimers Disease: Cell Specific Pathology Isolates the Hippocampal Formation, Science 225:1168-1170, 1984. Ihara, Y., Abraham, C., and Selkoe, D. J., Antibodies to Paired Helical Filaments in Alzheimers Disease Do Not Recognize Normal Brain Proteins, Nature 304:727-730, 1983. Iabal, K, Grundke-Iabal, I., Zaidi, T., et al., Are 152. 153. 154. 155. Alzheimers Neurofibrillary Tangles Insoluble Polymers? Life Sciences 38:1695-1700, 1986. Ishii, N., Nishihara, Y., and Imamura, T., (why Do Frontal Lobe Symptoms Predominate in Vascular Dementia With Lacunes? Neurology 36: 340-345, 1986, Jankovic, J., Progressive Supranuclear Palsy: Clinical and Pharmacologic Update, Neurology Clinics 2:473-486, 1984. Jenike, M. A., Monoamine Oxidase Inhibitors as Treatment for Depressed Patients With Primary Degenerative Dementia (Alzheimers Disease), American Journal of Psychiatry 142:763-764, 1985. Jonker, C., Eikelenboom, P., and Tavermier, P., Immunological Indices in the Cerebrospinal Fluid of Patients With Presenile Dementia of the Alzheimer Type, British Journal of Psychiatry 140:44-49, 1982. 156. Jorm, A. F., Subtypes of Alzheimers Dementia: A Conceptual Ana~sis and Critical Review) Psy157. 158 159. 160. 161. 162. chologcal Medicine 15:543-553, 1985. Judd, B. W., Meyer, J. S., Rogers, R. L,, et al., Cognitive Performance Correlates With Cerebrovas cular Impairments in Multi-Infarct Dementia, Journal of the American Geriatrics Society 34: 355-360, 1986. Kahn, R. L., Goldfarb, A. I., Pollack, M,, et al., Brief Objective Measures for the Determination of Mental Status in the Aged, American Journal of Psychiatry 117:326-328, 1960. Kaplan, J. G., Katzman, R., Horoupian, D. S., et al., Progressive Dementia, Visual Deficits, Amyotrophy, and Microinfarcts, Neurofogy 35:789-796, 1985, Kase, C. S., Multi-Infarct Dementia: A Real Entity? Journal of the American Geriatrics Society 34:482-484, 1986. Katzman, R., University of California at San Diego, personal communication, Dec. 24, 1985. Katzman, R., Brown, T., Fuld, P., et al,, Validation of a Short Orientation-Memory -Concentra tion Test of Cognitive Impairment, American Journal of Psychiatry 140:734-739, 1983. 163, Katzman, R., Lasker, B., and Bernstein, N., Accuracy of Diagnosis and Consequences of Misdiagnosis of Disorders Causing Dementia) contract report prepared for the Office of Technology Assessment, U.S. Congress, 1986. 164, Kawas, C., and Wolfson, L., Normal Pressure Hydrocephalus, Current Therapy in Neurologc Disease, 1985-1986, R.T. Johnson (cd.) (Philadelphia: B.C. Decker, 1985). 165. Kerzner, L. J., Diagnosis and Treatment of Alz- PAGE 129 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 125 heimers Disease, Advances in Internal A4edicine 29:447-470, 1984. 166. Khachaturian, Z. S., Diagnosis of Alzheimers Disease, Archives of Neurology 42:1097-1105, 1985. 167. Khansari, N., Whitten, H. D., Chou, Y. K., et al., Immunological Dysfunction in Alzheimers Disease, Journal of Neuroimmunologv 7:279-285, 1985. 168. Kidd, M., Allsop, D., and Landon, M., Senile Plaque Amyloid, Paired Helical Filaments, and Cerebrovascular Amyloid in Alzheimers Disease Are All Deposits of the Same Protein, Lancet, Feb. 2, 1985, p. 278. 169. Kish, S.J., Chang, L. J., Mirchandani, L., et al., Progressive Supranuclear Palsy: Relationship Between Extrapyramidal Disturbances, Dementia, and Brain Neurotransmitter Markers, Annals of Neurology 18:530-536, 1985. 170. Klein, L. E., Roca, R. P., McArthur, J., et a]., Diagnosing Dementia: Univariate and Mukivariate Analyses of the Mental Status Examination, Journal of the American Geriatrics Societtiv 33:483-488, 1985. 171. Knesevich, J. W., Toro, F. R., Morris, J. C., et al., Aphasia, Family History, and the Longitudinal Course of Senile Dementia of the Alzheimer Type, Psychiatry Research 14:255-263, 1985. 172. Koch, T. K., Berg, B. O., DeArmond, S.J., et al., Creutzfeldt-Jakob Disease in a Young Adult With Idiopathic Hypopituitarism, New England Journal of Medicine 313:731-733, 1985. 173. Keller, W. C., and Davenport, J., Genetic Testing in Huntington Disease, Annals of Neurolo@ 16:511-512, 1984. 174. Kosik, K. S., Duffy, L. K., Dowling, M. M., et al., Microtubule-Associated Protein 2: Monoc]onal Antibodies Demonstrate the Selective Incorporation of Certain Epitopes Into Alzheimer Neurofibrillary Tangles, Proceedings of the National Academy of Sciences, USA 81:7941-7945, 1984. 175. Koss, E., Friedland, R. P., Ober, B. A., et al., Differences in Lateral Hemispheric Asymmetries of Glucose Utilization Between Earlyand LateOnset Alzheimer-Type Dementia, American Journal of Psychiatry 142:638-642, 1985. 176. Kotila, M., Wahimo, O., Niemi, M. L., et al., Dementia After Stroke, European Neurologv 25:134-140, 1986. 177. Kuhl, D. E., Metter, E.J., Riege, W, H., et al., Patterns of Cerebral Glucose Utilization in Dementia, The Metabolism of the Human Brain Studied With Positron Emission Tomographuy, T. Greitz (cd.) (New York: Raven, 1985). 178. Kulmala, H, K., and Hutton, J.T., Role of the Senile Plaque in Neuropeptide Deficits of Alzheimers Disease, Progress in Neuro-Psychopharmaco]ogv and Biological Psychiatry, 9:625628, 1985. 179. Kumar, M., Eisdorfer, C., and Cohen, D., Serum IgG Antineurofilament Antibodies in Alzheimers Disease and Downs Syndrome, submitted. 180. Lancet, Editorial: Ergot for Dementia? Dec. 8, 1984, pp. 1313-1314. 181. Larson, E.B., Reifier, B. V., Sumi, S.M,, et al., Diagnostic Evaluation of 200 Elderly Outpatients With Suspected Dementia, Journal of Gerontol0~ 40:536-543, 1985. 182. Larson, E,B., Reifier, B. V., Sumi, S. M., et al., Diagnostic Tests in the Evaluation of Dementia: A Prospective Study of 200 Elderly Outpatients, in press. 183. Lees, A.J., Parkinsons Disease and Dementia, Lancet, Jan. 5, 1985, pp. 43-44. 184. Lees, A. J., and Smith, E., Cognitive Deficits in the Early Stages of Parkinsons Disease, Brain 106:257-270, 1983. 185. Leffell, M. S., Lumsden, L., and Steiger, W .A., An Analysis of T Lymphocyte Subpopulations in Patients With Alzheimers Disease, Journal of the American Geriatrics Societuv 33:4-8, 1985. 186. Leverenz, J., and Sumi, S. M., Parkinsons Disease in Patients With Alzheimers Disease, Archives of Neurology 43:662-664, 1986. 187. Levy, J. A., Shimabukuro, J., Hollander, H., et al., Isolation of AIDS-Associated Retroviruses from Cerebrospinal Fluid and Brain of Patients With Neurological Symptoms, Lancet, Sept. 14, 1985, PP. 586-588. 188. Levy, R.1., Causes of the Decrease in Cardiovascular Mortality, American Journal of Cardiol0~ 54:7C-14C, 1984. 189. Li, J. C., and Kaminskas, E., Deficient Repair of DNA Lesions in Alzheimers Disease Fibroblasts, Biochemical and Biophysics Research Communications 129:733-738, 1985. 190. Loring, D. W., and Largen, J. W., Neuropsychological Patterns of Presenile and Senile Dementia of the Alzheimer Type, Neuropsychologia 23:351-357, 1985. 191. Mace, N. L., and Rabins, P. V., The 36-Hour Day: A Family Guide to Caring for Persons With Alzheimers Disease, Related Cementing Illness, and Memory Loss in Later Life (Baltimore: Johns Hopkins University Press, 1981). 192. Maher, E. R., Smith, E. M., and Lees, A. J., Cognitive Deficits in the Steele-Richardson-Olszewski Syndrome (Progressive Supranuclear Palsy ), PAGE 130 126 Losing a Million Minds: Confronting the Tragedy of Alzheimers Disease and Other Dementias Journal of Neurology, Neurosurgery, and Psychiatry 48:1234-1239, 1985. 193. Mann, D. A., The Neuropathology of Alzheimers 194 Disease: A Review With Pathogenetic, Aetio]ogical and Therapeutic Considerations, A4echa nisms o~ A#ng and Development 31:213-255, 1985. Mann, D. M. A., Yates, P. O., and Marcyniuk, B., Alzheimers Presenile Dementia, Seniie Dementia of Alzheimer Type and Downs Syndrome in Middle Age Form an Age-Related Continuum of Pathological Changes, Neuropathology and Applied Neurobiology 10:185-207, 1984. 195. Manuelidis, E, E., Presidential Address: Creutz feldt-Jakob Disease) Journal of Neuropatholo@ and Experimental Neurology 44;1-17, 1985. 196. Manuelidis, E. E., Kim, J. H., Mericangas, J. R., et 197. 198< 199 200. 201 202. 203. al., Transmission to Animals of CreutzfeldtJakob Disease from Human Blood, Lancet, Oct. 19, 1985, PP. 896-897. Martin, J. B., Editorial Comment: Genetic Testing in Huntington Disease, Annals of Neurology 16:512-513, 1984. Marx, J. L., Nerve Growth Factor Acts in Brain, Science 232:1341-1343, 1986. Marx, J. L., Lost Neurons Identified in Alzheimers Disease, Science 232:1500, 1986. Mash, D. C., Flynn, D. D., and Potter, L. T., Loss of M2 Muscarine Receptors in the Cerebral Cortex in Alzheimers Disease and Experimental Cholinergic Denervation, Science 228:11151117, 1985. Massachusetts General Hospital Newsletter, Should Lumbar Puncture Be Part of the Workup for Dementia? Topics in Geriatrics 4:21,23, December 1985. Massachusetts General Hospital Newsletter, Dementia: A Contraindication to Donation of Blood, Topics in Geriatrics 4:27, February 1986. Masters, C. L., Gajdusek, D. C., and Gibbs, C. J., Jr., The Familial Occurrence of CreutzfeldtJakob Disease and Alzheimers Disease, Brain 104:535-558, 1981. 204. Mattis, S., (Mental Status Examination for Or205 206 207 ganic Mental Syndrome in the Elderly Patient, Geriatric Pso~chiatrwy, R. Bellack and B. Karasu (eds.) (New York: Grune and Stratton, 1976). Mayeux, R., Stern, Y., and Spanton, S., Heterogeneity in Dementia of the Alzheimer Type: Evidence of Subgroups, Neurology 35:453-461, 1985. McCarthy, R., Gresty, M., and Findley, L. J., Parkinsons Disease and Dementia) Lancet, Feb. 16, 1985, p. 407. McCartney, J. R., and Palmateer, L. M., Assess208 209 210 91< 212. 213 214. 215. 216. 217, 218. 219. ment of Cognitive Deficit in Geriatric Patients: A Study of Physician Behavior, Journal of the American Geriatrics Society 33:467-471, 1985. McGeer, P. L., Kamo, H., Harrop, R., et al., Positron Emission Tomography in Patients With Clinically Diagnosed Alzheimers Disease, Canadian Medical Association Journal 134:597-607, 1986. McGeer, P. L., McGeer, E. G,, Suzuki, J., et al., Aging, Alzheimers Disease, and the Cholinergic System of the Basal Forebrain, Neurology 34:741-745, 1984, McHugh, P. R., Occult Hydrocephalus, Quarterly Journal of Medicine 33:297-308, 1964. McKeel, D. W., The Autopsys Untimely Demise: Physicians Are Neglecting a Vital Medical Resource, The Sciences 26:30-35, July/August 1986, McKhann, G., Drachman, D., Folstein, M., et al., Clinical Diagnosis of Alzheimers Disease, Neurology 34:939-944, 1984. McLachlan, D. R. C., Lewis, P. N., Lukiw, W.J., et al., ( Chromatic Structure in Dementia, Annals of Neurology 15:329-334, 1984. Medical World News, AIDS Virus Casts Another Shadow, May 13, 1985, pp. 11-15. Medical World News, ( Pathologists Build Case for More Autopsies, Oct. 14, 1985, pp. 73-74. Medical World News, New Drug May Improve Memory, May 12, 1986, p. 37. Medical World News, New Alzheimers Necrologic Link, June 9, 1986, p. 35. Mesulam, M. M., Dementia: Its Definition, Differential Diagnosis, and Subtypes, Journal of the American Medical Association 253:2559-2561, 1985. Mesulam, M. M., Volicer, L., Marquis, J, K., et al., Systematic Regional Differences in the Cholinergic Innervation of the Primate Cerebral Cortex: Distribution of Enzyme Activities and Some Behavioral Implications) Annals of Neurology 19:144-151, 1986. 220, Miller, C., Haugh, M., Kahn, J., et al., The Cytoskeleton and Neurofibrillary Tangles in Alz heimers Disease, Trends in Neuroscience, February 1986, pp. 76-81. 221, Molsa, P. K., Paljarvi, L., Rinne, J. O., et al., Validity of Clinical Diagnosis in Dementia: A Prospecti~e Clinicopathological Study, Journal of Neurology, Neurosurgery, and Psychiatry 48: 1085-1090, 1985, 222. Morris, J.C., Cole, M., Banker, B. Q., et al., Hereditary Dysphasic Dementia and the PickAlzheimer Spectrum, Annals of Neurology 16: 455-466, 1984. 223. Mortimer, J. A., French, L. R,, Hutton, J. T,, et al., PAGE 131 Ch. 3The Diseases: Diagnosis, Treatment, and Scientific Background l 127 224 225 226. Head Injury as a Risk Factor for Alzheimers Disease, Neuro]ogv 35:264-267, 1985. (Also letter and reply, Neuro]ogv 35:1530-1531, 1985). Moss, M. B., Albert, M. S., Butters, N., et al., Differential Patterns of Memory Loss Among Patients With Alzheimers Disease, Huntingtons Disease, and Alcoholic Korsakoffs Syndrome, Archi\es of Neurologv 43:239-246, 1986. Muckle, T. J., and Roy, J .R., High-Density Lipoprotein Cholesterol in Differential Diagnosis of Senile Dementia, Lancet, May 25, 1985, pp. 1191-1192. Nagai, T., McGeer, P. L., Peng. J. H., et al., ( Choline Acetyltransferase Immunohistochemistry in Brains of Alzheimers Disease Patients and Controls, Neuroscience Letters 36:195-199, 1983. 227. National Institutes of Health Conference, Brain Imaging: Aging and Dementia, Annals of Internal Medicine 101:355-369, 1984. 228. National Institute on Aging, Task Force Report, Senility Reconsidered. Treatment Possibilities for Mental Impairment in the Elderly) Journal of the American Medical Association 244:259263, 1980. 229. Navia, B. A., Eun-Sook, C., Petite, C. K., et al., The AIDS Dementia Complex: II. Neuropathology Annals of Neurologv 19:525-535, 1986. 230. Navia, B. A., Jordan, B. D,, and Price, R. W., The AIDS Dementia Complex: 1. Clinical Features, Annals of Neurologv 19:517-524, 1986. 231. Neary, D., Snowden, J. S., Bowen, D. M., et al., Cerebral Biopsy in the Investigation of Presenile Dementia due to Cerebral Atrophy) Journal of Neurology, Neurosurgeqv, and Pstiychiat~v 49:157162, 1986. 232. Neary, D., Snowden, J. S., Bowen, D. M., et al., 233 234 235 236 Neuropsychological Syndromes in Presenile Dementia due to Cerebral Atrophy, Journal of Aleuro]ogv, Neurosurge